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Thesis Abstract  
The aim of this thesis was to establish the effect ovarian ageing has on receptor expression 
on granulosa cells, which surround the oocyte in the ovarian follicle, and to delineate the 
specific role of bone morphogenetic protein (BMP) in the regulation of ovulation rate and 
folliculogenesis. 
 
The first major body of work was to determine the direct cause of the mutation-induced, 
increased ovulation rate in Booroola Merino sheep (BB). Granulosa cells were removed from 
antral follicles pre and post-ovulation from five BB and 12 wild type (WT) Merino ewes. 
Immunofluorescent measurement of mature cell surface receptors using flow cytometry 
demonstrated a significant up-regulation of follicle stimulating hormone receptor (FSHR), 
transforming growth factor beta (TGFβ) type 1, bone morphogenetic protein receptor 
(BMPR1B), and luteinising hormone receptor (LHR) in the BB.  
 
The up-regulation of LHR provides evidence of an earlier acquisition of receptors with 
greater expression density at an earlier follicle size in the BB compared to the WT genotype.  
The increased density of FSHR and LHR provided novel evidence of a mechanism for 
increasing the number of follicles that are recruited during dominant follicle selection. The 
compounding increase of receptors with increasing follicle size maintained the multiple 
follicles and reduced the apoptosis, which contributed to the high ovulation rate in the BB 
sheep. In addition, we report a mutation-independent mechanism of down-regulation of 
receptor density of the leading dominant follicle in sheep. The suppression of receptor 
density coincided with the cessation of mitogenic growth and steroidogenic differentiation as 
part of luteinisation of the follicle. The suppression of receptor density coincided with the 
cessation of mitogenic growth and steroidogenic differentiation as part of luteinisation of the 
follicle. The BB mutation-induced attenuation of BMPR1B signalling, led to an increased 
density of the FSHR and LHR, with a concurrent reduction in apoptosis or necrosis, which 
increased the ovulation rate. The role of BMPs in receptor modulation was implicated in the 
development of multiple pre-ovulatory follicles. 
 
The second major body of work aimed to profile the expression of BMPR1B, FSHR, LHR 
and growth hormone receptor (GHR), and the level of apoptosis or necrosis in IVF patients, 
in a range of ovarian primordial follicle depletion. Reproductive ageing is linked to the 
declining capacity to regenerate cells, causing irreversible changes to ovarian cellular 
dynamics, which ultimately reduce the capacity to reproduce. The 415 ovarian follicles 
collected from 54 IVF patients, in a range of diameter from 4 to 27 mm, and ~8000 granulosa 
cells, per follicle, were analysed. The density of the granulosa cell surface, mature receptor 
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protein was measured by immunofluorescent labelling and analysed by flow cytometry. 
Ovarian reserve was measured indirectly by the antral follicle count (AFC). AFC is the 
number of follicles between 2-10 mm in size that are present on day 2-5 of a cycle.  
 
A decline in BMPR1B density in granulosa cells occurred at the time of cyclic dominant 
follicle selection, and again during the maturation stage of folliculogenesis in young IVF 
patients (23-30 years (y)) with a good ovarian reserve. The older patients with poor ovarian 
reserve (40+ y), experienced a reversal of the biphasic pattern of receptor density. The 
reversal seen with declining AFC rather than chronological age provides compelling 
evidence of a fundamental shift in granulosal BMPR1B receptor density with ovarian ageing. 
High levels of granulosal FSHR density were observed in the smaller antral follicles, and the 
depletion of the ovarian reserve did not generally disrupt the expression. Conversely, the 
down-regulation of granulosal FSHR density during the maturation process was disrupted by 
ovarian reserve depletion. The LHR density was lower and failed to be down-regulated 
during pre-ovulatory maturation in the older patients with a poor ovarian reserve compared to 
the younger patients. Ovarian ageing appears to disrupt the prerequisite down-regulation of 
granulosal FSHR, BMPR1B and LHR density required for maturation of the follicle before 
ovulation. 
 
The level of GHR density was generally reduced with ovarian ageing, yet a correlation was 
evident between the increasing level of recombinant FSH (rFSH) treatment and the increase 
in GHR of the small antral follicles. The effect of exogenous rFSH to increase the GHR 
expression, diminished in the older age groups with the poorest ovarian reserve. The results 
demonstrate the disrupting effect that age-induced depletion of the ovarian reserve has on 
receptor density at the two stage-specific, critical time points of dominant follicle selection 
and pre-ovulatory maturation. This dysregulation is potentially responsible for the reduction 
in oocyte quality in older patients. 
 
The level of apoptosis increased during dominant follicle selection and during pre-ovulatory 
maturation in young IVF patients with an uncompromised ovarian reserve. The granulosal 
BMPR1B and FSHR density was strongly associated with a reduction in apoptosis; and the 
reduced level of apoptosis in the poor ovarian reserve patients was also strongly correlated to 
the level of rFSH drugs administered. The greater level of apoptosis and necrosis of the 
young uncompromised ovarian reserve patients, compared to the older poor ovarian reserve, 
may reflect the overall greater mitogenic proliferation in the younger patient cohort.  
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The third major body of work examined the effect of growth hormone (GH) co-treatment on 
the changes to granulosal BMPR1B, FSHR, LHR, and GHR density, and the level of 
apoptosis or necrosis during follicle development. Previously, GH co-treatment during IVF 
increased the pregnancy rate of infertility patients with a poor ovarian reserve. In an attempt 
to reverse the poor prognosis of older patients with a poor ovarian reserve, GH was provided 
to 11 patients as an adjunct to IVF treatment. The 72 ovarian follicles collected from GH co-
treated IVF patients ranged in diameter from 4 to 23 mm, and ~8000 granulosa cells, per 
follicle were analysed. The density of the granulosa cell surface, mature receptor protein, was 
measured by immunofluorescent labelling and analysed by flow cytometry.  
 
The GH co-treatment increased the receptor density of BMPR1B, FSHR, and LHR, and 
restored the pre-requisite down-regulation during pre-ovulatory maturation which may 
improve oocyte quality as observed in GH co-treated patients. The study has revealed several 
cellular mechanisms that could contribute to an improved oocyte quality in GH co-treated 
IVF patients with a poor ovarian reserve. The dysregulation of the ovarian micro-
environment caused by ovarian depletion was partially reversed, providing an explanation for 
the positive pregnancy rate associated with GH co-treatment. GH co-treatment of the 40+ y 
poor ovarian reserve patient group did not significantly change the level of apoptosis or 
necrosis in the same age group and AFC, when compared to those without GH co-treatment. 
Preliminary data on recombinant GH (rGH) co-treated older patients, with good ovarian 
reserve, demonstrated an increased level of apoptosis or necrosis. 
 
In the fourth major body of work, biochemical analysis of the serum and follicular fluid 
obtained from patients with a range of ovarian reserves from the previous three bodies of 
work was undertaken. Follicular fluid aspirated from follicles of ~20 mm did not reveal any 
significance in the level of oestrogen, progesterone, or LH, whereas FSH levels were 
correlated to the rFSH treatment dose. Serum oestrogen synthesis was reduced as the ovarian 
reserve depleted, and the level of FSHR density was not changed with reduced ovarian 
reserve, which indicates that the decrease in oestrogen synthesis capability may be 
downstream of the FSHR. Progesterone concentrations were consistent for each age class, 
except for the decrease in the, poor ovarian reserve groups. The reduced oestrogen synthesis 
could also be associated with a reduced progesterone serum level, and may be related to 
granulosal receptor density.  
 
The LH serum level, corresponding to the peak oestrogen level of the follicular phase, in an 
IVF cycle increased as the ovarian reserve became depleted. The LH concentration was 
significantly greater in the older IVF patients with a poor ovarian reserve compared to the 
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younger patient group. The level of FSH at the start of the cycle was significantly greater in 
the older patients with a poor ovarian reserve compared to the younger patients during a 
natural cycle or during an IVF cycle. The FSH level at the time of peak oestrogen (FSH 
surge) was not significantly different between the old and young patients during a natural 
cycle. However, during an IVF cycle, the FSH surge was substantially greater in the older 
patients with a dose-dependent increase as the ovarian reserve declined. 
 
The GH co-treatment did not alter the oestrogen, progesterone, FSH, or testosterone level in 
the follicular fluid or serum levels, from older, poor ovarian reserve patients. GH co-
treatment increased the granulosal FSHR density, yet had no effect on the serum or follicular 
fluid oestrogen synthesis. The level of FSHR expression was not significantly reduced in the 
poor ovarian reserve patients, which indicates that the conversion of androstenedione to 
oestradiol in the granulosa cell is adversely impacted on, downstream of the hormone-
receptor interphase in ovarian ageing. 
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CHAPTER 1 INTRODUCTION 
The ovarian process of recruitment and folliculogenesis involves a complicated paradigm of 
dynamic fluctuations of steroid hormones, and cell proliferation and differentiation. The 
process culminates in the production of a mature ovarian follicle, which ruptures and releases 
the oocyte with the potential to be fertilised and form a new life.  
 
Primordial germ cells migrate to the gonads and proliferate during gestation which generates 
a vast sum of oocytes surrounded by epithelium pre-granulosa cells that forms the primordial 
follicle. The primordial follicle’s growth is arrested at the diplotene stage of meiosis. 
Activation of the primordial follicle to grow beyond this stage is of particular interest 
because, once activated, the primordial follicle develops into a primary follicle where it is 
subject to the regulatory mechanisms involved in growth, selection, maturation, and 
ultimately, ovulation. The vast majority of follicles succumb to atresia, and are permanently 
lost from the primordial pool of follicles. 
 
The primordial follicles are continuously being activated, and the number of small antral 
follicles at the beginning of the menstrual cycle is an indirect measurement of the ovarian 
reserve of primordial follicles. At the onset of puberty, high levels of gonadotrophins are 
released from the pituitary, and the menstrual cycle begins. Folliculogenesis during the 
menstrual cycle is driven by follicle stimulating hormone (FSH) and luteinising hormone 
(LH) in conjunction with many growth factors and inhibitors interrelated in a complex web 
of regulatory balance. 
 
The bone morphogenetic protein (BMP) signalling system has a major role to play in many 
species, including the human, in the generation of transcription factors that influence 
proliferation, steroidogenesis, cell differentiation and maturation prior to ovulation of the 
oocyte. BMPs are also involved in stimulation of the anterior pituitary gonadotrophin cells’ 
generation of FSH.  
  
2 
 
 
 
 
 
 
 
 
 
LITERATURE REVIEW 
  
3 
 
CHAPTER 2 LITERATURE REVIEW 
2.1 Overview of folliculogenesis 
The underlining mechanics of reproduction for the survival of the species are similar in 
humans and higher order animals. The oocyte or egg in the female is encapsulated by layers 
of follicular cells that proliferate, and later differentiate and mature in the ovary. The mature 
follicle wall ruptures and the oocyte is expelled from the follicle and is potentially destined 
for fertilisation. The recruitment of the follicles, their growth, and the expulsion of the oocyte 
are dependent on a complex signalling mechanism involving the hypothalamic-pituitary-
gonadal axis. Neurotransmitters from the hypothalamus stimulate the release of 
gonadotrophin releasing hormone (GnRH) into the hypophyseal portal system, which in turn, 
stimulates the anterior pituitary to release gonadotrophic hormones that act on the ovary to 
promote follicular growth. Several growth factors which regulate the transcription of genes 
and control the recruitment and selection of the dominant follicles, belong to the 
transforming growth factor beta (TGFβ) superfamily including the BMPs, inhibins and 
activins (Knight and Glister 2006).  
 
Figure 2.1.1 Primordial germ cell proliferation (PGC) and oogenesis before birth, and the 
loss of primordial follicles from birth to menopause. 
Based on (Baerwald, et al. 2012a, Fabre, et al. 2006, Knight and Glister 2006, Matsuda, et al. 2012, 
Skinner 2005, Webb 2007) 
4 
 
The sperm and the oocyte come together at the time of conception to form the embryo. At 
approximately 26 weeks of gestation in humans, the reproductive potential of the foetus is 
initiated (Childs, et al. 2010). It is at this time that the primordial follicles are fully formed, 
and begin a lifelong process of initial activation followed by eventual demise (Figure 2.1.1) 
(Pangas 2012). The primordial follicles grow and differentiate into pre-antral follicles (Figure 
2.1.2). With further development pre-antral follicles mature into antral follicles with the 
formation of a fluid filled central compartment (Rodgers and Irving-Rodgers 2010b). At the 
onset of puberty, the level of gonadotrophin secreted from the anterior pituitary increases 
FSH to a threshold point sufficient to rescue a growing cohort of small antral follicles and 
initiate cyclic folliculogenesis (Figure 2.1.2) (Gougeon 1986, Richards 1994). 
Figure 2.1.2 Folliculogenesis: Activation of the primordial follicle, dominant follicle 
selection, growth and maturation before ovulation 
. 
Antral follicles contain an oocyte, surrounded by cumulus granulosa cells suspended in fluid, 
and anchored to the follicle wall. The follicle wall is composed of granulosa and theca cells 
separated by the basal lamina membrane. Stromal cells within a connective tissue matrix are 
encapsulated by epithelial cells at the follicle surface (Erickson and Shimasaki 2003, Rodgers 
and Irving-Rodgers 2010b). 
 
The process of folliculogenesis involves the stage-dependent expression of growth factor 
receptors that regulate the process of follicular growth (Erickson and Shimasaki 2003). The 
Sheena Regan 2015 
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follicle undergoes proliferation of the granulosa and thecal cells, followed by differentiation 
of the role of the follicular cells, as the follicle matures (Gougeon 1986). The mature follicle 
or pre-ovulatory follicle completes differentiation and becomes luteinised (morphological 
and steroidogenic capacity changes) prior to ovulation, and then ruptures, releasing the 
oocyte into the fallopian tube cavity (Ainsworth, et al. 1980, Rodgers and Irving-Rodgers 
2010b).  
 
The number of pre-ovulatory follicles selected for dominance and ovulation is dependent on 
the regulation by the gonadotrophins follicle stimulating hormone (FSH) and luteinising 
hormone (LH), and the interaction with intraovarian growth factors that are involved in 
folliculogenesis (Ginther, et al. 2005, Gougeon 1986). 
  
  
Figure 2.1.3 Overview of the TGFβ and the growth hormone kinase signalling interaction. 
Based on (Amsterdam, et al. 2003, Fan, et al. 2009, Manna, et al. 2002, Miyazono, et al. 2010, Moore, 
et al. 2001b, Rice, et al. 2007, Tajima, et al. 2003).  
 
As depicted in Figure 2.1.3, the TGFβ family members, bone morphogenetic proteins 
(BMP)s, have been shown to play a major role in the recruitment and growth of the ovarian 
follicle (Knight and Glister 2006). The type 1 TGFβ receptor bone morphogenetic protein 
receptor (BMPR1B), binds to the BMP ligands 2, 4, 6, 7, and 15,which culminates in gene 
transcription (Miyazono, et al. 2005). A point mutation of the BMPR1B gene in the Booroola 
Merino (BB) sheep results in the partial attenuation of the receptor function, and increases 
Erk1/2 
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the ovulation rate (Mulsant, et al. 2001, Souza, et al. 2001, Wilson, et al. 2001). In the human 
model, the ovulation rate is increased during in vitro fertilisation (IVF) treatment by the 
administration of FSH to stimulate the growth of multiple follicles (Edwards, et al. 1996, 
Edwards and Steptoe 1983). The mode of action of BMPR1B and its interaction with the 
signalling of follicle stimulating hormone receptor (FSHR) and luteinising hormone receptor 
(LHR), are therefore central to this thesis (Figure 2.1.3). In addition, programmed cell death 
or apoptosis forms another mode of regulation of ovulation rate; and the BMPs have also 
been implicated in the regulation of apoptosis (Haÿ, et al. 2004, Hussein, et al. 2005, 
Kayamori, et al. 2009, Zhu, et al. 2013).  
 
The effectiveness of the exogenous recombinant DNA follicle stimulating hormone (rFSH) 
treatment to increase the ovarian response diminishes with age, and declines as the 
primordial follicle reserve is depleted in the ovary (Yovich, et al. 2012). Patients showing a 
poor ovarian response to rFSH have previously been shown to have an improved pregnancy 
rate (Tesarik, et al. 2005, Yovich and Stanger 2010). In the ovary growth hormone receptors 
(GHR) are found on the theca, granulosa cells, and the oocyte (Abir, et al. 2008b, Carlsson, 
et al. 1992, Kölle, et al. 1998, Sharara and Nieman 1994, Tamura, et al. 1994). The effect of 
growth hormone (GH) treatment on the expression of the BMPR1B, FSHR, and LHR is 
elaborated upon in this thesis.  
2.1.1 The ovarian reserve 
Oogonia proliferate in the ovary before undergoing meiosis at approximately week 9-11 of 
gestation in humans (Figure 2.1.1). The oogonia are infiltrated by the somatic cells, forming 
primordial follicles with a single layer of cells surrounding the oocyte (Pangas 2012). The 
somatic cells differentiate into granulosa cells, and the oocyte resides in the   
dictyate-stage of meiotic prophase 1 until the mid-cycle LH surge triggers further 
development (Edwards, et al. 1996). The decline of the ovarian reserve is well documented, 
and is related to chronological age (Figure 2.1.1) (Almog, et al. 2011, Hansen, et al. 2011).  
 
The oocyte number increases from 100 to 6,000,000 just before birth, and at birth the number 
of oocytes has already fallen by 83% (Monniaux, et al. 2014). At puberty the levels of 
gonadotrophins increase sufficiently to promote primary to tertiary follicles to continue 
growth, and to resist apoptosis (Figure 2.1.1and Figure 2.1.2) (Matsuda, et al. 2012). 
Estimates of the number of small antral follicles growing (AFC) or the level of anti-mullerian 
hormone (AMH) secretion by the small antral follicles is strongly correlated to the ovarian 
reserve (Hansen, et al. 2011, van Rooij, et al. 2005).   
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2.1.2 Intra-ovarian regulators of folliculogenesis 
Inducement of FSHR and LHR expression appears to be under the control of various 
intraovarian growth and development regulators as depicted in Figure 2.1.2 and Figure 2.1.3 
(Erickson, et al. 1979). BMP ligands, inhibins, activins, and BMP binding proteins have been 
implicated directly or indirectly, in vivo, by experiments that involve treatments, such as 
ligand infusion and active or passive immunisation (Al-Samerria, et al. 2015, Campbell, et al. 
2009, Juengel, et al. 2004, Knight, et al. 2012), and by natural mutations, and knockout gene 
models in several species (Araújo 2010, Di Pasquale, et al. 2006, Feary, et al. 2007, McNatty, 
et al. 2007). In vitro culture of granulosa and theca cells have provided data on the influence 
of these growth factors on steroidogenesis and cell proliferation (Brankin, et al. 2005, 
Campbell, et al. 2006, Glister, et al. 2004b, McNatty, et al. 2009).  
 
Figure 2.1.4 BMP signalling and the formation of the ovarian reserve through to 
ovulation. 
The involvement of BMP signalling in embryonic ovarian formation of primordial follicles; activation 
of the primordial to primary follicle; antral follicle formation and recruitment into cyclic 
folliculogenesis to ovulation. 
 
The ligands that bind with BMPR1B are BMP2, 4, 6, 7, 15, and AMH (Figure 2.1.3) 
(Mazerbourg and Hsueh 2006). Numerous studies have provided strong evidence that the 
action of the BMP ligands associated with BMPR1B inhibit progesterone synthesis and 
promote oestrogen production (Figure 2.1.5 and Figure 2.2.1 ), and supress early luteinisation 
of the follicular cells in the rat (Shimasaki, et al. 1999), cow (Glister, et al. 2004b), hamster, 
mice and sheep (Fabre, et al. 2003, Kayamori, et al. 2009, Young, et al. 2008), and humans 
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(Shi, et al. 2012, Shi, et al. 2009b, Shi, et al. 2010). In addition, the BMPR1B knockout mice 
exhibit an increase in the granulosal FSHR expression levels (Edson, et al. 2010).  
2.1.3 Hypothalamic-pituitary-ovarian axis  
Androgen receptors are first expressed in the transitional follicle between primordial and 
primary stage, and are early regulators of ovarian development, particularly the inducement 
of FSHR on the granulosa cell (Figure 2.1.5) (Erickson, et al. 1979, Rice, et al. 2007, Sen and 
Hammes 2010, Sen, et al. 2014). Granulosa cells are unique because they express FSHRs 
which are required for the synthesis of oestrogen (Figure 2.2.1) (Miller 2011). Theca cells 
express LHRs and synthesise androgens which are used by the granulosa cells as substrate 
for oestrogen synthesis. 
Figure 2.1.5 The stage-specific relationship between granulosal receptor expression and 
oestrogen activity during folliculogenesis. 
Dominant follicle selection takes place when the androgen receptor and FSHR expression decreases, 
and LHR expression increase (indicated by the blue upwards-arrow). Down-regulation of FSHRs, 
LHRs and the cessation of proliferation occurs in the pre-ovulatory follicles in humans and animals, 
(indicated by the black downwards-arrow). CYP19A1 is the gene that encodes aromatase, essential for 
the production of oestrogen. Based on (Gasperin, et al. 2014, Jeppesen, et al. 2012). 
 
In the small pre-antral follicle, theca cells express LHRs, CYP11A1, and HSD3B1, and have 
the capacity to produce androstenedione and other androgens prior to granulosal FSHR 
expression (Sen, et al. 2014). Androstenedione accumulates in the theca cells in preparation 
for the commencement of steroidogenesis in the granulosa cell (Figure 2.2.1) (Rice, et al. 
2007, Sen, et al. 2014). The androstenedione diffuses out of the theca to the adjacent 
granulosa cells where FSH interaction with FSHR acts via the adenylate cyclase, cyclic 
adenosine 3´,5´-monophosphate, protein kinase (AC-cAMP-PKA) pathway to stimulate the 
conversion via CYP19A1 to oestradiol (Figure 2.2.1) (Manna, et al. 2002). Mid-follicular 
phase (~ day 7) is the time of divergence which results in dominant follicle selection (Figure 
Sheena Regan 2015 
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2.1.5) (Mihm and Evans 2008a). Granulosal FSHRs induce LHRs on small antral recruited 
follicles (Mihm, et al. 2006, Minegishi, et al. 1997, Yung, et al. 2014). 
 
As pituitary FSH secretion is reduced, the follicles with granulosal LHRs have the capacity to 
supplement the FSH-dependent synthesis of oestrogen. The follicle(s) with granulosal-
expressed LHR continue to grow and become the selected dominant follicle(s) (Figure 2.1.2). 
The extent of androstenedione conversion to oestrogen continues to increase, which creates a 
positive oestrogen feedback loop to the hypothalamic-pituitary complex leading to further 
GnRH and LH release, (Figure 2.2.1) (Faure, et al. 2005). Proliferation of the granulosa and 
theca cells continues as the rise in oestrogen level promotes proliferation until a threshold 
level is reached which culminates in the generation of the ovulation-induced LH surge 
(Figure 2.2.1) (Austin, et al. 2001, Ginther, et al. 2005). In the event that reduced conversion 
of androstenedione to oestrogen occurs, androgen levels rise creating an androgen dominant 
follicle. Greater androstenedione to oestrogen ratios have been shown to result in an elevated 
level of granulosa cell apoptosis and follicle demise (Yuan and Giudice 1997). 
2.2 Ovulation rate  
The ability of the follicle to reach the FSH-oestrogen threshold and establish sufficient 
granulosal LHR mid-cycle, appears to be of paramount importance to the survival of the 
selected dominant follicle; alternatively, follicular regression proceeds, followed by atresia, 
(Figure 2.1.2) (Campbell, et al. 1999, Ginther, et al. 2012, Luo, et al. 2011, Picton and 
McNeilly 1991). The BMP ligands are well established as regulators of granulosa cell 
proliferation in sheep (Chen, et al. 2008, Fabre, et al. 2003, Kayamori, et al. 2009, Mulsant, 
et al. 2001, Young, et al. 2008), cows (Austin, et al. 2001, Glister, et al. 2004b, Kayamori, et 
al. 2009, Kayani, et al. 2009, Knight and Glister 2003), and in humans (Di Pasquale, et al. 
2006, Dooley, et al. 2000, Shi, et al. 2012, Shi, et al. 2009b, Shi, et al. 2010, Shimasaki, et al. 
1999). 
 
The time of follicle divergence occurs when pituitary FSH secretion reduces and LH 
secretion increases (Figure 2.1.2) (Austin, et al. 2001, Edwards, et al. 1996). During a natural 
cycle, the follicles with a higher density of receptors are presumed to be more responsive to 
the gonadotrophins, and continue to increase in size (Bächler, et al. 2014, Gougeon 1986, 
LaPolt, et al. 1992). The number of pre-ovulatory follicles stimulated can be artificially 
enhanced by exogenous rFSH stimulation or by a naturally occurring mutation-induced 
increase in responsiveness, such as that seen in the Booroola Merino sheep, (Mulsant, et al. 
2001, Souza, et al. 2001, Wilson, et al. 2001).  
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The suppression of granulosal progesterone synthesis in favour of oestrogen, appears to be 
governed by the action of the BMP growth factors from the TGFβ superfamily (Knight and 
Glister 2006, Moore, et al. 2001b). The BMP ligands which strongly activate the BMPR1B 
(Miyazono, et al. 2010), and the role of BMPs in the regulation of gonadotrophin receptor 
expression has been previously reported (Figure 2.1.4) (Shi, et al. 2012, Shi, et al. 2011, Shi, 
et al. 2010, Zhu 2013). 
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Figure 2.2.1 Hypothalamic-pituitary ovarian axis of regulation, and the granulosa and 
theca cell interaction. 
Based on (Bao, et al. 1997, Chen, et al. 2008, Dijke, et al. 2003, Feary, et al. 2007, Fitzpatrick, et al. 
1997, Hillier, et al. 1994a, Hussein, et al. 2005, Kayani, et al. 2009, Miller and Bose 2011, Miyazono, 
et al. 2005, Miyoshi, et al. 2007, Moore, et al. 2001b, Nicol, et al. 2008, Pierre, et al. 2004, Rice, et al. 
2007, Seger, et al. 2001, Sugawara, et al. 2000, Sullivan, et al. 1999, Takeda, et al. 2012, ten Dijke, et 
al. 2003, Yamamoto, et al. 2002, Yuan 1998 )   
R 
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2.2.1 LH surge and the role of the BMPs 
The BMP ligands, 2, 4, 6, 7, and 15 form a receptor-ligand complex with the BMPR1B, and 
recruit the type 2 TGFβ receptor BMPR2 (Miyazono, et al. 2010). The complex initiates 
phosphorylation of the intracellular substrate molecules, receptor-regulated c. elegans protein 
mothers against decapentaplegic (Smad)s. The Smad forms a complex with a common 
mediator, Smad 4, and translocates to the nucleus where transcription of genes required by 
the cell takes place (Moore, et al. 2003). Smad signalling is modulated by repressor and 
activator molecules in the nucleus, cytoplasm and in the extracellular matrix. Alternatively, 
BMPs can activate the non-Smad pathway, mitogen activated protein kinases (MAPK) such 
as ERK 1 and ERK 2 (Inagaki, et al. 2009). The cross-talk between the Smads and the 
extracellular signal regulated kinases 1 and 2 (ERK 1/2) signalling, adds another dimension 
to the complex signalling which regulates folliculogenesis (Tajima, et al. 2003). Specifically 
BMP15 increases proliferation of granulosa cells and cytodifferentiation, independent of 
FSH, yet BMP15 supresses FSH-induced synthesis by reducing steroid acute regulatory 
protein (StAR) and P450 side chain cleavage enzyme (CYP11A1) in the rat (Otsuka, et al. 
2001b). BMP6 also inhibited progesterone synthesis; however, the biological activity in 
granulosa cells was directed downstream of the FSHR without affecting the synthesis of 
oestrogen in the rat (Otsuka, et al. 2001a). 
 
In the ovary, granulosa cell signalling induced by the gonadotrophins, FSH and LH, activate 
the FSHR or LHR and stimulate cAMP-PKA which increases the P450 aromatase 
(CYP191A ) aromatase to facilitate oestrogen synthesis (Figure 2.1.3 and Figure 2.2.1). 
Progesterone synthesis is inhibited by BMP4 the suppression of StAR (Pierre, et al. 2004, 
Tajima, et al. 2003, Val, et al. 2003) which is essential for progesterone synthesis in the 
granulosa cell (Figure 2.2.1) (Moore, et al. 2001b). Alternatively, or in addition, BMPs 
inhibit ERK 1/2 signalling providing inhibitory control over the balance of progesterone and 
oestrogen (Figure 2.2.1) (Miyoshi, et al. 2007, Nakamura, et al. 2012, Ogura Nose, et al. 
2012).  
 
BMP signalling activity has been established not only in the ovary but also in the pituitary 
where ERK and janus nuclease kinase (JNK) signalling have been shown to increase LHβ 
(Harris, et al. 2002), and BMP15 via ERK to increase FSHβ (Figure 2.2.1) (Otsuka and 
Shimasaki 2002). In addition, BMP6 and 7 were shown to regulate FSHβ expression 
(Takeda, et al. 2012). Given the above regulatory evidence, it is not surprising that the spatial 
and temporal relationship of BMP expression patterns change with an increase in follicular 
size (Otsuka 2010).  
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There are few previously published studies that cover the changing follicular gene expression 
pattern during folliculogenesis as the ovarian reserve is depleted. In particular, the common 
practice is to pool the follicles into size ranges, a practice which fails to recognise the 
sometimes subtle change over time, or the dramatic fall in gene expression as the follicle 
matures. The LH surge is characterised by a dramatic shift from proliferation to 
differentiation and maturation of the follicle prior to ovulation (Peng, et al. 1991b, Richards, 
et al. 1998). The LH surge initiates irreversible morphological changes to the granulosa cells 
in preparation for the shift from oestrogen production to progesterone production (Byrne, et 
al. 1995, Micevych, et al. 2003). The BMPs have been described as locally produced 
inhibitors of follicle luteinisation, however the exact characterisation of the biological 
component that reduces pituitary responsiveness to GnRH has not been identified (Dimitraki, 
et al. 2014, Kita, et al. 1994, Messinis, et al. 1991). The gonadotrophin surge attenuating 
factor (GnSAF) is one possible candidate. GnSAF bioactivity is measured indirectly by its 
ability to attenuate the LH secretory response  of pituitary cells to GnRH (Fowler, et al. 
2001). Evidently, the GnSAF is characterised as being produced by the cohort of recruited 
small antral follicles in the ovary. It has been proposed that these small follicles regulate 
folliculogenesis by desensitising the pituitary to suppress LH secretion until mid-cycle 
(Dimitraki, et al. 2014, Fowler, et al. 2001).  
 
GnSAF bioactivity in follicular fluid has been shown to be greater in patients receiving IVF 
treatment than during natural cycles (Fowler, et al. 2001); and the effect of a declining 
ovarian reserve with age, results in reduced GnSAF bioactivity (Martinez, et al. 2002). 
Previously, an inverse relationship between follicle size and GnSAF was demonstrated 
(Figure 2.1.2) (Fowler, et al. 2001). In the largest human follicles of 25 mm, GnRH-induced 
LH secretion was severely reduced compared to the 5-8 mm follicles (Fowler, et al. 2001). 
 
Figure 2.2.2 LH surge attenuation factor (GnSAF) during folliculogenesis in a natural 
cycle. Modified 
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In a later study, the level of GnSAF was measured at two time points corresponding to the 
time of dominant follicle selection and at the time of human chorionic gonadotrophin (hCG) 
injection or the equivalent of the largest follicle,19-24 mm (Martinez, et al. 2002). The good 
ovarian response younger patients had high levels of GnSAF at the time of dominant follicle  
selection that reduced dramatically at the end of folliculogenesis (Figure 2.2.3). The opposite 
was true for the poor ovarian response older patients of the study (Figure 2.2.3). The 
comparatively higher level of GnSAF would be accounted for by the increase in the number 
of follicles producing the attenuating substance, which was greater in the younger patients 
compared to the older.  
Figure 2.2.3 A comparison of the LH surge attenuation factor (GnSAF) during 
folliculogenesis in young and older IVF patients. 
The ovarian response to rFSH was determined by the number of growing large antral 
follicles.Modified 
 
It was concluded that the bioactivity of the GnSAF has an endocrine role to play in 
preventing the premature onset of the LH surge; which would accord with the local 
intraovarian role of BMPs as an inhibitor of luteinisation (Otsuka 2010, Shimasaki, et al. 
1999). The dysregulation of GnSAF or BMP signalling would impede the process of 
luteinisation and prevent maturation of the follicle (Gordon, et al. 2008).  
2.3 LHR expression and the LH surge  
LHRs are acquired at the time of dominant follicle selection in granulosa cells, in response to 
the increased density of FSHRs and the stimulation of oestrogen production (Xu, et al. 1995, 
Yung, et al. 2014). The level of granulosal LHR in a natural cycle peaks as the estrogen level 
reaches a threshold mid-cycle before the LH surge (Peng, et al. 1991b). The LH surge 
induced by the positive feedback action of oestradiol, causes degradation of the LHR mRNA, 
and the expression of the LHRs is reduced dramatically (Lu, et al. 1993, Minegishi, et al. 
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1997, Nair, et al. 2006). The granulosal LHR expression returns to normal shortly after the 
end of the LH surge, and rises in the luteal phase (Micevych, et al. 2003).  
 
Clinical administration of hCG or the natural cycle LH surge, induces cytoskeletal 
reorganisation of the granulosa cell, cessation of mitogenic proliferation, cumulus expansion, 
gap junction closure, resumption of meiosis, and maturation of the oocyte (Fan, et al. 2009, 
Izadyar, et al. 1998b). These changes have an effect on the LHR mRNA or mature LHR 
protein density (LaPolt and Lu 2001, Lapolt, et al. 1990, Peng, et al. 1991b). The down-
regulation of granulosal LHRs in the ovulating follicle has been previously reported in the 
bovine and human (Jeppesen, et al. 2012, Ndiaye, et al. 2005, Ophir, et al. 2014, Xu, et al. 
1995); however, conflicting reports exist (Irving-Rodgers, et al. 2009, Jakimiuk, et al. 2001, 
Maman, et al. 2012). When comparing reported levels of receptor density, it is important to 
consider whether or not exogenous IVF stimulation was administered, and if the follicles had 
been exposed to a LH/hCG surge. In addition, pooling of follicles would potentially mask the 
down-regulation by averaging out the LHR density, and thereby reducing the accuracy of the 
data. 
2.3.1 The LH surge and the cumulus granulosa cells 
Cumulus cells experience high levels of oocyte secreted BMPs in a concentration gradient 
radiating outwards from the oocyte, supressing luteinisation and apoptosis, and promoting 
cell proliferation (Hussein, et al. 2005). At the time of antral formation the granulosa cells 
closest to the oocyte differentiate into cumulus cells. The cumulus cells have very low levels 
of LHR, progesterone receptor, and have low EGF concentrations in the follicular phase 
(Shimada, et al. 2003, Shimada and Terada 2002, Shimada, et al. 2004). Cumulus cell gap 
junctions are disrupted, severing the influence of the oocyte secreted growth factors such as 
BMP15 and 6 (Sutovský, et al. 1993). Just before the LH surge, changes in EGF and 
progesterone receptor expression increase (Prochazka, et al. 1998), resulting in numerous 
changes to the cumulus cells; one of which is the expression of LHR, and results in the 
cessation of mitogenic proliferation (Shimada, et al. 2003, Shimada and Terada 2002).  
2.3.2 BMP signalling and reproduction. 
The body of work investigating the role of BMPs is extensive, and ranges from studies on 
primordial germ cell migration to the inducement of ovulation and corpus luteum formation 
(Erickson and Shimasaki 2001, 2003, Knight and Glister 2006, Miyazono, et al. 2010, Otsuka 
2013, Pangas 2012, Shimasaki, et al. 2004). Several research models exist; the lower order 
species; Drosophila and zebra fish; poly-ovulatory rodents; mono-ovulatory animals, and 
human models. The ability to create gene knockout models in mice and to use natural and 
created mutations or specific cell lines add to the research tool box. Furthermore, the in vivo 
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and in vitro infusion of growth factors and the blocking of receptors and signalling pathways 
provide other methods of examination available to researchers. In human studies, in vivo and 
in vitro research has progressed substantially with the rise of ART centres, providing an 
unobtrusive source of follicular material. Non-pathogenic human ovarian tissue, free from 
exogenous gonadotrophin stimulation, is rare, and is therefore infrequently used in research 
(Bomsel Helmreich, et al. 1979, Fowler, et al. 2001, Garcia, et al. 1981, Gougeon 1986, 
Klein, et al. 2000, MacNaughton, et al. 1992). Given the stage-specific nature of ovarian 
regulation and species peculiarities, caution should be used when interpreting results 
(Erickson and Shimasaki 2003, Otsuka 2010). In addition, the complex interaction between 
growth factors and the hypothalamic-ovarian axis of control, impedes research of specific 
growth factors or the cellular regulatory mechanisms involved in ovarian function (Zeleznik 
2001). 
2.4 BMP and BMP receptor expression patterns within the ovary   
The TGFβ type 1 BMPR1B has been localised on sheep granulosa cells from the primordial 
follicle onwards (Al-Samerria and Almahbobi 2014 , Chen, et al. 2008, Erickson and 
Shimasaki 2003, Estienne, et al. 2015, Gasperin, et al. 2014). The level of expression 
increased sequentially from primordial to antral follicles in sheep. BMPR1B is expressed 
mainly on granulosa cells and the oocyte in bovines, and to a lesser degree in their theca cells 
(Glister, et al. 2004a). It has also been demonstrated that BMP ligands are produced in a 
stage-specific manner by follicular cells in animals and humans (Gasperin, et al. 2014, 
Glister, et al. 2004a, Regan, et al. 2015). 
 
BMP2 is mainly produced by the granulosa cells in the first half of follicle development 
(Pangas 2012). BMP2 has a low affinity with BMPR1B, and binds preferentially with 
another type 1 TGFβ receptor, BMPR1A (Miyazono, et al. 2010). BMP2 is involved in 
oocyte endowment, primordial pool assembly, and activation of primordial follicles (Lawson, 
et al. 1999, Ying and Zhao 2001).  
 
BMP4 is produced by the theca and granulosa cells in the bovine and human model (Glister, 
et al. 2004b, Khalaf, et al. 2013). BMP4 has been shown to bind precociously (Fabre, et al. 
2006) with BMPR1A, BMPR1B, ACVR1, and ACVR1B in sheep, signalling via the Smad 
intermediate molecules to modulate ovarian function. In addition, BMP4 is reported to 
mediate cell function via alternative signalling pathways involving MARK family, in 
particular ERK1/2. In the absence and presence of FSH, BMP4 inhibits progesterone 
production in granulosa cells by negatively influencing the downstream gene synthesis from 
FSH to cAMP, StAR, and CYP11A1 in small antral follicles (Fabre, et al. 2003, Mulsant, et 
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al. 2001). In contrast, large antral follicles are not responsive to BMP4 ligand-induced 
progesterone secretion or mitogenic growth, which indicates that BMP4 may be more 
involved in the regulation up to dominant follicle selection, (Fabre, et al. 2006, Tanwar and 
McFarlane 2011).  
 
FSH-induced progesterone biosynthesis was inhibited by BMP4, while it was shown to 
enhance FSH-induced oestrogen production in the rat (Shimasaki, et al. 1999), and in sheep 
(Fabre, et al. 2003, Mulsant, et al. 2001). In addition, in sheep it was revealed that BMP4 via 
BMPR1B signalling activated Smad 1 to inhibit StAR and CYP11A1 gene expression to 
inhibit progesterone synthesis. BMP4 also inhibited granulosa cell luteinisation by reducing 
SF-1 transcriptional activity on LHβ promoter (Pierre, et al. 2004). SF-1 is a key activator of 
steroidogenic endocrine function, and BMP4 and SF-1 are also found in gonadotrope cells 
that produce LH in the anterior pituitary (Ingraham, et al. 1994, Val, et al. 2003). The direct 
link between BMP4 and LH synthesis via the BMPR1B signalling phosphorylation of Smad 
1, provides an explanation for the increase in LHR as the BMPs decline during 
folliculogenesis that releases the inhibitory effect (Figure 2.1.5) (Nicol, et al. 2008). BMP4 
inhibits ovine pituitary FSHβ expression and the concentration of FSH (Faure, et al. 2005). 
BMP4 is also involved in oocyte endowment, primordial pool assembly, and activation to 
primary follicles (Lawson, et al. 1999, Ying and Zhao 2001). 
 
BMP7 is consistently produced in bovine theca cells, with a small amount being produced in 
human granulosa cells (Glister, et al. 2004a, Khalaf, et al. 2013). BMP7 has a similar 
biological effect on the granulosal proliferation and suppression of FSH-induced 
progesterone biosynthesis as BMP4 ,6 and 15 in the rat by increasing FSH-FSHR induced 
CYP19A1 expression (Lee, et al. 2001, Shimasaki, et al. 1999). In the monovulatory species 
the regulation was inconsistent; in the bovine the FSH-induced hormone secretion was not 
altered by BMP7; yet, in the goat BMP7 increased FSHR and decreased LHR mRNA 
expression; whereas, BMP7 increased FSHR expression in humans (Shi, et al. 2010, Zhu 
2013). Differences in response are likely to be due to granulosa cells either being luteinised, 
caused by the addition of serum during culture, or the granulosa cells being collected after 
the LH surge in humans. 
 
BMP6 is produced in both granulosa cells and the oocyte in humans and other animals 
(Glister, et al. 2004b, Khalaf, et al. 2013, Wu, et al. 2007). BMP6 is involved in proliferation, 
steroidogenesis and cytodifferentiation of granulosa cells in a species specific manner in the 
ovary. In addition, BMP6 inhibits pituitary secreted FSHβ and the concentration of FSH in 
sheep (Faure, et al. 2005). In the goat, BMP6 did not increase granulosal FSHR, yet it had a 
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dramatic increasing effect on LHR (Zhu 2013). In humans, BMP6 increased FSHR mRNA 
whereas, in the rat its effect was downstream of the FSHR (Ogura Nose, et al. 2012, Otsuka, 
et al. 2001a). BMP6 has been shown to increase proliferation of granulosa cells, compared to 
BMP2 or BMP4, in cultured sheep granulosa cells. In the rat, however BMP6 had no effect 
on granulosa cell proliferation (Campbell, et al. 2006, Otsuka, et al. 2001a). 
 
BMP15 is exclusively secreted by the oocyte and has a strong affinity for BMPR1B in sheep 
and humans, yet bind precociously in mice, indicating that substantial species differences 
exist (Inagaki and Shimasaki 2010, Pulkki, et al. 2012). In primary follicles, the expression of 
BMP15 mRNA progressively increased from primary follicles, peaking in sheep early antral 
follicles, followed by a sequential decrease in the antral follicle (Feary, et al. 2007). In 
humans, BMP15 is secreted across a concentration gradient from the oocyte via the cumulus 
cells to the granulosa cells and has been shown to suppress apoptosis (Hussein, et al. 2005). 
Oocytes surrounded by cumulus cells with greater levels of BMP15 mRNA were shown to 
have an increased pregnancy rate after IVF (Li, et al. 2014) and reduced apoptosis (Hussein, 
et al. 2005). Moreover, an association between high levels of BMP15 in the follicular fluid 
and oocyte quality has been reported (Li, et al. 2014, Wu, et al. 2007).  
 
Ovulation rate may be associated with a reported increase in BMP15 in the Booroola 
mutation (Crawford, et al. 2011, Feary, et al. 2007). Furthermore, in the pituitary, BMP15 
has been associated with increasing FSHβ expression (Otsuka and Shimasaki 2002). It has 
also been shown that BMP15 decreased FSH-induced progesterone biosynthesis by 
decreasing FSHR mRNA, ultimately inhibiting luteinisation. (Moore, et al. 2003, Otsuka and 
Shimasaki 2002). In parallel, BMP15 promoted granulosa cell mitosis independent of FSHR-
Smad 1,5,8 pathway via activation of the ERK 1/2 pathway (Lee, et al. 2001, Moore, et al. 
2003, Otsuka, et al. 2001b, Shimasaki, et al. 1999). 
 
AMH and BMPs belong to the TGFβ family, and have an affinity to bind to both BMPR1B 
and BMPR1A. AMH therefore, may be involved in the complex interaction of cellular 
regulation of folliculogenesis in the Booroola. AMH peaks in the small antral follicles, 
followed by a decrease at the time of dominant follicle selection (Rice, et al. 2007). In sheep 
and humans, AMH is not present in granulosa cells from large antral follicles; however, it is 
present in the cumulus cells (Campbell, et al. 2012, Weenen, et al. 2004). AMH has been 
shown to be inhibitory to primordial follicle activation, and declines with a decrease in 
activin and FSH after dominant follicle selection (Rice, et al. 2007). 
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When AMH is blocked directly, the ovulation rate was shown to increase, whereas mitogenic 
activity of granulosa cells remained the same (Campbell, et al. 2012). AMH attenuation has, 
therefore, been identified as a possible contributor to the observed increase in ovulation rate 
of the mutation-affected Booroola sheep. When AMH binds to a specific type 2 TGFβ 
receptor, AMHR2 and the type 1 receptor, BMPR1B, phosphorylation of the Smad 1,5,8 
pathway takes place and results in gene transcription which regulates folliculogenesis (Josso 
and Clemente 2003). AMHR2 has been identified in the transitional follicles between 
primary and secondary follicles, but not in primordial follicles (Rice, et al. 2007). Recently, 
the link between the production of AMH and BMP has been made in sheep follicles, whereby 
BMP4, 6, and 15 increased the transcriptional activity of the AMH promotor activity via SF-
1 (Estienne, et al. 2015). In addition, human granulosa cells cultured with BMP6 showed 
increased AMH mRNA (Shi, et al. 2009b); and AMH induced the BMP-specific inhibitory 
Smad 6, and induced the Smad 1,5,8 pathway to activate BMP specific reporter genes (Josso 
and Clemente 2003).  
 
The interaction between BMP and AMH indicates a strong connection between the role of 
the BMPs and AMH, and the gonadotrophin-dependent regulation of ovulation rate. It still 
remains unclear as to why the immunisation against AMH increased ovulation rate but did 
not reduce proliferation of granulosa cells, as seen with the Booroola mutation. A possible 
explanation may be related to the stage-specific down-regulation of AMH after dominant 
follicle selection. The greatest mitogenic activity of granulosa cells occurs after divergence 
when AMH is low, whereas dominant follicle selection occurs when AMH is normally 
peaking (Austin, et al. 2001). Immunisation against AMH alone would therefore, increase 
ovulation rate but not granulosa cell proliferation. Immunisation against BMPR1B or an 
attenuating mutation such as the Booroola, would affect both proliferation and ovulation rate. 
2.4.1 Conclusion: BMP 
Substantial research has provided evidence of the contribution several BMP ligands provide 
in the cellular regulation of folliculogenesis in a variety of models. The overwhelming 
position is that the BMPs have a significant role in folliculogenesis to inhibit the onset of the 
LH surge from the anterior pituitary, and to promote proliferation of the follicular cells. In 
addition, BMPs inhibit cytomorphological changes, and steroidogenic differentiation of the 
granulosa cells into granulosa-lutein cells, thus acting as luteinisation inhibitors.  
2.5 Booroola Merino Sheep and Ovulation Rate 
The Booroola Merino (Figure 2.5.1) with a naturally occurring point mutation of the 
BMPR1B mutation has an increased ovulation rate (Fabre, et al. 2006, Mulsant, et al. 2001, 
Souza, et al. 2001, Wilson, et al. 2001). The response of both the ovary and the pituitary to 
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gonadotrophic stimulation appears responsible for the increased ovulation rate of the 
Booroola mutation (Campbell, et al. 2003, Fry, et al. 1988, Hampton, et al. 2004, Hudson, et 
al. 1999). In the past, it has been recognised that the increase in ovulation rate in the 
Booroola is due to the follicles being more sensitive to FSH at an earlier follicle size (Baird 
and Campbell 1998, McNatty, et al. 1985). BMPR1B is the common receptor for several 
BMP ligands that form a receptor ligand complex and activate either the Smad signalling 
pathway or an alternative non-Smad pathway such as the MAPK pathways (Kang 2001, 
Miyazono, et al. 2010). 
2.5.1 BMPs ligands and the Booroola mutation 
In support of the dynamic role of BMPs, it has also been shown that BMP6 reduces post-
dominant follicle selection in the rat, and is reduced completely in the ovulating dominant 
follicle (Erickson and Shimasaki 2003). Similarly, BMP15 and BMPR1B expression in the 
oocyte were down-regulated prior to ovulation in sheep (Feary, et al. 2007). In cultured rat 
granulosa cells, BMP15 reduced the expression of FSHR mRNA (Otsuka, et al. 2001b). In 
the goat and human, BMP2, 4, and 7 ligands have been shown to increase the level of FSHR 
mRNA and BMP6 increased LHR mRNA, which indicates a direct role in the regulation of 
receptor density (Ogura Nose, et al. 2012, Zhu, et al. 2013). It is possible that the attenuating 
mutation of the BMPR1B signal may therefore, reduce the suppression, and lead to an up-
regulation of FSHR in the Booroola, increasing the ovulation rate (Otsuka, et al. 2001c, 
Regan, et al. 2015).  
 
Figure 2.5.1 Wild type Merino sheep, Armidale NSW. 
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2.5.2 Booroola Mutation and the LHR 
The process of luteinisation appears to rely on LHR down-regulation in the leading dominant 
follicles, (Figure 2.7.1) (Fan, et al. 2009, Izadyar, et al. 1998b, Regan, et al. 2015). 
Furthermore, LHR density peaks in the pre-ovulatory follicle in the wild type (WT) and the 
Booroola, followed by a significant reduction in the leading dominant follicle during the LH 
surge which was also observe in human and rodent studies (Jeppesen, et al. 2012, LaPolt, et 
al. 1992, Ophir, et al. 2014, Regan, et al. 2015).  
2.5.3 Booroola mutation and follicle size and granulosa cell number 
The Booroola sheep follicles contained significantly fewer granulosa cells than the normal 
wild type (Campbell, et al. 2006, McNatty, et al. 1985). Studies conducted on the granulosa 
cells show that when stimulated in vitro with LH or FSH they produced more cAMP and 
oestrogen, from the same number of cells from the large antral follicle (Campbell, et al. 
2006). An increased capacity to deliver oestrogen would compensate for the reduced number 
of granulosa cells; however, the cellular mechanism has not been identified. In addition, the 
Booroola granulosa cells were reported to be more responsive to the BMP ligands than the 
wild type (Campbell, et al. 2006). Taken together, it is apparent that the multiple follicles are 
more responsive to gonadotrophin stimulation, yet they have reduced follicle cell number, 
which is attributed to the attenuated signalling of BMPR1B. 
2.5.4 Immunisation Sheep and Ovulation Rate 
In sheep, short term immunisation against BMP15 increased the ovulation rate from 1-2 to ≥3 
without affecting plasma progesterone concentration. (Juengel, et al. 2004, Juengel, et al. 
2011). In another study, complete neutralisation of BMP15 prevented exogenous FSH 
induced rescue that resulted in anovulation, which indicates that BMP15 is required for 
FSHR transcription (McNatty, et al. 2009). Sheep infused with BMP6 showed a reduced 
cycle length and size of the pre-ovulatory follicles (Campbell, et al. 2009). Although the 
effect of the infusion was short-lived the oestrogen and androstenedione increased with no 
change to the ovulation rate. In the Booroola, a combination of BMP15 and BMP6 
attenuation may be responsible for the reduced mitogenic activity and the increased ovulation 
rate. 
2.5.5 A BMP15-specific Mutation, Inverdale 
BMP15 has been associated with an increase in ovulation rate in sheep with specific 
mutations (Hanrahan, et al. 2004, McNatty, et al. 2009). Heterozygous Inverdale sheep with 
an inactivation mutation for BMP15 exhibit an increase in ovulation rate, whereas, the 
homozygous did not progress past primary follicle growth (Braw-Tal, et al. 1993, McNatty, 
et al. 2009).  
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2.6 Ovarian Ageing 
In human subjects a decline in the ovarian reserve of primordial follicles leads to a relative 
dysregulation of folliculogenesis and ovulation. The change to the micro-environment of the 
ovary and circulating hormone levels are responsible for the reduced fertility and a reduction 
in the quality of the ovulating oocyte (Klein N A, et al. 1996). Older patients typically have 
increased circulating FSH and reduced inhibin B, which gives rise to accelerated early 
follicle development and results in a shorter cycle length (MacNaughton, et al. 1992, 
Robertson 2009, Santoro, et al. 2003, Seifer, et al. 1999). In poor ovarian reserve patients, the 
later stages of follicular growth have a reduced rate of growth which reduces maturation of 
the follicle and oocyte (Santoro, et al. 2003). The granulosa cell proliferation was found to be 
reduced and the size of the follicle to be smaller in older patients (Bomsel Helmreich, et al. 
1979, Robertson 2009, Seifer 1996 , Seifer, et al. 1993).  
 
The follicle increases its capacity to produce oestrogen by increasing the number of 
granulosa cells, by increasing the size of the follicle and not the thickness of the granulosa 
layer (Bächler, et al. 2014). A shorter cycle and a reduction in the follicle size due to ovarian 
ageing would reduce the capacity of the follicle to produce sufficient oestrogen to down-
regulate pituitary FSH during dominant follicle selection. Potentially, reduced oestradiol 
output could also disrupt the positive feedback mechanism responsible for generating the pre-
ovulatory LH surge. Over thickening of the granulosa layer may also compromise oocyte 
quality if the diffusion rate changes the concentration gradient of serum to follicular fluid, 
FSH and LH (Bächler, et al. 2014). The lower density of the receptors have also been 
implicated in the reduced fertility, with a decline in ovarian reserve (Bächler, et al. 2014). In 
addition, it remains to be confirmed if the elevated FSH from the previous cycle causes early 
growth of the small antral follicles in the following cycle (Bomsel Helmreich, et al. 1979, 
Robertson 2009).  
 
In several studies in humans the magnitude of the LH surge has not been found to be 
significantly different (Klein N A, et al. 1996, Leach, et al. 1997, MacNaughton, et al. 1992, 
Pal, et al. 2010, Santoro, et al. 2003). Several inconsistencies exist in these studies, centring 
on the classification of old and poor ovarian reserve based on day three FSH level; or when 
the LH level of the follicular phase was recorded (on day 2 and 7). Convincing data from 
another study showed that the amplitude of the LH surge in the mare, is reduced with age 
(Ginther, et al. 2008). In the oldest mares the largest follicle was reduced in size and fewer 
follicles were present. 
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2.7 Ovarian Apoptosis 
The ovulation rate is generally governed by the number of follicles growing during a cycle, 
(Figure 2.1.2). Follicle growth is limited by the number of activated primordial follicles and 
the stimulation to continue growth to ovulation. Gonadotrophins FSH and LH govern the 
growth rates of the follicles particularly during the later stages of folliculogenesis. The level 
of gonadotrophin receptor density controls the response of the follicles to the stimulation 
from the anterior pituitary. Intraovarian growth factors, such as the BMPs, activins and 
inhibin, impact the receptor expression that ultimately controls the growth rate of the follicle. 
Reduced growth leads to an accumulation of precursor molecules (e.g. androgens) that can 
stimulate signalling pathways to induce programmed cell death or apoptosis. Apoptosis of 
granulosa cells with low responsiveness to FSH (within subordinate follicles) establishes the 
dominant follicle that continues to grow to ovulation (Yuan and Giudice 1997).  
2.7.1 Necrosis and Apoptosis 
Necrosis and apoptosis both culminate in cell death of the granulosa cell and nucleic dyes are 
commonly used to indicate the vitality of the cell (Figure 2.7.1) (Demchenko 2013). Necrosis  
results from a toxic or destroying exposure that causes swelling and disruption to the cell’s 
organelles that results in an irreversible breakdown of the cell’s membranes and the 
scattering of the cytoplasmic and nucleic contents (Bonfoco, et al. 1995). Apoptosis however, 
is caused by several distinctive signalling pathways which culminates in shrinkage of the 
cell, cytoplasmic blebbing, and compartmentalisation of organelles (Figure 2.7.2) 
(Amsterdam, et al. 1997, Bomsel-Helmreich, et al. 1979, Nottola, et al. 2006, Tilly 1992). 
The DNA condenses and genomic fragmentation evidenced by DNA laddering is typical 
(Guraya 1971). Although the cell membranes lose integrity they fold and encapsulate to 
prevent the contents from affecting neighbouring cells, and reorganisation of lipid/protein 
storage clustered around the nucleus (Figure 2.7.2) (Nottola, et al. 2006).  
 
 
 
 
 
 
 
 
 
Figure 2.7.1 Isolated granulosa cells and cell membrane integrity. 
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Trypan Blue indication of membrane breakdown in A, and exclusion of the dye in B. 
 
Figure 2.7.2 Granulosa cell, peri-luteal phase, showing extrusion of cytoplasm during 
apoptosis, and reorganisation of lipid/protein storage clustered around the nucleus. 
2.7.2 Primordial Follicle Apoptosis 
Initial recruitment or activation of the primordial follicles results in the progression from 
primary to secondary, to the pre-antral stage, (Figure 2.7.3). The formation of the fluid filled 
space signifies the development of the small antral follicle (Rodgers and Irving-Rodgers 
2010a). The cause of the extreme loss of primordial follicles during gestation to puberty 
remains controversial (Figure 2.1.1). Furthermore, apoptosis was not found in human 
primordial, primary and secondary follicles (Figure 2.7.3 12) (Abir, et al. 2002, Albamonte, 
et al. 2013, Yuan and Giudice 1997). However, secondary follicles just before antral follicle 
formation were found to exhibit apoptosis, (within the limits of the assay) (Negoescu, et al. 
1996, Yuan and Giudice 1997)). In contrast, ovarian foetal germ cells, in mice, underwent 
BAX-induced apoptosis regulated by aromatic hydrocarbon receptor transcription factor 
(AHR) (Matikainen, et al. 2002).  
Sheena Regan 2015 
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Follicle 1 
Healthy 
 
Follicle 2 
Atretic 
 
Figure 2.7.3 The level of apoptosis during follicle development 
Modified based on Yuan and Giudice, 1997.  
Apoptosis in the bovine ovarian follicle can be divided into two phenotypes with potentially 
different mechanisms of initiation and regulation (Irving-Rodgers, et al. 2003). The first, 
antral atresia, affects the antral granulosa cells, and progresses from the antrum towards the 
basal lamina. The second, basal atresia, occurs in the cells closest to the basal lamina 
membrane of small antral follicles. The cells luteinise and begin producing progesterone; 
however, they do not complete luteinisation and perish (Irving-Rodgers, et al. 2003). 
2.7.3 Hormonal Ratio of Oestrogen and Androgens 
The majority of apoptosis occurs in the antral granulosa cells during follicular development. 
The antral atretic granulosa cells have reduced oestrogen output compared to healthy 
follicles, and low progesterone in comparison; however, determination of the health status of 
a follicle, based on the ratio of oestrogen to progesterone or morphological differences are 
poor indicators of whether or not a follicle is atretic (Grimes, et al. 1987). In particular, a 
high progesterone level may be indicative of luteinisation of the granulosa cells as opposed to 
apoptosis (Grimes, et al. 1987). More recent data show that apoptosis increases dramatically 
around the time of dominant follicle selection when the ratio of androgen was greater than 
oestrogen (Figure 2.7.4).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.7.4 Apoptosis induced DNA Fragmentation in human small antral follicles. 
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Follicle 1 is healthy with a greater concentration of oestrogen than androgen due to the early 
acquisition of FSHRs, at the time of dominant follicle selection and the decline in pituitary FSH. 
Follicle 2 has insufficient FSHRs to induce LHRs. Based on data from (Yuan & Giudice 1997, Bao & 
Garverick 1998, Austin et al. 2001, Sen et al. 2014) 
The early acquisition of granulosal FSHR and LHR accelerates the dominant follicle growth 
as the pituitary FSH declines (Figure 2.7.4) (LaPolt, et al. 1992, Sen, et al. 2014). The LHR 
supplement the FSHR-mediated conversion of androstenedione to oestradiol by CYP19A1, 
maintaining a positive oestrogen to androgen ratio in the follicle. As the antral follicle 
increases in size, more oestrogen and anti-apoptotic factors are produced that ensures the 
survival of the dominant ovulatory follicle (Amsterdam, et al. 2003). With reduced FSHR 
and LHR density, the granulosa cells of subordinate follicles have a reduced capacity to 
convert theca derived androgens to oestrogen (Figure 2.7.4), and are destined for atresia 
(Hillier, et al. 1994a, Xu, et al. 1995).   
2.7.4 Factors that Activate Specific Signalling Pathways  
Apoptosis can be initiated by a number of factors that activate specific signalling pathways to 
trigger apoptotic mechanisms (Figure 2.7.5) (Amsterdam, et al. 2003, Matsuda, et al. 2012, 
Nottola, et al. 2006). Conversely, many growth factors such as FSH, and LH, are anti-
apoptotic which creates a micro-environment that ensures survival. During the highly prolific 
phase of folliculogenesis apoptosis is reduced by the inhibition of apoptotic signalling 
pathways by various growth factors. The BMP ligands have been shown to inhibit apoptosis 
signalling in a number of studies (Figure 2.7.5) (Hussein, et al. 2005, Kayamori, et al. 2009). 
BMP7 activated caspase 9 in granulosa cells, however, BMP4 and 7 had no effect on the 
levels of mitochondrial apoptotic factors, BAX and Bcl-x1 mRNA (Kayamori, et al. 2009). 
Cumulus granulosa apoptosis was reduced by BMP6, 7, and 15 (Hussein, et al. 2005). 
 
In vitro culture of caprine (goat) granulosa cells with BMP2, 4, 6, and 7 reduced apoptosis  
indicated by Hoechst 33342 staining and percentage DNA fragmentation (Zhu 2013). In the 
same study, FSHR silencing increased apoptosis significantly, whereas, BMP2, 4, and 7 
increased FSHR (Zhu 2013). The very low incidence of apoptosis in cumulus cells compared 
to granulosa cells has been reported to be due to the oocyte-secreted BMP6 and BMP15, 
forming a concentration gradient radiating out from the oocyte (Hussein, et al. 2005). In bone 
tissue BMP2 signalling via the BMPR1B, induced apoptosis, indicated by an increase in 
caspase 3, 6, 7, and 9. The action occurred independently of cell proliferation induced by 
BMP2, highlighting the dual action capability of BMPs (Haÿ, et al. 2004). 
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Figure 2.7.5 Diagram of Apoptosis induced by various factors and the involvement of the 
BMP ligands. 
 
There are two major pathways for the development of apoptosis in granulosa cells 
(Amsterdam, et al. 1997, Amsterdam, et al. 2003, Austin, et al. 2001). The first affects the 
mitochondrial function via BAX activation, and the second is via high levels of cAMP 
through granzyme B or caspases downstream of tumour necrosis factor alpha (TNFα) (Figure 
2.7.5). The steroid producing capacity of a follicle is reflected in the hormone levels in serum 
and follicular fluid from the antral cavity of the follicle (Amsterdam, et al. 2003). In an 
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apoptotic granulosa cell, DNA fragmentation, cytoplasmic blebbing and 
compartmentalisation of organelles protects the functional steroid capacity of the cell to 
ensure the maximum oestrogen synthesis. This protective mechanism involves reorganisation 
of the actin cytoskeleton to prevent contamination with neighbouring cells, and to centralise 
the still functioning mitochondria (Figure 2.7.6).  
 
Figure 2.7.6 Granulosa cell steroidogenic function during p53-induced apoptosis. 
Immortalised granulosa cells; n = nucleus, b = blebbing, m = mitochondria, v= microvlli. (A) 
Numerous mitochondria and apoptosis induced cytoplasmic blebbing (10 000 x). (A1) Actin 
cytoskeloton (red) StAR mitochondrial protein (green). (B) Condensed chromatin in the nucleus and 
blebbing (10 000 x).  (B1) Central reorganisation of the cytoskeloton. (C) Mitochondria with well 
defined crystae (indicate luteisation) (30 000 x) (Amsterdam, et al. 1999, Hosokawa, et al. 1998). 
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CHAPTER 3 GENERAL METHODS 
3.1 Sheep: Animals, ovaries, and follicles 
A total of 17 Merino sheep with an average age of 4 years and 9 months ±2 months were 
used (Table 3.1:1 and Table 3.2:1). The animals were housed in open paddocks at the 
University of New England, NSW, Australia, in accordance with NH & MRC Code of 
Practice for the Care and Use of Animals for Experimental Purposes. All experiments were 
approved by the University of New England Animal Ethics Committee. Five ewes were 
genetically confirmed as homozygous Australian Booroola strain (BB); with a flock average 
ovulation rate of four to six during peak breeding season, (Cummins, et al. 1983) and an 
ovulation rate of three, based on the corpus luteum (CL) formation in two Booroola sheep at 
the time of slaughtering, because of miss timed ovulation. Subsequently, the remaining 
follicles after ovulation were classified as luteinised (Table 3.2:1). The corpora lutea formed 
in the post-ovulation groups were included in the total number of follicles recruited per 
genotype, and they were added to the largest follicle size for that genotype (Table 3.2:1). The 
oestrous cycles of these animals were synchronised using flugesterone acetate sponges 
(Bioniche Animal Health, Armidale, NSW, Australia). The sponges were removed from the 
animals 14 days after insertion, and the animals received an intra-musculature injection of 
1000 IU of pregnant mare's serum gonadotrophin (PMSG). The animals were euthanised 
approximately 36 hours after sponge removal, and the ovaries collected (Evans 2003).  
Table 3.1:1 The number of individual follicles analysed prior to ovulation and post 
ovulation. 
Corpus Luteum (CL) 
 
Genotype 
Sheep before 
ovulation 
Follicles 
 
Dominant 
follicles 
Small 
(1.0-2.1 mm) 
Medium 
(2.2-2.9 mm) 
Large 
(3.0-4.5 mm) 
Extra large 
(4.6-7.0 mm) 
WT 8 64 8 25 19 14 6 
BB 3 20 3 9 5 6 0 
Genotype 
 
Sheep post- 
ovulation 
Luteinized 
follicles 
CL per 
sheep 
Small 
(1.0-2.1 mm) 
Medium 
(2.2-2.8 mm) 
Large 
(3.0-4.5 mm) 
Extra large 
(4.6-7.0 mm) 
WT 4 35 1.5 13 14 8 0 
BB 2 10 3 7 2 1 0 
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3.2 Sheep: Collection of granulosa cells  
 
Figure 3.2.1 Booroola Merino Sheep raised by Dr Tim O’Shea at University of New 
England. 
 
Follicle size was established by preparing standard blank volumes of 5µl increments from 5 
to 160 µl; these were placed in identical PCR tubes and visually compared to the follicular 
fluid aspirated from each follicle based on previously published techniques (Andersen, et al. 
2010, Jakimiuk, et al. 2002). The blank values were used as a reference to estimate the 
diameter of the follicle, and cross-referenced with a direct measurement of the diameter of 
the follicle using a fine ruler gauge before aspiration. The follicular fluid was aspirated from 
all of the visible follicles using a 25 gauge needle, and placed in PCR tubes. All of the visible 
surface follicles were harvested, and very small follicles (1-1.8 mm) of the same size were 
pooled in groups of three or four; whereas, all the medium, large, and extra-large follicles 
were analysed individually (Table 3.1:1).  
 
On a follicle by follicle basis, an in situ incision was made at the exposed surface of the 
follicle with a scalpel; granulosa cells were gently scraped with the blunt side of the scalpel, 
flushed repeatedly with phosphate buffered saline (PBS), and re-suspended in PBS. The 
sheets of granulosa cells were dispersed by mechanical pipetting, and centrifuged at an 
optimised lower speed of 300 g for 5 min to protect the cells from method-induced apoptosis 
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and to yield an uncontaminated population of granulosa cells. Collection without excision of 
the whole follicle prevents contamination with the theca or stroma cells and limits the 
amount of contamination with blood cells (Figure 3.2.1 and Figure 3.2.2).  
Figure 3.2.2 Collection of sheep ovaries. 
 
Based on the hierarchical down-regulation previously reported, the sheep follicles were 
divided into subordinate, dominant, and luteinised post ovulation follicles (Driancourt, et al. 
1985, Evans 2003). The largest follicle collected from each sheep before ovulation was 
classified as the dominant follicle, and the remaining follicles were classified as subordinated 
follicles Figure 3.2.3 (Gasperin, et al. 2014).  
 
 
 
 
Figure 3.2.3 An ovary and uterus from a wild type Merino sheep, showing a leading 
dominant follicle. 
 
 
 
Unstimulated abattoir 
Sheep, 3 years   
Synchronised wild type 
Merino Sheep, 4 years 
 
Synchronised Booroola 
Merino Sheep, 4 years 
Sheena Regan 2015 
Sheena Regan 2015 
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Table 3.2:1 Follicle size validation using follicular fluid collected from BB follicles. 
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Table 3.2:2 Follicle size validation using follicular fluid collected from WT follicles. 
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3.3 Human: ovaries and follicles 
A total of 487 follicles were collected from 68 patients undergoing standard fertility 
treatment previously reported in accordance with the PIVET Medical Centre Algorithm 
(Yovich, et al. 2012). Follicles were collected irrespective of previous aetiology, but limited 
to exclude, unusual medical conditions, hormonal dysfunction, and polycystic ovarian 
syndrome (PCO); patients were aged between 23 and 45 y (Table 3.3:1). Informed consent 
was obtained for the use of the follicular fluid samples collected during oocyte retrieval for 
the purpose of IVF and embryo transfer. Approval by the Human Research Ethics Committee 
of Curtin University of Technology was obtained for this study (HR RD26-10:2010-2016). 
One patient out of three patients undergoing risk reduction removal of the uterus and ovaries, 
was selected to represent an unstimulated natural healthy cycle prior to the LH surge, and 
was recruited from King Edward Memorial Hospital (KEMH) approved by the Women and 
Newborn Health Service ethics committee (WNHS). 
 
Table 3.3:1 Patient ovarian reserve, based on antral follicle count (AFC) and the number 
of follicles collected per group. 
 
Ovarian reserve measured indirectly by the Antral Follicle Count (AFC). AFC is the number of 
follicles between 2-10 mm on day 2-5 of a cycle: A+ = 30-39 follicles; A = 20-29; B = 13-19; C = 9-
12, D = 5-8; E = ≤4. 
 
3.3.1 Human IVF: Ovarian stimulation, follicular fluid and oocyte. 
Patient treatment consisted of one of three types of GnRH-LH suppression in conjunction 
with rFSH, from cycle day 2 (Puregon or Gonal F). A GnRH antagonist treatment (Cetrotide) 
(0.25 μg/day) was administered from day seven until ovulation induction. Alternatively, a 
GnRH flare agonist treatment (Lucrin) (0.25 μg/day) was administered in conjunction with 
rFSH on day 2, or a long agonist GnRH treatment (Synarel) (0.25 μg/day) on day 21 of the 
previous cycle, until ovulation induction. Ovulation was triggered with either 10 000 IU hCG 
derived from a urinary preparation (Pregnyl) or a pituitary derived analogue to LH (Ovidrel). 
Oocyte retrieval was scheduled for 36 hours post-trigger, by transvaginal oocyte aspiration 
(TVOA) (Yovich and Stanger 2010).  
 
AGE 
IVF 
patient 
Total  
follicle 
AFC 
Major 
Group 
Total  
Follicle 
Sub 
Group 
# 
Sub 
Group 
# 
Sub 
Group 
# 
Sub 
Group 
# 
21-30 11 101 20-40 A+ & A 96 A++ 14 A+ 31 A 64   
31-34 11 86 13-29 A & B 86 A 60 B 26 C 17   
35-39 16 102 9-19 B & C 66 A+ 6 B 50 C 16 D&E 30&6 
40-45 18 118 3-8 D & E 78 D 59 E 19 B 34 C 6 
40-45 GH 11 78 3-8 D & E 47 D 22 E 23 B 16 C 5 
40 Natural Cycle Healthy D 2       
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3.3.2 Human GH co-treated: Ovarian Stimulation  
Ovarian cycles were stimulated with fertility drugs (described above), in order to promote 
follicle development (Yovich, et al. 2012). GH was administered to 11 patients on day 21 of 
the previous cycle, and on day 2, 6, 8, 10, and 12 of the current cycle. In addition, the 
criterion for selection was based on women who had generated less than three metaphase II 
oocytes with maximum rFSH stimulation of 450 IU/day (Yovich and Stanger 2010). Poor 
ovarian response patients with three or more failed attempts to conceive through IVF 
treatment with gonadotrophin alone, were co-treated with a total of 10 IU GH, (Saizen, 
Serono, Australia).  
3.4 Antral follicle count  
Patients received rFSH based on the patients’ profile of age and AFC, to predict the rFSH 
dose required to stimulate multiple pre-ovulatory follicles (Figure 3.4.1). 
 
 
 
 
Figure 3.4.1 IVF exogenous rFSH dose with increasing age and declining antral follicle 
count. 
Based on data from Yovich et al, 2010. 
 
Ovarian reserve was measured indirectly by the antral follicle count (AFC). AFC is the 
number of follicles between 2-10 mm in size that are present on day 2-5 of a cycle. 
Determination of AFC was determined by transvaginal ultrasound and divided into groups 
based on the number of follicles counted, between 2 and 10 mm; group A++ 40+ group A+ = 
30-39 follicles; group A = 20-29; group B = 13-19; group C = 9-12, group D = 5-8; group E 
= ≤ 4 (Table 3.3:1) (Yovich, et al. 2012)  
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3.4.1 Human IVF & GH co-treated: Collection of Granulosa Cells 
The diameter of the follicle was calculated using ultrasound before the clinical aspiration of 
individual follicles (Figure 3.4.2). The first aspiration was collected without flush medium 
into a test tube, and handed to the embryologist to locate the oocyte and attached cumulus 
cells if present. Further flushing of the follicle (Quinn’s Advantage with Hepes, Sage Media, 
Pasadena, California) removed the loosely attached granulosa layers of cells at~ 1.24-1.72 
MPa. Once the oocyte was located and removed, the clinician proceeded to the next follicle 
and repeated the process (Figure 3.4.2).  
Figure 3.4.2 Ultrasound measurement of human follicles. 
(A) Gonadotrophin induced multiple follicles in a human ovary. (B) Ultrasound measurement of a 
follicle in a human ovary, bar 7.95 mm. 
Figure 3.4.3 Follicular fluid and flushing media from individual follicles. 
Individual follicle collection, of follicular fluid, and flush media 
Sheena Regan 2015 
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The sample of medium and granulosa/follicular fluid was then layered onto a histopaque 
ficoll gradient (Sigma Aldrich: Castle Hill, Australia) and centrifuged at 250 g for 30 min at 
25 ºC (Figure 3.4.3). The supernatant was removed and centrifuged at 300 g for 5 min, 
leaving behind the pellet of granulosa cells and approximately 300 µl of supernatant. The 
pellet was dispersed with gentle pipetting to manually separate the sheets of granulosa cells. 
Theca cells are bound by collagen fibers, and vaginal epithelium cells are very large, and if 
present, would have remained in the blood pellet after the first centrifuge or would be gated 
out during flow cytometric analysis (Whiteman, et al. 1991) 
 
 
 
 
Figure 3.4.4 Isolation of human granulosa cells from individual follicles. 
Ficoll gradient used to isolate granulosa cells; pink media at the top, granulosa cells at the interface, (at 
5 ml mark) and red blood pellet at the bottom of the test tube.  
3.4.2 Natural healthy unstimulated cycle collection  
The natural cycle patients scheduled for risk reduction (such as cancer) removal of the 
reproductive organ was timed to coincide with day 12 of the menstrual cycle. Before 
removal, ultrasound confirmation of the size of the follicles and the number of follicles 
present was made. After removal of the uterus and ovaries, the whole follicle was excised, 
and transported to the laboratory. The collection of follicular fluid, isolation of the granulosa 
cells and the analysis was performed as described above and below (Figure 3.4.5, Figure 
3.4.6 and Figure 3.5.1 ). 
Sheena Regan 2015 
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Figure 3.4.5 Human ovaries and uterus removed from an unstimulated healthy patient. 
Figure 3.4.6 Human ovaries, uterus and cervix. Recovery of a 10 mm follicle for collection 
of granulosa cells from KEMH. 
3.5 Immunolabelling  
3.5.1 Sheep: Immunolabelling sheep  
Aliquots of suspended granulosa cells (1x10⁶ cells in 100 µl) were immunolabelled using a 
double-indirect method as previously described (Abir, et al. 2008a, Cai, et al. 2007, Gao, et 
al. 2007). The cells were incubated separately with an optimised concentration of 4 μg/ml 
affinity purified polyclonal antibody to BMPR1B, FSHR or LHR, for 25 min at 5 ˚C 
(Millennium Science, Surrey Hills, Victoria Australia). Previously, we have established the 
Sheena Regan 2015 
Sheena Regan 2015 
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specificity in sheep, using immunofluorescence detection and 3D image analysis (Al-
Samerria and Almahbobi 2014 ).  
Figure 3.5.1 Natural healthy cycle human ovarian follicle removed from an ovary. 
 
The antibodies were polyclonal goat anti-BMPR1B (sc-5679), goat anti-FSHR (sc-7798) and 
goat anti-LHR (sc-26341), (Santa Cruz Biotechnology, Santa Cruz, CA, USA); anti-goat 
second antibody conjugated with Alexa 488 (Al-Samerria and Almahbobi 2014 ). In addition, 
the antibodies have been previously reported in human studies (Abir, et al. 2008a, Cai, et al. 
2007, Gao, et al. 2007, Haÿ, et al. 2004, Pidoux, et al. 2007); and using flow cytometry (Gao, 
et al. 2007). Immunolocalisation of LHR in human placental trophoblast demonstrated 
positive, strong staining with hCG, and no staining was observed in nonspecific isotypic 
negative controls (Pidoux, et al. 2007). In the same study, RT-PCR products were sequenced 
and confirmed to be LHR fragments (Pidoux, et al. 2007). BMPRIB, FSHR, and LHR were 
raised against a sequence of amino acids of human origin, with 88%, 80%, and 93% 
sequence identity to the sheep protein, respectively. Donkey anti-goat IgG conjugated with 
Alexa 488 (Life Technologies Australia, Victoria, Australia), with excitation wave length 
495 nm and an emission wave length 519 nm, was applied at an optimised concentration of 4 
μg/ml for 25 min and was repeat washed in PBS. Blocking peptides for BMPR1B and FSHR 
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indicated nonspecific binding applied to human granulosa cells (sc-5679P, sc5679P; 
Millennium Science, Surrey Hills, Victoria Australia), as previously published (Abir, et al. 
2008a, Cai, et al. 2007, Gao, et al. 2007, Haÿ, et al. 2004, Pidoux, et al. 2007).  
3.5.2 Human & GH co-treatment: Immunolabelling  
Aliquots of suspended granulosa cells (1x10⁶ cells in 100 µl) were immunolabelled using a 
double-indirect method as previously described (Abir, et al. 2008a, Cai, et al. 2007, Gao, et 
al. 2007). The cells were incubated separately with an optimised concentration of 4 μg/ml 
affinity purified polyclonal antibody to BMPR1B, FSHR, LHR or GHR for 25 min at 5 ˚C 
Previously, we have established the specificity in sheep, using immunofluorescence detection 
and 3D image analysis (Al-Samerria and Almahbobi 2014 ). The antibodies were polyclonal 
goat anti-BMPR1B (sc-5679), goat anti-FSHR (sc-7798) and goat anti-LHR (sc-26341), 
(Santa Cruz Biotechnology, Santa Cruz, CA, USA), and GHR (AF1210; Life Technologies, 
Victoria, Australia). In addition, the antibodies have been previously reported in human 
studies (Abir, et al. 2008a, Bozzola 1998 , Cai, et al. 2007, Gao, et al. 2007, Haÿ, et al. 2004, 
Pidoux, et al. 2007, Regan, et al. 2015, Weall, et al. 2014); and using flow cytometry (Gao, et 
al. 2007). 
 
Figure 3.5.2 Isolated granulosa cells from individual follicles, immunolabelled receptors. 
Sheena Regan Curtin University 2013.  
 
Sheena Regan 2015 
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The cells were washed with PBS and centrifuged at 300 g at 5˚C for 5 min. The routinely 
used monoclonal antibody CD45 was added to BMPR1B, GHR and LHR tubes to enable the 
subtraction of the positive leukocyte common antigen (~ 3%) not removed during isolation of 
the granulosa cells with the ficoll gradient, (555485; BD Biosciences, Perth, Australia).  
3.6 Flow cytometry  
3.6.1 Sheep: Flow cytometry  
The samples were prepared as a single cell suspension, stained for flow cytometric analysis, 
and immediately processed using a LSRII flow cytometer (BD, North Ryde, NSW, 
Australia). The data were analysed using FlowJo software (Figure 3.5.2) (Tree Star Inc., 
Ashland, OR, USA). Selective gating of the whole sample to identify a pure granulosa cell 
population with an average of ~4000 granulosa, was achieved by graphing forward scatter 
(increasing size) on the y-axis, and fluorescent intensity (Alexa 488) on the x-axis. A large 
gating box excluded small cellular fragments along the x-axis (letter ‘c’) and cell doublets on 
the top border (letter ‘d’), (Figure 3.6.1A and B). 
 
The resulting population was graphed on a histogram for the number of granulosa cells and 
the density of receptors (letters ‘a’ and ‘b’, Figure 3.6.1A and B). Negative control samples 
were assessed either as unstained samples or by the substitution of primary antibody with 
pre-immune goat IgG (Figure 3.6.2) (Millennium Science, Surrey Hills, Victoria Australia) at 
the same concentration as the primary antibody. The fluorescence intensity threshold gate at 
10³ (solid line) excludes emitted autofluorescence, number 4, and nonspecific binding 
number 1, 3, and 4, (letter ‘a’ combined Figure 3.6.1B).  
 
The resulting population contained a uniform granulosa cell population that revealed positive 
staining for the FSHR, which is unique to granulosa cells in the follicle (letter ‘b’ Figure 
3.6.1A and B) (Gao, et al. 2007, Stilley, et al. 2014). The predetermined gates were 
established and set for all of the samples. The positive quantitative signal (mean fluorescent 
intensity (MFI)) for the average granulosa cell receptor density  
(letter ‘b’) is indicated in Figure 3.6.1B. 
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Figure 3.6.1 Validation of the method of subtraction gating; removal of auto-fluorescence 
and nonspecific binding. 
(A) Flow cytometric dot plot, forward scatter representing size of cell, showing positively identified 
granulosa cells.  a; subtracted (gated box) cells due to either auto-fluorescence or nonspecific binding, 
b; average number of granulosa cells 4971; gating to exclude debris, c; and doublet cells, d. (B) 
Histogram of cell number and fluorescent intensity of the corresponding a, b, and d population in 
Figure A. Where b (blue) represents the mean granulosal receptor density; gated between 10³ and 10⁵, 
to exclude a, c and d combined. Nonspecific binding (2 = yellow); auto-fluorescence (4 = green); 1st 
antibody goat anti FSHR (1 = pink); and second antibody donkey anti goat (3 = red) combined (a) and 
gated at 10³ (c) and doublet cells, gated and >10⁵ (d) Scale arbitrary units. 
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Figure 3.6.2 Unstained control compared to IgG Isotope control for nonspecific binding 
and auto fluorescence. 
3.6.2 Human &GH co-treatment: Flow cytometry  
Selective gating of the whole sample to identify a pure granulosa cell population was 
achieved by graphing forward scatter to remove doublets (FSC-H verses FSC-A). Then 
Alexa Fluor 488 intensity against APC intensity to identify and gate the granulosa cells 
positively stained with antibody CD45, which emits in the Allophycocyanin (APC) spectrum. 
(Figure 3.6.3, and Figure 3.6.5).  
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Figure 3.6.3 Validation of spectral overlap exclusion.  
The samples were individually stained with antibodies with each follicle having a control unstained 
sample to increase accuracy and reduce spectral ovalap. 
Figure 3.6.4 Validation of gating to measure average receptor density in flow cytometry. 
An unstained sample control histogram and dot plot, FSHR expression with two peaks; the first peak is 
the auto-fluorescence and the second peak the positive population measured. The unstained control 
and the FSHR was overlayed to validate the gates used in analysis. 
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Figure 3.6.5 Measurement of mean receptor density using subtraction gating to remove 
auto-fluorescence and non- specific binding. 
Measurement of receptor density of receptors. 
 
Unstained samples or the substitution of primary antibody with pre-immune goat IgG (Figure 
3.6.2) (Millennium Science, Surrey Hills, Victoria Australia) at the same concentration of the 
primary antibody served as negative controls for auto-fluorescence; and blocking peptides for 
BMPR1B and FSHR indicating nonspecific binding, (sc-5679P, sc5679P; Millennium 
Science, Surrey Hills, Victoria Australia) as previously published (Abir, et al. 2008a, Al-
Samerria and Almahbobi 2014 , Bozzola 1998 , Cai, et al. 2007, Gao, et al. 2007, Haÿ, et al. 
2004, Pidoux, et al. 2007, Weall, et al. 2014). Immunolocalisation of LHR in human 
placental trophoblast demonstrated positive strong staining with hCG, while no staining was 
observed in nonspecific isotypic negative controls (Pidoux, et al. 2007). RT-PCR products 
sequencing confirmed the LHR fragments (Pidoux, et al. 2007). In the current study, the 
isotype goat IgG and unstained control MFIs were very similar for each individual follicle 
but different between follicles and patients; therefore, to optimise accuracy the auto-
fluorescence and the nonspecific binding was gated and subtracted for each individual 
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follicle (Figure 3.6.5 and Figure 3.6.6). The resulting population contained a uniform 
granulosa cell population that revealed positive staining for FSHR, which is unique to 
granulosa cells (Hermann and Heckert 2007). The data were analysed using FlowJo software 
(Tree Star Inc., Oregon, USA). 
 
 
 
 
 
Figure 3.6.6 Measurement of mean receptor density using subtraction gating to remove 
auto-fluorescence and non- specific binding. 
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3.6.3 Sheep & Human studies: Flow cytometry, Apoptosis 
The 7-AAD marker detects cell membrane disruption in cells undergoing DNA 
fragmentation apoptosis. However, the marker is limited because it does not differentiate 
between functionally intact mitochondria with cellular DNA fragmentation and combined 
mitochondrial and DNA total breakdown (Amsterdam, et al. 1997, Amsterdam, et al. 2003). 
In hindsight, a more appropriate detection of steroid capacity of a granulosa cell would be 
CYP19 (P450aromatase). The results however, are still valid because the level of DNA 
breakdown is a measure of cellular health, and further research is yet to determine how long 
the apoptotic luteal cells continue to contribute to steroidogenic activity in the corpus luteum, 
protected by the high levels of progesterone.  
Figure 3.6.7 Armidale NSW Collection, harvest and analyses of sheep samples. 
 
For the detection of apoptosis and necrosis, the assessment was applied on the same aliquots 
that were used for the immunolabelling of FSHR with a double-direct method, as previously 
described (Figure 3.6.7) (Demchenko 2013, Riccardi and Nicoletti 2006). Briefly, after 
washing the cells with the prescribed annexin V phospholipid-binding, calcium-dependent 
Separately immunolabelled granulosa cells 
from individual follicles. 
Arrival of sheep uterus and ovaries. 
Collection was spread over a two week 
period of time. 
Transported to CSIRO, Armidale, NSW. Flow cytometry CSIRO, Armidale, NSW. 
Sheena Regan 2015 
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buffer, a monoclonal antibody to annexin V conjugated to the fluorochrome phycoerythrin 
(PE) and the nucleic acid dye, 7-amino-actinomycin (7-AAD) (BD Biosciences, Perth, WA, 
Australia), were added at for a final concentration of 5 µl/1x10⁶ cells. In addition, 7-AAD is 
a nucleic acid dye used in place of propidium iodide (PI) to further reduce spectral overlap, 
and is excluded from cells with an intact cell membrane. The solution was incubated in the 
dark for 15 min at room temperature, as previously reported, and validated against propidium 
iodine (Schmid 1992, Vermes, et al. 1995). A combination of unstained cells, cells stained 
with only PE annexin V, and cells only stained with 7-AAD, were used as positive and 
negative controls, and to establish gating limits (Figure 3.6.8).  
Figure 3.6.8 Apoptosis and necrosis quantification by immunolabelling and flow cytometry. 
Flow cytometric analysis of granulosa cells stained with fluorescent antibodies for annexin V and 7-
AAD to depict the viability of the cells. Quadrant 1 (Q1); positive for annexin V and negative for 7-
AAD, which indicates only early apoptosis with an intact cell membrane. Q2; positive for annexin V 
and 7-AAD, which indicates apoptosis and necrosis. Q4; negative for annexin V and 7-AAD which 
indicates an intact cell membrane with no externalisation of the phospholipid phosphatidylserine and 
no apoptosis and necrosis. The frequency of granulosa cell apoptosis or unspecified cell death was 
graphed Q2. 
 
PE annexin V and 7-AAD were graphed into quadrants (Figure 8). Quadrant 1 (Q1) events 
were positive for PE annexin V and represent the very early stage of apoptotic granulosa 
cells. Q2 was positive for both PE annexin V and 7-AAD and therefore represents a later 
stage of apoptosis and necrosis. Cell membrane integrity breakdown in Q2 allowed 7-AAD 
to penetrate, whereas in Q4, unchanged cells showed no externalisation of the phospholipid, 
and were receptive to the annexin stain, yet were negative to 7-AAD penetration (Figure 
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3.6.8). All of the graphs for apoptosis and necrosis were based on Q2 that indicates a 
combination of apoptosis and necrosis. Q1 was not reliable because the positive stain for 
early apoptosis may have been induced during cell preparation, and therefore would not be a 
true indication of cell health status (Amsterdam, et al. 2003, Demchenko 2013). 
3.6.4 Human & GH co-treated: Flow cytometry, apoptosis 
For the detection of early DNA fragmentation, the assessment was applied on the same 
aliquots used for the immunolabelling of FSHR. The antibody CD45 was required because of 
the method of collection and blood contamination in the human study. CD45 was not used on 
the FSHR sample because of the uniqueness of FSHR on the granulosa cells; hence, there 
would be minimal spectral overlap.  
3.7 Fluorescent microscopy 
3.7.1 Sheep: Fluorescent microscopy 
Re-suspended 10 µl aliquots of FSHR, BMPR1B, and LHR immunolabelled, live granulosa 
cells were placed on slides and visualised to characterise and confirm receptor expression 
(Figure 3.7.1) using an Olympus DP 70 camera fitted to a Olympus BX-51 upright 
fluorescent microscope with a 40x UPlan N 0.4 NA objective (Olympus Imaging Australia, 
Macquarie Park, Australia). Pelleted aliquots of PE annexin V immunolabelled samples were 
similarly visualized for apoptosis. Fluorescent microscopy revealed a positive staining of the 
cell membrane-bound FSHR, BMPR1B, and LHR (Figure 3.7.2 E to G) as an intermittent, 
bright, ring-like pattern around the cells. Positive staining for early apoptosis was revealed by 
labelling of annexin V (Figure 3.7.2 H).  
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Figure 3.7.1 Characterisation of the presence of the receptors at the cell surface and early 
apoptosis. 
(A) Living un-luteinised granulosa cell (centre), red blood cell (top), and white blood cell (bottom) (E) 
polyclonal goat antibody FSHR anti-goat donkey IgG conjugated with Alexa 488, which demonstrates 
specific fluorescence for cell membrane expressed FSHR. (B and F) A granulosa cell labelled with 
anti-BMPR1B. (C and G) Labelled with anti-LHR. All showing cellular membrane receptor 
expression viewed under a fluorescent microscope and light microscope. (D and H) Granulosa cells 
labelled with annexin V conjugated to PE, showing cellular membrane phospholipid externalisation, 
indicative of early apoptosis. Viewed under a fluorescent microscope. Scale bar equal to 7.5 µm. 
 
3.7.2 Human & GH co-treated: Fluorescent microscopy 
Re-suspended 10µl aliquots of FSHR, BMPR1B, and LHR immunolabelled, live granulosa 
cells were placed on slides and visualized using an Olympus DP 70 camera fitted to a 
Olympus BX-51 upright fluorescent microscope with a 40x UPlan N 0.4 N.A. objective; 
(Olympus Imaging Australia, Macquarie Park, Australia),(Figure 3.7.2). Fluorescent 
microscopy revealed a positive staining of the cell membrane-bound FSHR, BMPR1B, and 
LHR as an intermittent, bright, ring-like pattern around the cells. All control samples showed 
negative staining. Granulosa cells ranged from 8 µm to 25 µm, the average of 15 µm for 
granulosa cells 
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Figure 3.7.2 Live human granulosa-luteal cells immunostained, positive cell surface 
receptor expression, and negative for nonspecific binding. 
Live human granulosa luteal cells with positive and negative (pre-absorbed or blocking agent). (AB) 
positive FSHR, (CD) negative FSHR (EF) positive BMPR1B (GH) negative BMPR1B (IJ) positive 
LHR (KL) negative LHR (MN) positive GHR (OP) negative GHR. Bar 10 µm 
3.8 Cell culture 
3.8.1 Human cell culture  
Human IVF granulosa cells, were collected and isolated as described above, and were then 
assessed for cell vitality using trypan blue exclusion using a Hemacytometer (Baxter 
Scientific). Trypan blue is excluded from the cell by an intact cell membrane. A cell 
suspension of 50 µl was mixed with 200 µl of culture medium and 250 µl of trypan blue 
solution (0.4% v/v). The sample was then diluted to a concentration of 75 000 viable cells/50 
µl. Cells were seeded into wells containing 200 µl pre-equilibrated medium to give a final 
concentration of 3 x 10⁵/ml. Plates were incubated in a 5% CO₂ and 95% , air humidified, at 
37 ºC (Shi, et al. 2010). Media was gently removed from the wells and replaced with 
conditioned media (175 µl) after three hours, 24 hours and at 48 hours. The collected media 
was stored at -80ºC until biochemical analysis. All cell cultures were repeated a minimum of 
three independent collections. 
3.8.2 Preparation of media 
Culture medium used throughout granulosa cell culture were based on protocols previously 
published (Campbell, et al. 1996, Glister, et al. 2004a, Glister, et al. 2001, Gutierrez, et al. 
1997, Knight and Glister 2001). The culture medium consisted of McCoy’s modified 
medium supplemented (Sigma, M-8403) supplemented with: Antibiotic/Antimycotic solution 
1% v/v (Sigma A9909), insulin 10 ng/ml, bovine pancreas, (Sigma, I-1882), L-Glutamine 2 
N 
P  O 
 M 
GHR 
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mM (Sigma, G-7513); HEPES (Sigma, H-4034) ; 10 mM, apo-transferrin 5 µg/ml (Sigma,T-
2036) and sodium selenite 5 ng/ml (Sigma, S-9133), BSA 0.1% (Sigma, A-9418), 
androstenedione 10-7 M. The cells were cultured in complete absence of serum to avoid 
spontaneous luteinisation. 
3.9 Biochemical Analysis  
Follicular fluid collected from follicles 17 to 23 mm were analysed for testosterone, FSH, 
and LH using a random access immunoassay system (Siemens Medical Solutions, Bayswater, 
Victoria, Australia). Follicular fluid, testosterone, FSH, and LH were analysed undiluted, 
whereas oestrogen and progesterone were diluted manually 1:1000 with a multi-diluent and, 
when required, a further manual dilution of progesterone; 10 x and oestrogen; 5 x. Percentage 
coefficient of variance (CV) for a concentration range 137.4 pmol/L to 3257 pmol/L was 
oestrogen = 5.2; LH = 3.9; FSH = 2.9; testosterone = 5.9; progesterone = 9.4. 
3.10 Statistical analysis 
3.10.1 Sheep: Statistical analysis 
MFI was obtained using an average of ~4000 granulosa cells/follicle for the direct 
measurement of mature functional receptor protein density. All of the data were subject to 
statistical verification by one-way ANOVA with an uncorrected Fisher’s least significant 
difference (LSD) for follicular size and genotype using GraphPad Prism 6 (GraphPad 
Software, Inc., CA, USA). Values in graphs are means ± S.E.M., and differences were 
considered significant if *p<0.05, **p<0.01, ***p<0.005, and ****p<0.001. The letter, such 
as ‘a’, signifies a statistical difference to the matching letter, and an attached asterisk (a*) 
indicates the significance level for the size follicle. The results from an analysis of a 
contingency table by a two tailed, Fisher’s exact test were used. 
3.10.2 Human IVF & GH co-treated 
Mean fluorescent intensity (MFI) was obtained using ~8000 granulosa cells per follicle for 
the direct measurement of receptor protein expression. The data were subjected to statistical 
verification using one-way ANOVA with an uncorrected Fisher’s LSD for follicular size 
using GraphPad Prism 6  Values in graphs are means ± S.E.M., and differences were 
considered significant if *p<0.05, **p<0.01, ***p<0.005, and ****p<0.001. The letter, such 
as ‘a’, signifies a statistical difference to the matching letter, and an attached asterisk (a*) 
indicates the significance level for the size follicle.  
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CHAPTER 4 Characterisation of granulosa cells & 
steroidogenesis 
4.1 Introduction  
The ovarian reserve of primordial follicles has been strongly correlated to the number of 
small antral follicles (AFC) at the start of a menstrual cycle in humans (Hansen, et al. 2011, 
van Rooij, et al. 2005). It has also been found that a lower AFC is associated with infertility 
(Rosen, et al. 2011, Scheffer, et al. 1999). Circulating hormone levels are a reflection of 
follicle growth and development of the oocyte. The granulosa cells within the follicle convert 
androgen to oestrogen under the control of the gonadotrophins FSH and LH, secreted by the 
anterior pituitary. Small antral follicles are stimulated to continue growing based on the 
density of FSHR and LHR during the time of dominant follicle selection (Mihm, et al. 2006, 
Zeleznik 2001). The dominant cohort of follicles continues to produce increasing amounts of 
oestrogen until a threshold for the cycle is reached, and cell differentiation begins. In the 
large antral follicle, the granulosa population is composed of cells at different stages of 
differentiation, luteinisation and apoptosis or necrosis (Figure 4.1.1).  
 
Towards the middle of the menstrual cycle, high levels of oestrogen and progesterone 
receptor activation trigger the LH surge, and many changes take place in the follicle which 
result in reduced proliferation and altered steroid production (Gordon, et al. 2010). These 
changes also induce maturation of the oocyte, facilitate rupture of the follicle, and expulsion 
of the oocyte (Fan, et al. 2009, Gordon, et al. 2008). 
 
The granulosa cell expands and reorganises the content of the cytoplasm, forming new 
organelles, particularly smooth endoplasmic reticulum (SER) for progesterone production 
(Figure 4.1.1) (Motta 1969). The SER and mitochondria are assembled in close association 
with the nucleus (Motta 1969, Nottola, et al. 2006). The mitochondria and large, round, lipid 
droplets are closely associated with the SER, all of which have substantially increased in 
number, and cluster around the nucleus to increase efficiency of steroid synthesis (Nottola, et 
al. 2006).  
 
During luteinisation, granulosa cells form irregular microvilli and tight junctions between the 
cells, whereas, in an apoptotic granulosa cell, the cell membrane disintegrates and spaces 
form (Guraya 1971 ). The apoptotic granulosa cell continues to produced steroids in large 
antral follicles until complete  mitochondrial breakdown (Figure 4.1.1) (Amsterdam, et al. 
2003). 
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The present study aims to characterise the morphological changes during folliculogenesis, 
and the associated change in steroid synthesis of the granulosa cell. 
Figure 4.1.1 Ovarian granulosa cell development and steroidogenic differentiation and 
apoptosis. 
The apoptotic granulosa cell continues to synthesise hormones until the mitochondrial membrane is 
disrupted. The functioning apoptotic granulosa cell undergoes reorganisation of the cell cytoplasm 
creating blebs of non-cytoplasmic organelles, whereas the luteinising cell creates microvilli and 
expands the cytoplasm. Based on findings from (Amsterdam, et al. 2003, Guraya 1971 , Motta 1969). 
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4.2 Collection Method  
Methods are described in detail in the General Methods Chapter (page 38). Granulosa cells 
were collected from hCG/LH induced follicles from patients receiving IVF exogenous 
gonadotrophins to artificially stimulate multiple follicles. Serum was analysed using 
biochemical analysis on the days leading up to collection and on the day of collection. 
Human IVF granulosa cells, were collected and isolated, and were then assessed for cell 
vitality using trypan blue exclusion using a Hemacytometer (Baxter Scientific). Cells were 
seeded into wells containing 200 µl pre-equilibrated medium to give a final concentration of 
3 x 10⁵/ml (General Methods Chapter, page 53). Plates were incubated in a 5% CO₂ and 
95%, air humidified, at 37 ºC (Shi, et al. 2010). Media were gently removed from the wells 
and replaced with conditioned media (175 µl). The collected media were stored at -80ºC until 
biochemical analysis. All cell cultures were repeated a minimum of three independent 
collections. 
 
The peak oestrogen concentration in serum was used to predict the follicular health of the 
follicle as opposed to the serum levels collected at the time of follicle aspiration. When the 
largest follicles reached 18 mm, a LH surge trigger injection of 10 000 IU hCG/LH was 
administered. Then 36 hours later, the follicles were punctured and aspirated by guided 
ultrasound to collect the fluid, granulosa cells and oocyte, via transvaginal oocyte aspiration 
(TVOA). Serum was analysed using biochemical analysis on the days leading up to 
collection, and on the day of collection.  
 
IVF patients undergoing treatment were examined in a natural cycle and during exogenous 
rFSH stimulated cycles. In addition, a patient with normal fertility (prior naturally conceived 
births) provided a control sample during a natural cycle. During IVF treatment, the patient is 
stimulated with rFSH to enhance follicular recruitment and growth, and suppression of LH 
and FSH release from the anterior pituitary. Sustained high doses of rFSH recruit and 
develop multiple antral follicles that produce oestrogen and progesterone by the follicular 
cells.  
 
The granulosa cells that lines the cavity of the follicle were suspended in the follicular fluid 
and the medium used to flush the follicle. The initial aspiration of the follicle was performed 
to yield a pure sample of follicular fluid for analysis. At the time of guided ultrasound for 
collection of the oocyte, measurement of the follicle diameter was made by the measurement 
of the pure follicular fluid, and cross-referenced with the measurement from the ultrasound 
(Figure 4.2.1). 
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Figure 4.2.1 Volume of follicular fluid surrounding the oocyte in a follicle. 
Measurement of the diameter of the ovarian follicle by ultrasound and by the quantity of follicular 
fluid collected during trans vaginal aspiration using guided ultrasound (TVOA). 
4.3 Results and Discussion 
Peri-luteal granulosa cells from different size follicles collected from IVF patients were 
cultured for 48 hours. The oestrogen and progesterone concentration was measured after one 
hour in culture, and later at 24 hours and 48 hours (Figure 4.3.1). The capacity of the 
granulosa-luteal cells from the small and medium follicles to produce oestrogen and 
progesterone was substantially lower than the large follicle during the one hour culture. All 
the follicles had been exposed to hCG/LH for a 36 hour period, and it was predicted that 
luteinisation would be in progress (Figure 4.3.2).  
 
The earliest signs of luteinisation are the appearance of large lipid droplets, which contain 
cholesterol for progesterone synthesis (Nottola, et al. 2006). In the current study the small 
follicles in culture produced greater amounts of progesterone than oestrogen, which indicates 
early luteinisation, and the transition from the follicular to the luteal phase previously 
documented (Westergaard, et al. 1986). Previously, follicles collected in a natural cycle, 
produced a greater concentration of oestrogen than progesterone up to 16 mm in diameter, 
but during pre-ovulatory maturation (17-20 mm), oestrogen reduced and progesterone 
synthesis increased exponentially. (Westergaard, et al. 1986). Moreover, the oestrogen levels 
in follicles less than 7 mm were very low.  
 
The acquisition of FSHR (~4-7 mm) gives the granulosa cell the ability to convert theca 
derived androstenedione to oestradiol. The increase in FSHR induces the expression of LHR 
on the granulosa cell surface (Figure 4.3.3). As the density of LHRs increase, the 
progesterone synthesis increases sequentially with follicle size and peaks in the pre-ovulatory 
follicle (Figure 4.3.1). During the follicular phase, the serum level of LH retains a basal rate 
Sheena Regan 2015 
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(Santoro, et al. 2003); inferring that, before the LH surge is initiated, the density of the 
receptor increases, not the level of pituitary LH secreted (Jeppesen, et al. 2012, Peng, et al. 
1991a). As the ovarian reserve is depleted, the basal LH rate increases, and has been shown 
to negatively influence pregnancy rate and fertility (LaPolt and Lu 2001, Rotmensch, et al. 
1986, Stanger and Yovich 1985).   
Figure 4.3.1 Oestrogen and progesterone synthesis from cultured granulosa cells collected 
from IVF patients during the peri-luteal phase. 
 
During an IVF cycle, the granulosa cells from small follicles appear more compact and 
smaller in diameter (Figure 4.3.3). The granulosa cells from large follicles have a 
heterogeneous group of granulosa cells in different stages of luteinisation (Figure 4.3.3). The 
luteinised granulosa cell has an expanded cytoplasm with prominent lipid droplets clustered 
around SER, and are closely associated with numerous mitochondria and well as defined 
golgi apparatus in the cytoplasm (Figure 4.3.2). The lipid droplets can be clearly observed in 
granulosa cells as grape like spaces (Figure 4.3.3). In the small follicle, viewed under a light 
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microscope, the cytoplasm was smaller and compact, with some evidence of expansion 
(Figure 4.3.3).  
 
The pre-ovulatory follicle granulosa cells obtained from a natural cycle, healthy patient, had 
compact large granulosa cells, with some cells exhibiting an expanded cytoplasm and lipid 
droplets (Figure 4.3.4). The LH surge was just starting (LH: 18 IU), and the progesterone 
surge had not commenced (Progesterone: 4.5 pmol/L) (Figure 4.3.4). In the cell culture, the 
small follicle progesterone synthesis was initially similar to the medium size follicle; 
however, the progesterone concentration in the small follicle after 48 hours in serum free 
culture was reduced, which indicates that the progesterone precursor cholesterol contained 
within the lipid droplets was probably depleted (Figure 4.3.2). The oestrogen synthesis was 
maintained at a constant level in all follicle sizes due to the androstenedione fortified 
medium. 
4.3.1 Conclusion 
In summary, when exposed to a hCG/LH surge, granulosa cells are stimulated to mature, 
which results in differentiation of small, medium and large antral follicles. The extent of 
luteinisation is dependent on the stage of development of the follicle, at the time of the LH 
surge.  
Figure 4.3.2 Granulosa cell undergoing luteinisation viewed by an electron microscope. 
 
Early signs of luteinisation are the accumulation of lipid droplets containing precursor cholesterol for 
progesterone synthesis in the granulosa cell. The nucleus (N) contains dispersed chromatin, and in the 
cytoplasm, the mitochondria (m) and smooth endoplasmic reticulum (SER) are in close association 
with the lipid droplets (L), transmission electron microscopy (TEM: x10000) (Nottola, et al. 2006). 
SER 
Nottola et al. 2006 
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Figure 4.3.3 In vivo small, medium, and large human IVF follicles containing granulosa 
cells at different stages of luteinisation. 
 
Small antral follicle of 8 mm, compact morphology with large nucleus compared to cytoplasm. (B) 
Medium size antral follicle of 15 mm post dominant follicle selection, showing larger granulosa cells 
with compact morphology similar to the small antral follicle. (C) Granulosa cells from a large antral 
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follicle of 23 mm, showing expanded cytoplasm with many lipid droplet spaces. A heterogeneous 
population with few granulosa cells with a compact morphology, and many with an expanded 
cytoplasm. Oil red O and Harris stained. Bar = 10 µm. granulosa cell. 
 
Figure 4.3.4 Peri-luteal granulosa cells and cell morphology. 
Granulosa cells from an 18.5 mm follicle during a natural cycle collected at the start of the LH surge, 
before the progesterone surge; a normal healthy patient 41 y with an AFC of D. (B) Granulosa-luteal 
cells from an IVF stimulated patient, post LH surge; 20 mm follicle. An expanded cytoplasm (a) 
clustering of organelles around nucleus (b), with cytoplasmic extrusions or blebbing indicating 
apoptosis (b) Expanding cytoplasm (c): Un-expanded small granulosa cell (d) Granulosa cell 
undergoing mitotic division (e). 
  
Natural Cycle IVF Cycle 
Sheena Regan 2014 
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CHAPTER 5 Ovulation Rate and Receptor Expression in Sheep 
5.1 Introduction 
Ovarian follicular maturation relies on the gonadotrophins, FSH and LH to regulate cyclic 
recruitment of dominant follicle selection that governs the ovulation rate in animals and in 
humans (Ginther, et al. 2005, McNatty and Henderson 1987b, Mihm and Evans 2008b). It is 
commonly believed that intra-ovarian growth factors such as the BMPs influence the 
steroidogenic activity of LH and FSH directly, and indirectly downstream of the receptor 
(Otsuka 2010). The cellular mechanism responsible for the selection of the dominant follicle 
cohort remains elusive (Andersen, et al. 1993, Ginther, et al. 2005, Knight and Glister 2006, 
Mihm and Evans 2008b, Westergaard, et al. 1986).  
 
Previous studies have delineated the initial role of FSH as a stimulatory growth factor for the 
proliferation of follicular cells and the oocyte, culminating in a mid-follicular peak of FSH 
(Mihm and Evans 2008b, Thomas, et al. 2005). A sharp decline in FSH causes the follicles 
still dependent on FSH to succumb to atresia, which results in a dominant follicle cohort. The 
follicles survive, because they are mature enough to be FSH independent, or they become 
more responsive to FSH, because of the greater concentration of FSHRs. Manipulation of 
FSH through the use of exogenous FSH forms the basis of artificial reproduction treatment 
(ART) in humans. By artificially increasing FSH in ART, the FSH concentration remains 
high, thereby supporting the smaller FSH-dependent follicles; this results in multiple pre-
ovulatory follicles for collection and fertilisation. Treatment with high doses of FSH is a 
systemic whole body approach to artificial stimulation, and has associated risks such as hyper 
stimulation, hormonal disruption, and discomfort. An in depth understanding of follicular 
regulation might lead to improved targeted approaches to infertility treatment. 
 
It has been known for some time that the Booroola Merino genotype (BB), with a naturally 
occurring point mutation of the superfamily of cytokines TGFβ type 1 receptor, BMPR1B, 
has an increased ovulation rate (Mulsant, et al. 2001). The cellular mechanism responsible, 
however, has not been revealed (Campbell, et al. 2003, Crawford, et al. 2011, Mulsant, et al. 
2001, Souza, et al. 2001, Wilson, et al. 2001). Evidence from the previous findings on the BB 
has shown that the attenuation of BMP signalling produces elevated FSH levels, and the 
initial number of primordial follicles are reduced; yet the rate of recruitment of primary 
follicles is substantially lower and results in a greater retention of the ovarian reserve in the 
mature ewe (Ruoss, et al. 2009, Xia, et al. 2003). Given that FSHRs are not expressed in 
primordial follicles, it is unlikely that FSH plays a role in this initial recruitment (Ruoss, et al. 
2009). The BMP ligands have been implicated in the stimulatory regulation of primordial to 
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primary follicle recruitment, particularly BMP4 and BMP7, which provides some 
explanation for the reduction reported (Ruoss, et al. 2009). 
 
The mutation in BMPR1B in BB sheep provides a unique opportunity to study the roles of 
BMPs in ovarian function including follicle development, growth, ovulation, and the clinical 
treatment of subfertility in humans. The response of both the ovary and the pituitary to 
gonadotrophic stimulation appears responsible for the increased ovulation rate of the BB 
mutation (Campbell, et al. 2003, Fry, et al. 1988, Hampton, et al. 2004, Hudson, et al. 1999). 
The results have led us to initiate further research to delineate the direct cellular mechanism 
responsible for the increased response of the ovary to gonadotrophins, which leads to an 
increased ovulation rate, and to provide further insight into the interplay between the intra-
ovarian BMP ligands and the regulatory FSH and LH in terminal-end folliculogenesis.  
 
It has been hypothesised that if there is reduced initial primary follicle recruitment, greater 
survival of antral follicles would be required to deliver a greater ovulation rate. Direct 
measurement by flow cytometry of the protein expression of FSH, LH, and BMP mature 
membrane-bound receptors on granulosa cells, and apoptosis and necrosis, was undertaken to 
fully delineate the natural point mutation effect of the BB responsible for the increased 
ovulation rate. We therefore, hypothesise that the attenuation of the BMP signal would 
provide a more direct and accurate intra-ovarian method of increasing the ovulation rate in 
ART.  
5.2 Materials and methods 
Methods are described in detail in the General Methods Chapter (page 38).  
A total of 17 Merino sheep with an average age of 4 years and 9 months ± 2 months were 
used (Table 5.2:1and Table 5.3:1). Five ewes were genetically confirmed as homozygous 
Australian Booroola strain (BB); with a flock average ovulation rate of four to six during 
peak breeding season, (Cummins, et al. 1983) and an ovulation rate of three, based on the 
corpus luteum (CL) formation in two Booroola sheep at the time of slaughtering, because of 
miss timed ovulation. Subsequently, the remaining follicles after ovulation were classified as 
luteinised (Table 5.2:1). The corpora lutea formed in the post-ovulation groups were included 
in the total number of follicles recruited per genotype, and they were added to the largest 
follicle size for that genotype (Table 5.3:1).  
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Table 5.2:1 The number of sheep and individual follicles analysed prior to ovulation and 
post ovulation. 
 
Corpus Luteum (CL) 
 
5.3 Results 
The largest follicle in BB ovaries was 4.5 mm, whereas the largest follicle in the WT animal 
was 7 mm (Table 5.3:1). The percentage of small follicles, including the pooled follicles, was 
similar between genotypes, 53% WT and 57% BB. The medium WT follicles collected 
contributed to 22% of the adjusted total, whereas, the medium BB follicles had significantly 
less, at 14%. The large follicle numbers were reversed, with the BB having significantly 
more large ovulatory follicles compared to the WT extra-large ovulatory, 28.6% and 9.3% 
respectively, p<0.011 (Table 5.3:1). The absolute relative frequency derived from the total 
number of follicles collected was compared to the number of ovulatory-size follicles (Figure 
5.3.1). The BB did not produce any extra-large follicles, and the corpora lutea formed was 
included in the largest follicle group for the genotype. 
 
Table 5.3:1 Recruitment and loss of follicles during folliculogenesis in WT and BB Merino 
sheep. 
*Significantly greater number of ovulating follicles: p<0.011            ñ   Including Corpus Luteum 
 
 
 
 
 
 
Genotype 
Sheep before 
ovulation 
Follicles 
 
Dominant 
follicles 
Small 
(1.0-2.1 mm) 
Medium 
(2.2-2.9 mm) 
Large 
(3.0-4.5 mm) 
Extra large 
(4.6-7.0 mm) 
WT 8 64 8 25 19 14 6 
BB 3 20 3 9 5 6 0 
Genotype 
 
Sheep post- 
ovulation 
Luteinised 
follicles 
CL per 
sheep 
Small 
(1.0-2.1 mm) 
Medium 
(2.2-2.8 mm) 
Large 
(3.0-4.5 mm) 
Extra large 
(4.6-7.0 mm) 
WT 4 35 1.5 13 14 8 0 
BB 2 10 3 7 2 1 0 
    
Small 
(1.0-2.1mm) 
Medium 
(2.2-2.9mm) 
Large 
(3.0-4.5mm) 
Extra Large 
(4.6-7.0mm) 
Genotype 
 
Total 
sheep 
Total 
follicles 
ñ 
Total 
per 
sheep 
Small 
follicles 
pooled 
Total 
collected 
Total 
(%) 
Total 
collected 
Total 
(%) 
Total 
collected 
Total 
(%) 
Total 
collected 
Total 
(%) 
WT 12 150 12.5 42 80 53 33 22 23 16 14 ñ 9.3a 
BB 5 49 9.8 12 28 57 7 14 14 ñ 28.6* 0 0 
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Figure 5.3.1 Relative frequency of ovulatory follicles for genotype. 
The total number of follicles (clear section of bar) from 1 mm to terminal-end of folliculogenesis and 
ovulation including corpus luteum are presented for the BB and WT sheep. The ovulatory follicles 
(black section of bar) being the largest follicles for the genotype, including CL, provide evidence of 
the relative survival of recruited follicles for the WT and the BB genotype. The letter ‘a’ signifies a 
statistical difference in the retention of ovulatory follicles during folliculogenesis. Analysis of the 
contingency table using a two tailed, Fisher’s exact test was performed with a p value of 0.011.  
5.3.1 Flow cytometry quantification of BMPR1B, LHR, and FSHR 
The genotype effect on density of BMPR1B expression in granulosa cells from small, 
medium and large subordinate follicles of BB sheep was significantly higher than that in the 
WT (p<0.05, p<0.01 and p<0.005, respectively, Figure 5.3.2 B). Similarly, the density of 
FSHR was significantly increased in the BB sheep from the small antral follicle to the large 
follicle (p<0.01, p< 0.01, p<0.005, respectively, Figure 5.3.2A); whereas, the LHR density 
was greater (Figure 5.3.2 C). 
WT BB 
A 
WT 
BB 
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Figure 5.3.2 Genotype comparison of WT and BB receptor density from granulosa cells 
from subordinate follicles. 
All of the follicles are subordinate follicles (i.e. the leading dominant follicle based on size; and the 
granulosa-luteal follicles were not included because of the mutation-independent down-regulation; see 
material and methods. (A) The average granulosa cell FSH receptor density, as measured by mean 
fluorescent intensity (MFI) of ~4000 granulosa cells harvested from individual follicles were analysed 
by immuno-fluorescent labelled, flow cytometry for BB (striped) and WT (clear) genotypes. Exclusion 
gating based on positive FSHR signal and comparative size difference produced a uniform granulosa 
sample. The same gating was applied to all samples, and auto-fluorescence and nonspecific binding 
were removed by subtraction gating. (B) The average BMPR1B receptor density MFI for small antral 
follicles was divided into smaller size classes to reflect the down-regulation. (C) The average LHR 
receptor density MFI for small antral follicles. Statistical verification using one-way ANOVA with an 
uncorrected Fisher’s least significant difference (LSD). Values in graphs are means ± S.E.M., 
*p<0.05; **p<0.01 and ***p<0.001. The letter, such as, ‘a’ signifies a statistical difference to the 
matching letter, with its attached asterisk (a*) which indicates the significance level for the size 
follicle. The number of subordinate follicles analysed is shown for each follicle size class. 
C 
WT 
BB 
B 
WT 
BB 
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The WT sheep had elevated levels of FSHR in the largest of the subordinate follicles 
(p<0.01), followed by down-regulation in the leading dominant follicles (p<0.05, Figure 
5.3.3A). The granulosa-luteal cells revealed that the FSHR level after ovulation was 
significantly higher than the dominant pre-ovulatory follicle was, and this finding was 
maintained across the follicle sizes (p<0.05, Figure 5.3.3A). In the WT sheep, the BMPR1B 
density was significantly decreased in a pattern of biphasic down-regulation as was seen with 
the 1.8 mm subordinate follicle and the 4.4-7 mm dominant follicle (p<0.05 and p<0.01, 
Figure 5.3.3B). The granulosa-luteal cells from the sheep ovaries that had ovulated, and 
contained one or more corpora lutea, revealed that the BMPR1B level after ovulation was 
significantly higher than in the dominant pre-ovulatory follicles, and this finding was 
maintained across the follicle sizes (p<0.05, Figure 5.3.3B). The LHR density was greater in 
the WT sheep, at 4.2 mm, and down-regulated in the 4.6 mm subordinate follicle and the 4.4 
mm dominant follicles (p<0.05, Figure 5.3.3C). The largest of the dominant follicles (5-7 
mm) had similar levels of LHR density to those of the granulosa-luteal cells, whereas the 
LHR expression increased and was then down-regulated in the smaller dominant follicles 
(p<0.05, Figure 5.3.3C). 
A 
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Figure 5.3.3 WT sheep receptor density and follicle size in granulosa cells from dominant 
compared to subordinate and luteal follicles. 
(A-C) Receptor density measured by mean fluorescent intensity (MFI) of subordinate (pre-ovulation) 
granulosa cells (clear) and (pre-ovulation), dominant follicle (blue); and (post-ovulation), granulosa 
luteal cells (grey) for different follicle size groups for the WT genotype. (A) FSHR; (B) BMPR1B; (C) 
B 
C 
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LHR. Statistical verification using one-way ANOVA with an uncorrected Fisher’s LSD. Values in 
graphs are means ± S.E.M., *p<0.05; **p<0.01. The letter, such as, ‘a’ signifies a statistical difference 
to the matching letter, with its attached asterisk (a*), which indicates the significance level for the size 
follicle. The number of dominant follicles and the number of follicles from ovulated sheep are 
indicated for each follicle size class. 
 
The FSHR demonstrated a trend of increasing FSHR followed by a significant down-
regulation of receptors in the dominant follicle and a significant up-regulation in the 
granulosa-luteal cells (p<0.05, Figure 5.3.4A). There was a significant steady increase from 
1.0 mm to 3.2 mm in subordinate granulosa cell BMPR1B density with follicle size in BB 
sheep (p<0.005, Figure 5.3.4B). The leading dominant follicles were down-regulated 
(p<0.005), followed by a trend of increasing levels of BMPR1B in the granulosa-luteal cells. 
The LHR density was significantly increased from 1.0 mm to 3-3.2 mm follicles (p<0.01), 
followed by the down-regulation of LHR density in the dominant pre-ovulatory follicles 
(p<0.01, Figure 5.3.4C). The granulosa-luteal cells demonstrated no significant difference to 
the down-regulated follicles of the dominant pre-ovulatory follicles in the BB sheep (Figure 
5.3.4C).  
 
 
 
 
 
A 
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Figure 5.3.4 Booroola receptor density and follicle size in granulosa cells from dominant 
compared to subordinate and luteal follicles. 
(A-C) Receptor density measured by mean fluorescent intensity (MFI) of subordinate (pre-ovulation) 
granulosa cells (clear) and (pre-ovulation), dominant follicle (blue); and (post-ovulation), granulosa-
luteal cells (grey) for different follicle size groups for the WT genotype. (A) FSHR; (B) BMPR1B; (C) 
B 
C 
74 
 
LHR. Statistical verification using one-way ANOVA with an uncorrected Fisher’s LSD. Values in 
graphs are means ± S.E.M., *p<0.05; **p<0.01 and ***p<0.005. The number of dominant follicles 
and the number of follicles from ovulated sheep are indicated for each follicle size class. 
5.3.2 Flow cytometry quantification of apoptosis  
The apoptosis and necrosis levels were significantly elevated in the largest of the subordinate 
follicles of the WT sheep (p<0.01, Figure 5.3.5). The BB genotype did not demonstrate 
elevated levels in the largest of the subordinate follicles. The WT dominant follicle reported 
greater apoptosis and necrosis levels as compared to the BB dominant follicle of 3 mm (b, 
p<0.05, Figure 5.3.6). An unusually large BB follicle was recorded, and the level of its 
apoptosis and necrosis was similar to the WT largest subordinate follicle of 40%. The level 
of apoptosis and necrosis in the BB 1 mm follicles was greater post-ovulation as compared to 
the WT subordinate follicles (c, p<0.05), but not as compared to the WT post ovulation 
follicles (Figure 5.3.6). 
 
 
Figure 5.3.5 WT sheep compared to BB genotype: apoptosis and necrosis of granulosa 
cells from subordinate follicles. 
All follicles are subordinate follicles, (i.e. the leading dominant follicle based on size was not included 
because of the mutation-independent down-regulation). Statistical verification using one-way ANOVA 
with an uncorrected Fisher’s LSD Values in graphs are means ± S.E.M., *p<0.05 and **p<0.01. The 
letter ‘a’ signifies a statistical difference to the matching letter, with its attached asterisk (a*), which 
indicates the significance level for the size follicle.  
WT 
BB 
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Figure 5.3.6 Comparison of genotype granulosal apoptosis and necrosis during follicle 
development. 
WT sheep comparison of percentage apoptosis and necrosis in granulosa cells from dominant 
compared to subordinate and luteal follicles. Apoptosis and necrosis of subordinate follicles (pre-
ovulation granulosa cells) (clear) and dominant follicles (blue); and post-ovulation granulosa luteal 
cells (grey) of different follicle size classes for WT genotype. (B) BB sheep comparison of apoptosis 
and necrosis in granulosa cells from dominant compared to subordinate follicles and granulosa luteal 
cells. Apoptosis and necrosis of subordinate follicles (pre-ovulation granulosa cells) (clear) and 
dominant follicle (blue); and post-ovulation granulosa luteal cells (grey) of different follicle size 
classes for BB genotype. Statistical verification using one-way ANOVA with an uncorrected Fisher’s 
LSD. Values in graphs are means ± S.E.M., *p<0.05 and **p<0.01. The letter, such as, ‘a’ signifies a 
statistical difference to the matching letter, with its attached asterisk (a*), which indicates the 
significance level for the size follicle. The number of follicles is indicated for each follicle size class. 
5.4 Discussion 
The BMP signalling axis has been strongly associated with the gonadotrophins, FSH and LH, 
in the pituitary-ovarian axis of control in regulation of follicle recruitment, growth, and 
ovulation rate (Miyoshi, et al. 2006, Otsuka, et al. 2001b, Takeda, et al. 2012).The BMP 
ligands 4, 6, 7, and 15 have a stage dependent, high affinity to bind to the TGFβ type 1 
receptor, BMPR1B (Mazerbourg and Hsueh 2006). The Booroola mutation that impacts the 
BMPR1B has been studied extensively, but the findings mainly focused on the indirect 
heightened physiological responsiveness of the BB compared to the WT (Campbell, et al. 
2006, Fabre, et al. 2006, McNatty, et al. 1985).  
WT BB 
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In the present study’s novel approach, the mature cell surface protein for FSHR, LHR, and 
BMPR1B were measured by flow cytometric analysis. Immunolabelled granulosa cells were 
collected from individual antral follicles, and harvested in situ to reduce contamination with 
other ovarian or blood cells. The receptor density was quantified by the average fluorescent 
intensity of ~4000 isolated granulosa cells per follicle. The selected antibodies have been 
previously validated by immunolocalisation in sheep by our research group (Al-Samerria and 
Almahbobi 2014 ). Positive and negative signals were used to subtract auto-fluorescence and 
nonspecific binding; whereas, the uniqueness of the FSHR on granulosa cells and the relative 
size of other cells, positively identified the population of granulosa cells. 
5.4.1 Major Findings 
The receptor density of BMPR1B, FSHR, and LHR was significantly increased in the 
granulosa cells of developing antral follicles of BB compared to the WT (Figure 5.3.2). 
Furthermore, the leading dominant follicle from both genotypes had reduced receptor density 
in comparison with subordinate follicles, indicating a vital prerequisite down-regulation prior 
to ovulation (Figure 5.3.3 and Figure 5.3.4).  
 
The direct in vivo quantitative analysis between genotype for BMPR1B and LHR expression 
has been previously reported, with acknowledged limitations of follicle class and sensitivity 
of the technique (McNatty, et al. 1986b, Mulsant, et al. 2001). Previously, qualitative data 
reported that the level of BMPR1B mRNA in follicles from 1.to 3 mm antral follicles 
indicated that the BMPR1B mRNA was not reduced in the BB (Mulsant, et al. 2001). 
Recently, quantitative findings have shown that the level of BMPR1B mRNA in 1 to 3 mm 
follicles to be equivalent in the BB, which is not consistent with the findings (Estienne, et al. 
2015). In the Estienne et al. (2015) study, the follicles were divided into small (1-3 mm) and 
large (3-5 mm) groups, preventing an accurate comparison of the genotype effect due to the 
large range of development within the 1-3 mm range (McNatty, et al. 1985), and the down-
regulation of the leading dominant follicle in the 3-5 mm range (Gasperin, et al. 2014). It has 
been reported previously (McNatty, et al. 1986a) that the BB follicles reach steroidogenic 
capacity at 2 to 2.5 mm compared to the WT at 4 to 4.5 mm. The pooling of follicles would 
mask the cellular changes taking place during the follicular development in this range. In 
addition, in the present study the translated mature FSHR, BMPR1B, and LHR proteins were 
measured, as opposed to measuring the mRNA for the receptor. Differences may therefore, 
have resulted, seeing as the mRNA measurement would also include immature and mature 
proteins, that are potentially not expressed (Ascoli, et al. 2002).  
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5.4.2 Pattern of biphasic down-regulation in the WT 
An unexpected finding of the study was the reduction in density of BMPR1B in the WT at 
two stages of folliculogenesis (Figure 5.3.3B). The density of BMPR1B was elevated at the 
time of divergence (1-1.7 mm), followed by down-regulation after dominant follicle selection 
(1.8 mm), which lead to a steady increase in density to a peak in the largest of the 
subordinate follicles (3-4.6 mm) (Figure 5.3.3). In both the BB and the WT, the leading 
dominant follicle (4.4-7 mm) had significantly reduced density of receptors, which 
demonstrated the presence of a hierarchical organisation of the follicles that has been 
reported to be present in sheep (Figure 5.3.3 and Figure 5.3.4). (Evans, et al. 2002, Gasperin, 
et al. 2014). 
 
Chen, et al. (2009) and Estienne, et al. (2015) have also reported that the WT granulosa cells 
have increasing BMPR1B with follicle size, which is consistent with the present finding of an 
increased density of BMPR1B in subordinate follicles from 1.8 mm to the 4.6 mm, which 
were the largest of the subordinate follicles (p<0.010, Figure 5.3.2 B). 
 
In the present study, the high BMPR1B in the BB was not present in the 1-1.7 mm follicles, 
possibly due to the earlier onset of development, which is typical of the BB genotype 
(McNatty, et al. 1985). The high level of receptor density may have occurred at a smaller BB 
follicle size of < 1 mm. In the BB, however, the down-regulation of the dominant follicle was 
comparable to the WT, albeit at a reduced size (Figure 5.3.3 and Figure 5.3.4). It is, 
therefore, apparent that the down-regulation mechanism is independent of the mutation as it 
occurred in both genotypes. BMP4, 6, 7, and 15 signal via the BMPR1B, and have been 
previously shown to play a regulatory role in the suppression of progesterone production 
before through to ovulation (Ryan, et al. 2008, Takeda, et al. 2012). The up-regulation of 
extracellular signal regulated kinases 1 and 2 (ERK1/2) signalling (Fan, et al. 2009) occurs 
coincident with the down-regulation of BMPR1B activity which suppresses progesterone 
synthesis (Feary, et al. 2007, Miyoshi, et al. 2006). The failure to down-regulate the 
BMPR1B activity would, therefore impede the process of luteinisation and prevent 
maturation of the follicle (Gordon, et al. 2008).   
5.4.3 Gonadotrophin regulation and FSHR signalling 
FSHR and LHR were found to be greater in follicles from another prolific breed (Romanov) 
compared to the  le-de-France ewes; and in the Chinese prolific Small Tail Han sheep with a 
mutation of the BMPR1B gene (Abdennebi, et al. 1999, Jia, et al. 2007). The quantitative data 
from the current research confirm and expand these observations, and propose that the 
mutation-induced changes to the BMPR1B signalling in the BB sheep are responsible for the 
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significantly up-regulated density of BMPR1B, FSHR, and LHR, and they have a cumulative 
effect as the follicle increases with size (Figure 5.3.2).  
 
Quantitative genotype data on the FSHR have not been previously reported, although, FSH 
stimulation and granulosa cell responsiveness in the BB sheep have been previously reported 
(Henderson, et al. 1985). Moreover, the BMP2, 4, and 7 ligands in the WT goat, and human 
have been shown to increase the level of FSHR mRNA, whereas BMP6 was shown to 
increase LHR mRNA, which indicates a direct role for BMPs in the regulation of receptor 
density (Ogura Nose, et al. 2012, Zhu, et al. 2013). Furthermore, ovine granulosa cells 
cultured with both FSH and oestrogen increased the expression of BMPR1B (Chen, et al. 
2009), which supports the present findings of an increased BMPR1B density in the growing 
subordinate follicles, and the reduced BMPR1B activity observed in the down-regulation of 
FSHR and BMPR1B in preparation for ovulation of the dominant follicle (Chen, et al. 2009). 
In another study, FSH and BMP ligand-induced production of oestrogen was significantly 
increased in the BB compared to the WT, which is also supportive of the present findings of 
an increased density of FSHR and LHR in the BB (Figure 5.3.2) (Campbell, et al. 2006). 
 
In support of the dynamic role of BMPs, it has also been shown that BMP6 reduces post-
dominant follicle selection in the rat, and is reduced completely in the ovulating dominant 
follicle (Erickson and Shimasaki 2003). Similarly, BMP15 and BMPR1B activity in the 
oocyte has been shown to be down-regulated before ovulation in sheep (Feary, et al. 2007). 
Furthermore, in cultured rat granulosa cells, BMP15 reduced the expression of FSHR mRNA 
(Otsuka, et al. 2001b). It is therefore possible that the attenuating mutation of the BMPR1B 
signal may reduce the suppression and lead to the up-regulation of FSHR in the BB (Otsuka, 
et al. 2001c).  
5.4.4 Down-regulation in peri-luteal and corpus luteum  
In humans, the BMP2, 6, 7, and 15 were previously, all shown to increase FSHR mRNA 
(Ogura Nose, et al. 2012). The granulosa cells, however, were not cultured in serum free 
culture and therefore spontaneously luteinised. This was acknowledged by the authors of the 
paper. They suggested that the cells were not representative of granulosa cells, but were 
rather granulosa-luteal cells. A reduction in the BMP inhibition therefore seems to be an 
initiating change towards luteinisation. The brief stage-specific, peri-ovulatory decline in 
oestrogen production coincides with the cessation of mitogenic growth and steroidogenic 
differentiation (Komar, et al. 2001). In the present study, the follicles that were not destined 
to ovulate continued to express a high density of receptors across all sizes in the WT, 
whereas, in the BB, they were inconsistent (Figure 5.3.3 and Figure 5.3.4). The possible 
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mechanism involved may be related to the ability of the BB to prepare multiple follicles for 
ovulation.  
5.4.5 Steroidogenic differentiation & LHR earlier acquisition 
In the past, it has been recognised that the increase in ovulation rate in BB sheep is a result of 
the follicles being more sensitive to FSH at an earlier follicle size (Baird and Campbell 1998, 
McNatty, et al. 1985). The previously reported increased sensitivity to both FSH and LH can 
now be attributed to the novel findings in this study, of an increased density of the mature 
FSHR and LHR at the cell surface, which has not previously been reported (Figure 5.3.2A 
and Figure 5.3.2 C). In particular, the cAMP response to FSH and LH stimulation was 
previously shown to increase at >3-4 mm, and >2-3 mm respectively, in the BB, which is 
consistent with the present findings (Figure 5.3.2A and Figure 5.3.2C) (Henderson, et al. 
1985).  
 
The up-regulation of LHR provides expanded evidence of an earlier acquisition of receptors 
with greater expression density at an earlier follicle size of 3 mm in the BB compared to 4.2 
mm in the WT genotype (Figure 5.3.2). Furthermore, we demonstrated that the LHRs are 
present in granulosa cells from antral follicles. This was previously reported to be first 
expressed in secondary follicles in humans, but it was not observed in the rodent until late 
antral stage (Camp, et al. 1991, Yung, et al. 2014).  
 
Consistent with other authors, LHR density in the present study was accelerated in the pre-
ovulatory follicle in the WT and the BB and it was followed by a significant reduction in the 
leading dominant follicle of each animal (Figure 5.3.3C and Figure 5.3.4 C) (Jeppesen, et al. 
2012, LaPolt, et al. 1992, Ophir, et al. 2014). The ovine granulosa cells in the present study 
would have been exposed to the LH surge that initiates cytoskeletal reorganisation, the 
cessation of proliferation, and the alteration of steroidogenic capacity. The process of 
luteinisation appears to rely on LHR down-regulation of the leading dominant follicles 
(Figure 5.3.4B) (Fan, et al. 2009, Izadyar, et al. 1998b).  
5.4.6 Ovulation rate and apoptosis 
There are several ways that a high prolificacy breed increases ovulation rate, and it appears 
that the BB follicles may mature early because of an increased receptor density and a 
reduction in atretic follicles or apoptosis, as was reported in the present study and previous 
studies (Driancourt, et al. 1985, Estienne, et al. 2015, McNatty, et al. 1986a). The increased 
FSHR and the ability to wait up to two days allows the subordinate follicles to continue to 
grow, which resulted in the three fold increase in the terminal-end follicles that was reported 
in the present study (Figure 5.3.6) and by others (Driancourt, et al. 1985, McNatty, et al. 
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1986a). It was indeed evident that the post-ovulation BB sheep produced three corpus lutea, 
and that the very large BB pre-ovulatory follicle of 4.5 mm had not ovulated, possibly 
because the next subordinate follicle was only 2.4 mm, which thereby delayed ovulation 
(Figure 5.3.5) (Driancourt, et al. 1985, McNatty, et al. 1986a). The prolonged delay may 
have initiated the exceptionally high level of apoptosis and necrosis that was observed, 
seeing that the size of the follicle was not typical for the genotype. 
 
The finding of significantly less apoptosis and necrosis in the pre-ovulatory follicles of the 
BB is consistent with the number of follicles recorded at the ovulatory size in the BB, which 
was three times the amount remaining in the WT (Table 5.3:1, Figure 5.3.4 and Figure 5.3.5). 
The high level of apoptosis and necrosis in the largest of the subordinate follicles in the WT 
is supportive of the increased rate of follicle loss and results in fewer ovulations than the BB 
(Figure 5.3.6 ). Moreover, the WT dominant and luteal follicles continued to have high levels 
of cell death, whereas, in the BB, the levels were generally low pre- and post-ovulation 
(Figure 5.3.5). It is important to note that, in the present study, we did not excluded any 
follicles on the basis of oestrogen production or morphological indications of programmed 
DNA Fragmentation, because previous findings have demonstrated that the LHR binding 
assays did not reveal any difference between the follicles that were deemed non-atretic in the 
same size class (McNatty, et al. 1986b). Furthermore, it has also been reported more recently 
that granulosa cell apoptosis (which is indicated by DNA fragmentation and cytoplasmic 
blebbing) can be present with functional steroidogenic mitochondria (Amsterdam, et al. 
2003). It is, however, acknowledged that the levels of follicle apoptosis and cell DNA 
fragmentation are lower in antral follicles with greater oestrogen production compared to 
androgen production (Yuan and Giudice 1997). The reduction in BB apoptosis may be a 
result of the maintained, elevated levels of FSH after divergence as compared to the declining 
FSH in the WT (Baird 1987), or due to the increased FSHR density being more responsive to 
the FSH levels available.  
5.4.7 Conclusion 
In conclusion, these results provide further insight into the mechanism that governs the 
interaction between gonadotrophins and intra-ovarian BMPs in the regulation of ovulation 
rate. These results are significant and central to the development of a new clinical approach 
to improve human female fertility. Rather than focusing on increasing the patient’s response 
to exogenous gonadotrophins, in order to increase the ovulation rate, a targeted approach 
could be incorporated by manipulating the signalling pathways of BMPs. A new approach 
would be particularly beneficial to sub-fertile patients who respond poorly to gonadotrophin 
stimulation.  
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CHAPTER 6 Ovarian Ageing and BMPR1B 
6.1 Introduction 
Reproductive ageing is linked to the declining capacity to regenerate cells and tissues, 
causing irreversible changes to ovarian cellular dynamics and ultimately reducing the 
capacity to reproduce. As the average age of fertility-challenged patients climbs towards 40 
years, there is an urgency to characterise the cellular changes that occur in the ovary with 
time. The response of the ovaries to cyclic recruitment of primordial follicles forms the basis 
of the clinical documentation of the AFC (Almog, et al. 2011). The AFC and age are highly 
correlated to histologically determined ovarian primordial reserve (Hansen, et al. 2011, van 
Rooij, et al. 2005). As the primordial follicle reserve declines, the endocrine, paracrine, and 
autocrine regulation adapts to a changing environment. It is this changing landscape that 
requires further investigation to provide alternative treatment to preserve the primordial 
follicles and to adjust the cellular regulation to achieve oocyte competence and improve 
fertility rates in older patients.  
 
The earlier research has highlighted the role BMP signalling has in regulating ovulation rate 
in sheep, and has led us to further investigate the molecular regulation of folliculogenesis by 
the BMPs (Regan, et al. 2015, Ruoss, et al. 2009). During a natural cycle small antral 
follicles with sufficient FSHR are recruited in response to the intercycle rise in FSH and one 
of these is subsequently selected to become the dominant follicle. Follicles with reduced 
FSHR and LHR become less responsive as the dependence from pituitary FSH stimulation 
shifts to LH, and circulating FSH concentrations decline (Lapolt, et al. 1990, Xu, et al. 1995, 
Zeleznik, et al. 1974). These subordinate follicles are destined for atresia. The selected 
dominant follicle is the one with greatest gonadotrophin responsiveness, and is dependent on 
the acquisition of FSHR-induced LHR by granulosa cells; and this follicle continues growing 
to the ovulatory stage.  
 
Previous research has shown that at the time of declining FSH levels, a reduction in BMP 6 
(Erickson and Shimasaki 2003), BMP 15 (Feary, et al. 2007) and the type 1 TGFβ receptor 
BMPR1B (Feary, et al. 2007) occurs after dominant follicle selection. Once selected, follicle 
growth and cellular proliferation continues, leading to an increased oestrogen and inhibin 
production by the granulosa cells. Together, these hormones suppress pituitary FSH output 
further, ensuring the demise of subordinate follicles. When the threshold for oestrogen’s 
positive feedback action on the hypothalamus-pituitary axis is met, preparation for the 
ovulation phase begins with a cessation of cell proliferation and early luteinisation changes 
taking place.  
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During cellular and steroidogenic differentiation activin (Young, et al. 2012), insulin-like 
peptide 3 (INSL3) (Anand-Ivell, et al. 2013), AMH (Andersen, et al. 2010, Ogura Nose, et al. 
2012, Weenen, et al. 2004), and gonadotrophin surge attenuating factor (GnSAF) activity 
declines from dominant follicle selection to the termination of folliculogenesis at ovulation 
(Martinez, et al. 2002).  
 
The BMP ligands, 2, 4, 6, 7, and 15 form a receptor-ligand complex with the type 1 TGFβ 
receptor BMPR1B, and recruit the type 2 TGFβ receptor BMPR2. The complex initiates 
phosphorylation of the intracellular substrate molecules, receptor-regulated Smads. The 
Smad forms a complex with a common mediator, Smad 4, and translocates to the nucleus 
where transcription of genes required by the cell takes place. Smad signalling is modulated 
by repressor and activator molecules in the nucleus, cytoplasm and in the extracellular 
matrix. Alternatively, BMPs activate the non-Smad pathway MAPK such as ERK 1/2. 
(Inagaki, et al. 2009). 
 
In the ovary, granulosa cell signalling induced by the gonadotrophins, FSH and LH, activate 
the FSHR or LHR and stimulate cAMP-PKA, which increases the CYP19A1 aromatase to 
facilitate oestrogen synthesis. Progesterone synthesis is inhibited by the suppression of StAR 
(Pierre, et al. 2004, Tajima, et al. 2003, Val, et al. 2003), which is essential for progesterone 
synthesis in the granulosa cell (Moore, et al. 2001b). Alternatively, or in addition, BMPs 
inhibit ERK 1/2 signalling, which provides inhibitory control over the balance of 
progesterone and oestrogen (Miyoshi, et al. 2007, Nakamura, et al. 2012, Ogura Nose, et al. 
2012). BMP signalling activity has been established not only in the ovary but in the pituitary, 
where ERK and JNK signalling has been shown to increase LHβ (Harris, et al. 2002), and 
BMP 15 via ERK, to increase FSHβ (Otsuka and Shimasaki 2002). In addition, BMP 6 and 7 
were shown to regulate FSHβ (Takeda, et al. 2012). Given the above regulatory evidence, it 
is not surprising that the spatial and temporal relationship of BMP expression patterns change 
with an increase in follicular size (Otsuka 2010).  
 
The current study aimed to comprehensively profile the expression of BMPR1B in a range of 
patients, of different ages and stages of ovarian primordial follicle depletion, who were 
receiving treatment for infertility. Previous reports documenting ovarian BMPR1B 
expression have evaluated expression at the mRNA level in pooled follicles from different 
size classes. mRNA expression does not necessarily reflect expression of translated 
functional BMPR1B protein on the cell surface (Chen, et al. 2009, Estienne, et al. 2015). In 
contrast, we collected an average of ~8000 granulosa cells from individual follicles over a 
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comprehensive range of follicle diameters from 4 mm to 38. In addition, we have measured 
the granulosa cell surface-expressed mature receptor protein density for BMPR1B by 
immunofluorescent labelling via flow cytometry. 
6.2 Methods  
Methods are described in detail in the General Methods Chapter (page 38).  
Granulosa cells were collected from hCG/LH induced follicles from patients receiving IVF 
exogenous gonadotrophins to artificially stimulate multiple follicles (Table 6.2:1). The 
granulosa cells were isolated and incubated with antibodies to detect the level of BMPR1B, 
mature protein. In addition, apoptosis and necrosis were also determined by immunolabelling 
via flow cytometric analyses (page 39).  
 
 
Table 6.2:1 Patient ovarian reserve, based on antral follicle count (AFC) and the number 
of follicles collected per group. 
 
Ovarian reserve measured indirectly by the Antral Follicle Count (AFC). AFC is the number of 
follicles between 2-10 mm on day 2-5 of a cycle: A+ = 30-39 follicles; A = 20-29; B = 13-19; C = 9-
12, D = 5-8; E = ≤4.  
  
AGE 
Year 
IVF 
Patient 
Total   
Follicle AFC 
Major 
Group  Number of Follicles Collected Per Group 
      Sub 
Group # 
Sub 
Group # 
Sub 
Group # 
Sub 
Group # 
21-30 8 95 20-40 A+ &A  A+ 31 A 64 C 6   
31-34 11 86 13-29 A & B  A 60 B 26 C 17   
35-39 16 102 9-19 B & C  A+ 6 B 50 C 16 D 30 & E 6 
40-45 18 118 3-8 D & E  D 59 E 19 B 34   
              
40          1         Natural Cycle Healthy D 2       
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6.3 Results 
The level of granulosal BMPR1B expression was down-regulated in the 23-30 y IVF patients 
with a combined AFC of A+ & A in a biphasic receptor density pattern (Figure 6.3.1). The 
receptor density of BMPR1B initially decreased from 8 mm to 10 mm (p<0.05), followed by 
an up-regulation in the follicles to 16 mm (p<0.01); followed by a significant decline in 
follicles to the terminal-end of folliculogenesis of 24-26 mm (p<0.05), (Figure 6.3.1). In 
marked contrast, in the 40+ y group the BMPR1B density increased with follicular size 
(p<0.01) in a monophasic manner, (Figure 6.3.1). In a natural health cycle the receptor 
density of granulosa cells, were collected from a healthy 40+ y with an AFC of D. The two 
follicles of 10 mm and 18.5 mm when combined had a significantly lower density of 
BMPR1B compared to the largest follicles of the 40+ y IVF patients with an AFC D & E 
(Figure 6.3.1). 
 
Figure 6.3.1 Granulosal BMPR1B density from follicles of different sizes collected from 
young and older IVF patients compared to an unstimulated natural healthy cycle. 
 
Granulosal BMPR1B protein density and follicle size profile of a natural healthy unstimulated patient 
of 41y with an AFC of D before the LH surge, (blue). Patients, 23-30y stimulated, IVF cycle with an 
AFC of A+ & A, (olive green). Patients, 40+y stimulated IVF cycle with an AFC of D & E, (orange). 
Ovarian reserve measured indirectly by the antral follicle count (AFC). AFC is the number of follicles 
between 2-10 mm on day 2-5 of a cycle. Mean fluorescent intensity (MFI) was obtained using an 
average of ~8000 granulosa cells per follicle for the direct measurement of receptor protein expression. 
The data were subjected to statistical verification using one-way ANOVA with an uncorrected Fisher’s 
LSD for follicular size. Values in graphs are means ± S.E.M., and differences were considered 
significant if *p<0.05 and **p<0.01. The letter, such as ‘a’ signifies a statistical difference to the 
matching letter, and an attached asterisk (a*) indicates the significance level for the size follicle. 
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In the youngest age group 23-30 y, the majority of the patients had an AFC of A+ & A 
(Figure 6.3.2). There was no significant difference between the A+ group and the A; 
whereas, when the ovarian reserve declined there appears to be a wide range of expression of 
receptors (Figure 6.3.2). The follicles from the C group patients had increased BMPR1B 
expression compared to the similar size follicles in the A+ & A group (p<0.05 to p<0.001, 
Figure 6.3.2) 
 
Figure 6.3.2 Granulosal BMPR1B density and ovarian reserve depletion in 23-30 y. 
Ovarian reserve measured indirectly by the antral follicle count (AFC). AFC is the number of follicles 
between 2-10 mm on day 2-5 of a cycle. Mean fluorescent intensity (MFI) was obtained using an 
average of ~8000 granulosa cells per follicle for the direct measurement of receptor protein expression. 
The data were subjected to statistical verification using one-way ANOVA with an uncorrected Fisher’s 
LSD for follicular size. Values in graphs are means ± S.E.M., and differences were considered 
significant if *p<0.05 and **p<0.01. The letter, such as ‘a’ signifies a statistical difference to the 
matching letter, and an attached asterisk (a*) which indicates the significance level for the size follicle. 
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In the 31-34 y age group the decline in ovarian reserve was associated with a loss of receptor 
density of BMPR1B in the granulosa cells from a peak in the 19 mm follicles in the A group 
to a significantly lower number in the B and C groups (p<0.05, Figure 6.3.3). 
 
. 
 
Figure 6.3.3 Granulosal BMPR1B density and ovarian reserve depletion in 31-34 y. 
Ovarian reserve measured indirectly by the antral follicle count (AFC). AFC is the number of follicles 
between 2-10 mm on day 2-5 of a cycle. Mean fluorescent intensity (MFI) was obtained using an 
average of ~8000 granulosa cells per follicle for the direct measurement of receptor protein expression. 
The data were subjected to statistical verification using one-way ANOVA with an uncorrected Fisher’s 
LSD for follicular size. Values in graphs are means ± S.E.M., and differences were considered 
significant if *p<0.05. The letter, such as ‘a’ signifies a statistical difference to the matching letter, and 
an attached asterisk (a*) indicates the significance level for the size follicle. 
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The 35-39 y B & C group demonstrated a significant down-regulation in the 14 mm to 16 
mm follicles (p<0.05), similar to the youngest age group. With a further decline of the 
ovarian reserve (D & E) the receptor density in the smaller follicles was reduced, (p<0.05), 
followed by a steady increase with increasing follicular size (Figure 6.3.4).  
 
Figure 6.3.4 Granulosal BMPR1B density and ovarian reserve depletion in 35-39 y. 
Ovarian reserve measured indirectly by the antral follicle count (AFC). AFC is the number of follicles 
between 2-10 mm on day 2-5 of a cycle. Mean fluorescent intensity (MFI) was obtained using an 
average of ~8000 granulosa cells per follicle for the direct measurement of receptor protein expression. 
The data were subjected to statistical verification using one-way ANOVA with an uncorrected Fisher’s 
LSD for follicular size. Values in graphs are means ± S.E.M., and differences were considered 
significant if *p<0.05.  
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The 40+ y patients ranged in AFC from B to E, and were between 40-45 y, (Figure 6.3.5). 
The B & C patients combined demonstrate a higher BMPR1B receptor density in the small 
follicles followed by significant down-regulation of receptors as follicle size increased. With 
a decline in the ovarian reserve to D, the receptor density in the smaller follicles was reduced, 
compared to B. With a further decline of ovarian reserve to E (p<0.05, Figure 6.3.5) the 
receptor density significantly increased with follicle size similar to the ageing effect observed 
in the poor ovarian reserve youngest C patients (Figure 6.3.2). 
 
Figure 6.3.5 Granulosal BMPR1B density and ovarian reserve depletion in 40+ y. 
Ovarian reserve measured indirectly by the antral follicle count (AFC). AFC is the number of follicles 
between 2-10 mm on day 2-5 of a cycle. Mean fluorescent intensity (MFI) was obtained using an 
average of ~8000 granulosa cells per follicle for the direct measurement of receptor protein expression. 
The data were subjected to statistical verification using one-way ANOVA with an uncorrected Fisher’s 
LSD for follicular size. Values in graphs are means ± S.E.M., and differences were considered 
significant if *p<0.05 and **p<0.01. The letter, such as ‘a’ signifies a statistical difference to the 
matching letter, and an attached asterisk (a*) which indicates the significance level for the size follicle. 
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6.4 Discussion 
A continuous process of activation of primordial follicles in the ovary leads to the inevitable 
depletion of the ovarian reserve in women (Almog, et al. 2011). The gradual decline in 
ovarian reserve can be indirectly measured by the number of small antral follicles at the 
beginning of a cycle termed the AFC (Hansen, et al. 2011). The response of the ovary to 
exogenous gonadotrophins used to treat infertility declines with age, which is strongly 
correlated to the ovarian reserve (Hansen, et al. 2011). Patients with a poor ovarian reserve 
are treated with increasing doses of rFSH in an attempt to increase the number of small antral 
follicles with sufficient FSHR to develop into pre-ovulatory follicles.  
 
In sheep, the ovulation rate was increased when BMPR1B signalling was attenuated by the 
Booroola natural mutation (Chapter 5) (Regan, et al. 2015). Therefore, the role of BMPR1B, 
and the ovarian ageing effect on ovulation rate are under investigation. In an alternative 
approach used in the present study, the density of expression of mature cell surface protein 
for BMPR1B was measured by flow cytometric analysis. In the study a reduction in the 
number of growing follicles was linked to the sequential disruption to BMPR1B density 
during both dominant follicle selection, and pre-ovulatory maturation. 
6.4.1 Major Findings 
The major finding of this study was that a decline in granulosal BMPR1B receptor density 
occurs at the time of cyclic dominant follicle selection, and again during the terminal stage of 
folliculogenesis in the best prognosis IVF patients aged 23-30 years. The older, 40+ y poor 
ovarian reserve patients experience a reversal of this pattern (Figure 6.3.1). 
 
The biphasic down-regulation of the density of the TGFβ type I receptor, BMPR1B protein 
during folliculogenesis was similar to the finding in young adult normal sheep, presented 
earlier in Chapter 5 and below Figure 6.4.1. During dominant follicle selection in sheep and 
in humans granulosal expression of BMPR1B was reduced followed by a sequential increase 
with follicle size, peaking, and then reducing in the pre-ovulatory follicle in humans or in the 
leading dominant follicle in the wild-type sheep (Figure 6.4.1). In other studies granulosa cell 
expression of BMPR1B has been shown to increase with follicle size which is consistent with 
the findings (Chen, et al. 2009, Estienne, et al. 2015). However, the pre-ovulatory, leading 
dominant follicle in sheep was pooled with smaller follicles in these studies, which would 
mask the down-regulation. The down-regulation of granulosa cell BMPR1B expression in the 
study was consistent with findings for sheep dominant follicles compared to the subordinate 
follicles reported in another recent study (Gasperin, et al. 2014). The interrelationship 
between FSH and BMP regulation has been previously reported (Miyoshi, et al. 2006, Shi, et 
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al. 2009a, Shi, et al. 2010), and the drop in pituitary FSH secretion initiating the dominant 
follicle selection process would, therefore, be closely related to the decline in BMPR1B 
expression on the granulosa cell surface.  
Figure 6.4.1 Sheep WT BMPR1B density with increasing follicular size. 
SF subordinate follicle 3.2-4.6 mm, and DF Dominant Follicle, 4.4-7 mm. Mean fluorescent Intensity 
(MFI) was obtained using an average of ~8000 granulosa cells per follicle for the direct measurement 
of receptor protein expression. The data were subjected to statistical verification using one-way 
ANOVA with an uncorrected Fisher’s LSD for follicular size. Values in graphs are means ± S.E.M., 
and differences were considered significant if *p<0.05 and **p<0.01. The letter, such as ‘a’, signifies a 
statistical difference to the matching letter and an attached asterisk (a*) indicates the significance level 
for the size follicle.  
 
In the current study, granulosal BMPR1B density provides an indication of possible BMP 
ligand receptor signalling. The signalling potential activity of BMPR1B is measured by the 
density of the receptor which is common to several TGFβ superfamily members. The BMPs 
4, 6, 7, and 15 signal via the TGFβ type 1 receptor BMPR1B, and have been previously 
shown to have a regulatory role in the suppression of progesterone production prior to 
ovulation (Ryan, et al. 2008, Takeda, et al. 2012).  
 
The degenerative ageing of granulosal BMPR1B density is highlighted by the observation 
that 40+ y patients with a favourable AFC of B & C exhibit a pattern of declining receptor 
density with follicle size, whereas the pattern in the 40+ y AFC D & E patient group is 
reversed (Figure 6.3.5). Further evidence of ovarian ageing is apparent in the down-
regulation of BMPR1B density in the 35-39 y in the 14 to 16 mm follicle size class in the B 
& C group; whereas, in the D & E group, a steady increasing density was observed (Figure 
6.3.4). In addition, evidence of ovarian ageing also occurs in the youngest patients of 23-30 y 
with an AFC of C, demonstrating a compensatory over-expression of BMPR1B, destabilising 
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the biphasic expression pattern previously found in young adult Merino sheep, and young 
patients with ample ovarian reserve (Figure 6.4.1) The reversal seen with declining AFC 
rather than chronological age provides compelling evidence of a fundamental shift in 
granulosal BMPR1B receptor density with ovarian ageing.  
 
In the literature there are few studies covering the changing landscape of the follicular gene 
expression with increasing follicular size. In particular, the common practice is to pool the 
follicles into size ranges which have failed to recognise the sometimes subtle change over 
time or the dramatic fall in gene expression as the follicle prepares for ovulation. The 
comprehensive individual nature of the collection has provided compelling evidence of the 
regulatory nature of signal activation by the receptors with changing follicular development 
indicated by size.  
 
The LH surge is characterised by a dramatic shift from proliferation to differentiation and 
maturation of the follicle prior to ovulation. The BMPs have been described as inhibitors of 
the LH surge and luteinisation, however the characterisation of the ovarian molecule that 
reduces pituitary LH secretion has not been identified (Dimitraki, et al. 2014). GnSAF is 
characterised as being produced by the cohort of recruited small antral follicles, which 
regulate folliculogenesis by their desensitising effect on the pituitary to supress LH release 
until the mid-cycle (Dimitraki, et al. 2014). The GnSAF bioactivity is measured indirectly by 
applying steroid free follicular fluid to rat or ovine cultured anterior pituitary cells. 
Figure 6.4.2 Relationship between follicle size and the LH surge attenuating factor 
GnSAF 
Based on data from (Fowler, et al. 2001) 
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The relationship between follicle size and GnSAF has been demonstrated as an inverse 
relationship with follicle size (Figure 6.4.2) (Fowler, et al. 2001). The pituitary 
responsiveness to secrete LH has also been shown to be greater in patients receiving IVF than 
during natural cycles which is consistent with the greater level of BMPR1B reported in the 
current study (Figure 6.3.1) (Fowler, et al. 2001). In addition, the effect of a declining 
ovarian reserve with age resulted in reduced GnSAF bioactivity (Martinez, et al. 2002). The 
comparatively higher level of GnSAF would be accounted for by the greater number of 
follicles producing the attenuating substance in the younger patients compared to the older 
patients (Figure 6.4.3).  
Figure 6.4.3 Ovarian reserve and the relationship between follicle size and the LH surge 
attenuating factor GnSAF. 
Based on data from (Martinez, et al. 2002) 
 
The level of GnSAF was measured at two time points matching the current study’s follicle 
size of 8 mm, (dominant follicle selection), and 19-24 mm (hCG injection or the equivalent 
of the largest follicle), (Martinez, et al. 2002). The younger patients with good ovarian 
response, had high levels of GnSAF at the time of dominant follicle selection which reduced 
dramatically by the end of folliculogenesis (Figure 6.4.3). The opposite was true for the poor 
ovarian response older patients of the study (Figure 6.4.3).  
 
In the current study the granulosal BMPR1B density in the young and the old mimic, in 
reverse, the effect of GnSAF described by Martinez et al. (2002). (Figure 6.4.3). Martinez et 
al. (2002), concluded that the bioactivity of the GnSAF prevented the premature onset of the 
LH surge, which is not dissimilar to the role of BMPs as an inhibitor of luteinisation 
described by others (Otsuka 2010, Shimasaki, et al. 1999). From a clinical perspective, 
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reduced fertilisation rates are common in older patients, due to a higher serum level of FSH, 
LH and inhibin B (Hale 2007, Stanger and Yovich 1985). In the older patient the reduced 
BMPR1B could have the potential to limit the suppression of LH in the pituitary and 
progesterone in the ovary (granulosal) at the time of dominant follicle selection (Chapter 7). 
6.4.2 Conclusion 
Taken together, the results demonstrate the disrupting effect that ageing-induced depletion of 
the ovarian reserve has on granulosal BMPR1B receptor density in antral follicles. Likewise, 
ageing-induced depletion is associated with a biphasic down-regulation of granulosal 
BMPR1B density at the two stage-specific, critical time points of dominant follicle selection 
and pre-ovulatory maturation. The findings extend previous research by the comprehensive 
nature of the range of follicle sizes and age groups studied, together with measurement of the 
translated mature, BMPR1B protein as opposed to measurement of receptor expression at the 
mRNA level (Ascoli, et al. 2002). Further work is needed to confirm the identity of the 
locally-produced TGFβ family ligand(s) (BMP 4, BMP6, BMP 7, and BMP15) whose 
signalling may be impacted by this change in BMPR1B receptor density on the granulosa cell 
surface, and also to explore the consequences of altered signalling.   
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CHAPTER 7 Ovarian Ageing and FSHR 
7.1 Introduction 
At the onset of puberty, the levels of gonadotrophin FSH secreted from the anterior pituitary 
increase to a threshold point sufficient to rescue a cohort of the primordial follicles and 
initiate cyclic folliculogenesis. The primordial follicles grow and differentiate into pre-antral 
follicles, and with further development and the formation of a fluid filled central 
compartment, mature to become antral follicles (Rodgers and Irving-Rodgers 2010b). The 
oocyte is suspended in a fluid filled cavity, which is surrounded by specialised cumulus 
granulosa cells which anchor the oocyte to layers of mural granulosa cells. The follicle wall 
is composed of mural granulosa cells enclosed in a membrane that is wrapped in a layer of 
theca cells. The follicle undergoes proliferation of the granulosa and thecal follicular cells, 
followed by differentiation of the role of the follicular cells as the follicle matures. The 
number of antral follicles selected for dominance and ovulation is dependent on the 
regulation of the gonadotrophins FSH and LH produced in the anterior pituitary, and the 
density of FSHR and LHR on the granulosa cells (Ginther, et al. 2005, Rice, et al. 2007, Sen 
and Hammes 2010, Sen, et al. 2014). 
 
As the FSH level falls, the growth of the smaller subordinate follicles is reduced, and only 
the follicles with sufficient FSHR and LHR continue to develop further because of the 
capacity to convert androstenedione to oestrogen for growth (Loumaye, et al. 2003). Pre-
ovulatory follicles reach an oestrogen threshold promoting a change from a proliferation to 
differentiation of the granulosa cells in preparation for ovulation. Substantial reorganisation 
of the cytoplasm occurs during this maturation stage, reflected by a change to receptor 
density. The relative expression of FSHR and the stage of follicle development have been 
shown to have a negative effect on the ovarian response to gonadotrophin stimulation (Cai, et 
al. 2007) and diminished LHR in the oocyte quality (Maman, et al. 2012).  
 
Artificially increasing the level and the duration of circulating FSH extends the window of 
growth, producing multiple ovulatory follicles. As the ovarian primordial follicle reserve 
declines, the rate of recruitment to primary follicles is reduced, which leads to a diminished 
recruitment of follicles into the cycle. The number of small antral follicles at the beginning of 
each cycle is representative of the ovarian reserve of primordial follicles remaining in the 
ovary (Almog, et al. 2011, Baerwald, et al. 2012b, Hadlow, et al. 2013, Hansen, et al. 2011, 
van Rooij, et al. 2005). AMH and chronological age also have a strong correlation to ovarian 
reserve; however, AFC demonstrates a more sensitive test over a time course (van Rooij, et 
al. 2005) and, in the case of AMH, in the older patients (i.e. the lower range of 0-1ng/ml) 
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(Hansen, et al. 2011). During an IVF cycle, the concentration of exogenous FSH required to 
maintain a cohort of follicles to grow to ovulatory size increases sequentially with a 
reduction of ovarian reserve or AFC. Clinicians have developed protocols based on past 
patient ovarian responses to rFSH stimulation, which can be highly predictable (Yovich, et 
al. 2012). Superovulation syndrome has become a rare complication using best practice 
principles. With the increase in the average age of patients seeking assistance, to 39 years in 
Australia, the number of patients that respond poorly to gonadotrophin stimulation has risen. 
 
We aim to comprehensively profile the receptor expression of FSHR in a range of patients of 
different ages and stages of ovarian primordial depletion, who are receiving treatment for 
infertility. Previous accounts of receptor expression have utilised the mRNA of the receptors, 
which would include a large proportion of non-functional immature FSHR (Ascoli, et al. 
2002, Jeppesen, et al. 2012, Pidoux, et al. 2007). However, in contrast, for the current study 
an average of ~8000 granulosa cells from an individual follicle was collected from a 
comprehensive range of follicle sizes from 4 mm to 27 mm. In addition, we measured the 
granulosa cell surface-expressed mature receptor protein density for FSHR by 
immunofluorescent labelling via flow cytometry. 
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7.2 Method 
Methods are described in detail in the General Methods Chapter (page 38).  
Granulosa cells were collected from hCG/LH induced follicles from patients receiving IVF 
exogenous gonadotrophins to artificially stimulate multiple follicles (Table 7.2:1). The 
granulosa cells were isolated and incubated with antibodies to detect the level of FSHR 
mature protein. In addition, apoptosis and necrosis were also determined by immunolabelling 
via flow cytometric analyses (page 39).  
Table 7.2:1 Patient ovarian reserve, based on antral follicle count (AFC) and the number 
of follicles collected per group. 
 
 
Ovarian reserve measured indirectly by the Antral Follicle Count (AFC). AFC is the number of 
follicles between 2-10 mm on day 2-5 of a cycle: A+ = 30-39 follicles; A = 20-29; B = 13-19; C = 9-
12, D = 5-8; E = ≤4.  
 
  
AGE 
Year 
IVF 
Patient 
Total   
Follicle AFC 
Major 
Group  Number of Follicles Collected Per Group 
      Sub 
Group # 
Sub 
Group # 
Sub 
Group # 
Sub 
Group # 
21-30 8 95 20-40 A+ &A  A+ 31 A 64 C 6   
31-34 11 86 13-29 A & B  A 60 B 26 C 17   
35-39 16 102 9-19 B & C  A+ 6 B 50 C 16 D 30 & E 6 
40-45 18 118 3-8 D & E  D 59 E 19 B 34   
              
40          1         Natural Cycle Healthy D 2       
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7.3 Results 
In the 23-30 y patient group, with an AFC of A+ & A combined, the FSHR was significantly 
down-regulated after dominant follicle selection in follicles of 8 mm to 10 mm, and again 
from follicles of 16 to 24 mm (p<0.05 and p<0.05, respectively, Figure 7.3.1). In the oldest 
group of 40+ y AFC D & E combined, there was significant elevation of density in the 4 mm 
follicle in keeping with the 23-30 y density pattern, but not in the terminal-end 19 mm 
follicles, where no down-regulation occurred compared to the young patients (p<0.0001, 
Figure 7.3.1). In addition, the natural healthy cycle follicles appeared to have a lower density 
than the IVF patients; however, this did not reach significance (Figure 7.3.1). 
 
Figure 7.3.1 Granulosal FSHR density from follicles of different sizes collected from 
young and older IVF patients compared to an unstimulated natural healthy cycle. 
Granulosal FSHR density and follicle size profile of a natural healthy unstimulated patient of 41y with 
an AFC of D before the LH surge, (blue). Patients, 23-30y stimulated, IVF cycle with an AFC of A+ 
& A, (olive green). Patients, 40+y stimulated IVF cycle with an AFC of D & E, (orange). Ovarian 
reserve measured indirectly by the antral follicle count (AFC). AFC is the number of follicles between 
2-10 mm on day 2-5 of a cycle. Mean fluorescent intensity (MFI) was obtained using an average of 
~8000 granulosa cells per follicle for the direct measurement of receptor protein expression. The data 
were subjected to statistical verification using one-way ANOVA with an uncorrected Fisher’s LSD for 
follicular size. Values in graphs are means ± S.E.M., and differences were considered significant if 
*p<0.05 and **p<0.01.  
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In the young patient group of 23-30 y with a good ovarian reserve down regulation of FSHR was 
observed during dominant follicle selection and during the pre-ovulatory maturation phase in the 
largest follicles(p<0.05, Figure 7.3.2). The young patient with a poor ovarian reserve of C produced 
elevated levels of FSHR density which increased with an increase in follicle size (p<0.01, Figure 
7.3.2).  
 
Figure 7.3.2 Granulosal FSHR density and ovarian reserve depletion in 23-30 y. 
Granulosal FSHR density and follicle size of the young 23-30 y patients with declining ovarian reserve 
from A+ & A to C. Mean fluorescent Intensity (MFI) was obtained using an average of ~8000 
granulosa cells per follicle for the direct measurement of receptor protein expression. The data were 
subjected to statistical verification using one-way ANOVA with an uncorrected Fisher’s LSD for 
follicular size. Values in graphs are means ± S.E.M., and differences were considered significant if 
*p<0.05 and **p<0.01. The letter, such as ‘a’ signifies a statistical difference to the matching letter, 
and an attached asterisk (a*) which indicates the significance level for the size follicle.   
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In the 31-34 y patient group, the follicles had increasing levels of granulosal FSHR density 
with increasing follicle size, whereas the follicles from the 35-39 y B & C patient group 
partially mimicked the younger pattern of density, whereby the peak reached at 14 mm was 
followed by a significant down-regulation in the 19 mm follicles (p<0.05, Figure 7.3.3 and 
Figure 7.3.4). The FSHR density was significantly up-regulated in the terminal-end follicles 
(19-24 mm) from both the 31-34 y and 35-39 y patients compared to the 23-30 y patient 
group (p<0.01 and p<0.001 respectively, Figure 7.3.3and Figure 7.3.4, compared to Figure 
7.3.2).  
 
Figure 7.3.3 Granulosal FSHR density and ovarian reserve depletion in 31-34 y. 
Granulosal FSHR density and follicle size of the 31-34 y patients with declining AFC from A to B & 
C. Ovarian reserve measured indirectly by the antral follicle count (AFC). AFC is the number of 
follicles between 2-10 mm on day 2-5 of a cycle. Mean fluorescent intensity (MFI) was obtained using 
an average of ~8000 granulosa cells per follicle for the direct measurement of receptor protein 
expression. The data were subjected to statistical verification using one-way ANOVA with an 
uncorrected Fisher’s LSD for follicular size. Values in graphs are means ± S.E.M., and differences 
were considered significant if *p<0.05. The letter ‘a’ signifies a statistical difference to the matching 
letter, and an attached asterisk (a*) which indicates the significance level for the size follicle.   
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Figure 7.3.4 Granulosal FSHR density and ovarian reserve depletion in 35-39 y. 
Granulosal FSHR density and follicle size of the 35-39 y patients with declining AFC from B & C 
combined to D&E combined. Ovarian reserve measured indirectly by the antral follicle count (AFC). 
AFC is the number of follicles between 2-10 mm on day 2-5 of a cycle. Mean fluorescent Intensity 
(MFI) was obtained using an average of ~8000 granulosa cells per follicle for the direct measurement 
of receptor protein expression. The data were subjected to statistical verification using one-way 
ANOVA with an uncorrected Fisher’s LSD for follicular size. Values in graphs are means ± S.E.M., 
and differences were considered significant if *p<0.05. The letter, such as ‘a’ signifies a statistical 
difference to the matching letter, and an attached asterisk (a*) which indicates the significance level 
for the size follicle. 
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The granulosal FSHR density of 40+ y patient group, with an ovarian reserve of B & C, 
mimicked the 23-30 y ovarian reserve A pattern shown in Figure 7.3.2, with an initial 
significant down-regulation at 10 mm followed by an up-regulation at 16 mm (p<0.001 and 
p<0.05, respectively, Figure 7.3.5). As the ovarian reserve declined, the granulosal FSHR 
density of the 40+ y, D & E groups was not down-regulated. The granulosal FSHR density of 
the 40+ y ovarian reserve, D group was not significantly different to the E group (Figure 
7.3.5). 
 
 
Figure 7.3.5 Granulosal FSHR density and ovarian reserve depletion in 40+ y. 
Granulosal FSHR density and follicle size of the 40+ y patient group with declining AFC from B & C 
combined to D and E. Ovarian reserve measured indirectly by the antral follicle count (AFC). AFC is 
the number of follicles between 2-10 mm on day 2-5 of a cycle. Mean fluorescent intensity (MFI) was 
obtained using an average of ~8000 granulosa cells per follicle for the direct measurement of receptor 
protein expression. The data were subjected to statistical verification using one-way ANOVA with an 
uncorrected Fisher’s LSD for follicular size. Values in graphs are means ± S.E.M., and differences 
were considered significant if *p<0.05, **p<0.01, ***p<0.005, and ****p<0.001. The letter, such as 
‘a’ signifies a statistical difference to the matching letter, and an attached asterisk (a*) which indicates 
the significance level for the size follicle. 
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7.4 Discussion 
The gonadotrophin FSH has been strongly associated with the regulatory control of cyclic 
folliculogenesis (Yong, et al. 1992). The level of granulosal FSHR density has been 
previously shown to fluctuate during folliculogenesis, at the time of dominant follicle 
selection and at the terminal-end prior to ovulation (Cai, et al. 2007, Jeppesen, et al. 2012, 
Ophir, et al. 2014). In a novel approach, the mature cell surface receptor protein for FSHR 
was measured in the current study by flow cytometric analysis. Immunolabelled granulosa 
cells were collected from individual antral follicles during the peri-ovulatory stage, from 
patients receiving IVF treatment for infertility. The receptor density was quantified by the 
average fluorescent intensity of ~8000 isolated granulosa cells per follicle from a range of 
follicle sizes.  
 
The continuous process of ovarian ageing reduces the primordial follicle reserve, and can be 
indirectly measured by the number of small antral follicles developing (Almog, et al. 2011, 
Baerwald, et al. 2012b, Hansen, et al. 2011, van Rooij, et al. 2005). A depleted reserve 
generates a natural state of menopause, and results in the loss of ovarian function. The 
decline in the AFC predominantly coincides with an increase in chronological age; however, 
at any given age there is an overlap in the range of AFC. Premature ovarian failure does 
occur in younger patients; however, it is an uncommon form of infertility (1-2%) (Shelling 
2010). Rather, a general reduction of fertility occurs with the decline of the ovarian reserve 
that results in subtle changes to ovarian regulation with time. The present study provides a 
novel description of the change to the granulosal FSHR density that occurs with ovarian 
ageing during the defining stages of follicular development, dominant follicle selection and 
pre-ovulatory follicle maturation.  
7.4.1 Major Findings 
The major findings of the current study were the high level of granulosal FSHR density in the 
smaller antral follicles, and that the depletion of the ovarian reserve did not generally disrupt 
the expression. Conversely, the down-regulation of granulosal FSHR density during the 
maturation process was disrupted by ovarian reserve depletion. In addition, a rise in 
granulosal FSHR density was evident between dominant follicle selection and pre-ovulatory 
maturation. 
7.4.2 Dominant follicle selection 
The dominant follicle selection (8 mm) and terminal-end maturation (19 mm) down-
regulation in the granulosal FSHR density observed in the current study, was similarly 
observed in WT Merino sheep (Chapter 5) (Regan, et al. 2015).  
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As part of the dominant follicle selection process, follicles with a greater density of FSHR 
would induce more LHRs (Rice, et al. 2007). As the level of pituitary FSH is reduced, 
follicles with LHRs retain the capacity to produce oestrogen from androgens, whereas those 
follicles without sufficient LHR succumb to atresia (Ginther, et al. 2001, Mihm, et al. 2006).  
In the present study, granulosal FSHR density was high in the smaller antral follicles and was 
consistent with a change from FSH dependency before dominant follicle selection, and 
pituitary FSH secretion decline during dominant follicle selection.  
 
The finding of a high density of granulosal FSHR density in the 8 mm follicles from the 23-
30 y patient group (A+ & A) appears not to be disrupted by ovarian reserve depletion in the 
older patient groups. However, in the 35-39 y B & C group the 5 mm follicles did not have 
high levels of granulosal FSHR density which indicates a possible inadequacy in receptor 
density during dominant follicle selection (Figure 7.3.4). In several patient groups the smaller 
follicle size was not collected, and therefore, the high granulosal FSHR density would not 
have been observed. 
 
Consistent with the current study, Jeppesen et al., (2012) have previously reported a high 
expression of FSHR mRNA in granulosa cells from small antral follicles of ~ 6 mm collected 
from a wide range of patients (7-38 y). The elevated FSHR mRNA levels were followed by a 
constant, lower level of expression from ~ 9 to 15 mm, which is also consistent with the 
present study’s findings (Jeppesen, et al. 2012). The current study confirms and expands their 
data by reporting that, after dominant follicle selection, the high level of granulosal FSHR 
density was dramatically reduced in the 10 mm follicles, followed by an increase in FSHR in 
the 16 mm follicles from the 23-30 y patient group A & A+ (Figure 7.3.2).  
7.4.3 Maturation of the pre-ovulatory follicle 
At the terminal-end of folliculogenesis, proliferation of the granulosa cell is reduced and 
divergence of steroidogenic capacity to predominantly synthesis progesterone commences 
during the maturation process before ovulation. Ovarian ageing appears to disrupt the 
prerequisite down-regulation of granulosal FSHR density observed in the 23-30 y patient 
group (A+ & A) (Figure 7.3.1). In the older patient groups granulosal FSHR density 
increases or remains constant as the ovarian reserve depletes (Figure 7.3.1- Figure 7.3.5) 
 
In the sheep study, the down-regulation of granulosal FSHR density during the pre-ovulatory 
follicle maturation was evident in both the WT and BB sheep (Chapter 5) (Regan, et al. 
2015). The sheep were young (four years old) hence their ovarian reserve would be 
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uncompromised, and therefore comparable to the young IVF patients with a good ovarian 
reserve in the current study. 
 
7.4.4 Natural cycle compared to an IVF stimulated cycle 
The Jeppesen’s et al. (2012), study was conducted primarily on patients that were not 
receiving rFSH stimulation, whereas only one patient in the current study was recruited 
without IVF stimulation, and produced two follicles (Figure 7.3.1). The natural cycle follicles 
provided a benchmark for the 40+ y AFC D patient group, and indicated that either the levels 
of granulosal FSHR density was lower in a natural cycle compared to an IVF cycle or the 
biphasic down-regulation had occurred in the natural cycle. In addition, rFSH has been 
previously shown to steadily increase FSHR in granulosa cells of the rat, followed by a 
decrease in FSHR caused by the hCG/LH bolus (LaPolt, et al. 1992). Therefore, it is probable 
that the level of FSHR in an IVF stimulated patient appears higher than in an unstimulated 
cycle (Figure 7.3.1).  
7.4.5 Conclusion 
In conclusion, it is apparent that ovarian ageing, as measured by the reduction in antral 
follicle count, may disrupt the down-regulation of the granulosal FSHR density required for 
maturation of the follicle before ovulation. 
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CHAPTER 8 Ovarian Ageing and LHR 
8.1 Introduction 
The process of folliculogenesis involves the stage dependent expression of growth factor 
receptors that regulate follicular growth (Erickson and Shimasaki 2001). The oocyte is 
surrounded by specialised cumulus granulosa cells in a fluid filled antral cavity, which is 
anchored to the follicle wall, composed of granulosa and theca cells separated by the basal 
lamina membrane (Baerwald, et al. 2012b, Foxcroft and Hunter 1985, Guraya 1971). The 
follicle undergoes proliferation of granulosa and theca cells, followed by morphological 
differentiation as the follicle matures (Fricke, et al. 1996). The mature pre-ovulatory follicle 
begins to luteinise prior to ovulation, when the follicle wall ruptures, releasing the oocyte for 
capture by the fallopian tube (Eppig 2001, Mihm, et al. 2006, Rodgers and Irving-Rodgers 
2010b, Zeleznik 2001). The number of small antral follicles recruited for dominance and 
ovulation is dependent on the regulation of the gonadotrophins FSH and LH, and the 
interaction with other growth factors during folliculogenesis (Ginther, et al. 2005, Hillier 
2001).  
 
LHRs are induced by FSHRs, and are localised on granulosa cells from small antral follicles 
onwards (Minegishi, et al. 1997, Yung, et al. 2014). Once LHRs are expressed on granulosa 
cells, progesterone produced by the granulosa cells diffuses into the thecal cell, and can be 
converted from pregnenolone to androstenedione in the theca cell. Androstenedione from the 
theca cell can then be converted by the granulosa cell to oestrogen, which is essential for 
growth of the follicle and the oocyte (Miller 2011, Yuan 1998 ). As the oestrogen levels 
reach a threshold point, the pituitary produced FSH is reduced. Follicles with insufficient 
FSHR and LHRs mid-cycle do not sustain growth, and follicular regression proceeds, 
followed by atresia (Campbell, et al. 1999, Ginther, et al. 2012, Luo, et al. 2011, Picton and 
McNeilly 1991).  
 
The suppression of progesterone synthesis in favour of oestrogen appears to be governed by 
the action of the growth factor BMP from the TGFβ family of cytokines (Knight and Glister 
2006, Moore, et al. 2001b). The BMP ligands signal via the type 1 TGFβ receptor BMPR1B 
(Miyazono, et al. 2010), and the role of BMP in the regulation of LHR expression has been 
previously reported (Shi, et al. 2012, Shi, et al. 2011, Shi, et al. 2010, Zhu 2013). The down-
regulation of BMPR1B and FSHR density appears to be fundamental to the process of 
luteinisation of the follicle, presented earlier (Chapter 5 and 6), and previously supported by 
data from Gasperin, et al. (2014) and Regan et al. (2015).  
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With the reduction in BMPR1B density, the LH surge (including the simultaneous 
progesterone and FSH surge) stimulate a myriad of changes to completely reorganise and 
differentiate the granulosa and thecal cells for corpus luteum function (Micevych, et al. 2003, 
Nottola, et al. 2006). Therefore, the density of ovarian LHR during folliculogenesis would 
impact the growth and maturation of the follicle and the oocyte.  
 
A continuous process of activation of primordial follicles reduces the ovarian reserve over 
time (Hansen, et al. 2011). Depletion of the ovarian reserve reduces the number of growing 
follicles available for recruitment into the menstrual cycle. The ovarian reserve can be 
indirectly measured by the number of small antral follicles growing, and is referred to in a 
clinical setting as the AFC (Almog, et al. 2011). Ageing depletes the ovarian reserve, 
creating a state of menopause and results in the loss of ovarian function (Nelson, et al. 2013). 
Chronological age correlates well with the rate of depletion of the ovarian reserve; however, 
for any age group, there is an overlap of the AFC (Almog, et al. 2011, van Rooij, et al. 2005). 
Given the average age of women seeking assistance in Australia is 39 years, the need exists 
to investigate the age related changes occurring in the ovary as the ovarian reserve 
diminishes.  
 
The current study aimed to comprehensively profile the ovarian granulosal LHR density in a 
range of patients of different ages and stages of ovarian primordial depletion, who were 
receiving treatment for infertility. Previous reports documenting ovarian LHR expression 
have evaluated expression at the mRNA level in pooled follicles from different size classes. 
mRNA expression does not necessarily reflect expression of translated functional LHR 
protein on the cell surface (Ascoli, et al. 2002, Jeppesen, et al. 2012, Pidoux, et al. 2007). In 
contrast, a much larger number of granulosa cells (~8000) were collected in the current study, 
from individual follicles over a comprehensive range of follicle diameters from 4 to 27 mm. 
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8.2 Methods  
Methods are described in detail in the General Methods Chapter (page 38).  
Granulosa cells were collected from hCG/LH induced follicles from patients receiving IVF 
exogenous gonadotrophins to artificially stimulate multiple follicles (Table 8.2:1). The 
granulosa cells were isolated and incubated with antibodies to detect the level of BMPR1B, 
FSHR, LHR, and GHR mature protein. In addition, apoptosis and necrosis were also 
determined by immunolabelling via flow cytometric analyses (page 39).  
 
Table 8.2:1 Patient ovarian reserve, based on antral follicle count (AFC) and the 
number of follicles collected per group. 
 
 
Patient ovarian reserve, based on antral follicle count (AFC) and the number of follicles collected per 
group. Ovarian reserve measured indirectly by the Antral Follicle Count (AFC). AFC is the number of 
follicles between 2-10 mm on day 2-5 of a cycle: A+ = 30-39 follicles; A = 20-29; B = 13-19; C = 9-
12, D = 5-8; E = ≤4.   
  
AGE 
Year 
IVF 
Patient 
Total   
Follicle AFC 
Major 
Group  Number of Follicles Collected Per Group 
      Sub 
Group # 
Sub 
Group # 
Sub 
Group # 
Sub 
Group # 
21-30 8 95 20-40 A+ &A  A+ 31 A 64 C 6   
31-34 11 86 13-29 A & B  A 60 B 26 C 17   
35-39 16 102 9-19 B & C  A+ 6 B 50 C 16 D30 &E6 
40-45 18 118 3-8 D & E  D 59 E 19 B 34   
              
40          1         Natural Cycle Healthy D 2       
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8.3 Results  
In the youngest patients of 23-30 y with an AFC of A+ & A, the level of LHR density was 
consistent from the 8 mm follicle to the 19 mm follicle whereas, in the largest follicles of 24 
mm, a significant down-regulation was apparent, (p<0.05, Figure 8.3.1). The pre-ovulatory 
follicle density of LHR in the natural, healthy, unstimulated patient of 40+ y, with an AFC of 
D was comparable to the level reached in both the young or older IVF patients whereas, the 
10 mm follicle in the natural cycle was substantially lower (Figure 8.3.1). 
 
 
 
Figure 8.3.1 Granulosal LHR density from follicles of different sizes collected from young 
and older IVF patients compared to an unstimulated natural healthy cycle. 
Granulosal LHR protein density and follicle size profile of a natural healthy unstimulated patient of 
41y with an AFC of D before the LH surge, (blue). Patients, 23-30y stimulated, IVF cycle with an 
AFC of A+ & A, (olive green). Patients, 40+y stimulated IVF cycle with an AFC of D & E, (orange). 
Ovarian reserve measured indirectly by the antral follicle count (AFC). AFC is the number of follicles 
between 2-10 mm on day 2-5 of a cycle. Mean fluorescent intensity (MFI) was obtained using an 
average of ~8000 granulosa cells per follicle for the direct measurement of receptor protein expression. 
The data were subjected to statistical verification using one-way ANOVA with an uncorrected Fisher’s 
LSD for follicular size. Values in graphs are means ± S.E.M., and differences were considered 
significant if *p<0.05.  
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In addition, the follicles from patients with an AFC of C within the 23-30 y group expressed 
more LHR in the 10 mm range (p<0.01 and p<0.01, respectively), which was significantly 
down-regulated with increasing follicular size (p<0.05,Figure 8.3.2). The level of expression 
in the C AFC was much greater than that of the uncompromised A+ & A group, however 
there were only two follicles analysed per follicle size in the C patient group, hence the 
significance was weak. 
 
Figure 8.3.2 Granulosal LHR density and ovarian reserve depletion in 23-30 y. 
Ovarian reserve measured indirectly by the antral follicle count (AFC). AFC is the number of follicles 
between 2-10 mm on day 2-5 of a cycle. Mean fluorescent Intensity (MFI) was obtained using an 
average of ~8000 granulosa cells per follicle for the direct measurement of receptor protein expression. 
The data were subjected to statistical verification using one-way ANOVA with an uncorrected Fisher’s 
LSD for follicular size. Values in graphs are means ± S.E.M., and differences were considered 
significant if *p<0.05. The letter ‘ω or Φ’ signifies a statistical difference to all other follicles of the 
A+ & A patient group. 
.  
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In the follicles from the 31-34 y AFC group A, there was a significant up-regulation from the 
14 mm to the 19 mm follicles, (p<0.01, Figure 8.3.3). The density of LHR was significantly 
reduced in the B and C AFC groups in the largest follicles of 19 mm (p<0.01, p<0.005, 
respectively, (Figure 8.3.3); and with a decline in AFC, the overall density of LHR declined 
(Figure 8.3.3). 
 
Figure 8.3.3 Granulosal LHR density and ovarian reserve depletion in 31-34 y. 
Ovarian reserve measured indirectly by the antral follicle count (AFC). AFC is the number of follicles 
between 2-10 mm on day 2-5 of a cycle. Mean fluorescent intensity (MFI) was obtained using an 
average of ~8000 granulosa cells per follicle for the direct measurement of receptor protein expression. 
The data were subjected to statistical verification using one-way ANOVA with an uncorrected Fisher’s 
LSD for follicular size. Values in graphs are means ± S.E.M., and differences were considered 
significant if *p<0.05, **p<0.01 and ***p<0.005. The letter, such as ‘a’ signifies a statistical 
difference to the matching letter. and an attached asterisk (a*) which indicates the significance level 
for the size follicle. 
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In the 35-39 y B & C group, the LHR density was significantly down-regulated from 10 mm 
towards the terminal-end follicles of 24 mm; whereas the small 4 mm follicles from patients 
with a D & E AFC patient group had significantly reduced granulosal LHR density (p<0.05, 
Figure 8.3.4). In further support of a sequential ageing effect, the changes in receptor density 
can be observed in the 35-39 y patient groups as the ovarian reserve declines (Figure 8.3.4). 
The B & C group is down-regulated to the terminal-end of folliculogenesis; whereas the 
poorest AFC group of D & E have a general lower density in the smaller follicles, and an up-
regulation with follicle size which was similar to the 40+ y E group (Figure 8.3.5).
 
Figure 8.3.4 Granulosal LHR density and ovarian reserve depletion in 35-39 y. 
Ovarian reserve measured indirectly by the antral follicle count (AFC). AFC is the number of follicles 
between 2-10 mm on day 2-5 of a cycle. Mean fluorescent intensity (MFI) was obtained using an 
average of ~8000 granulosa cells per follicle for the direct measurement of receptor protein expression. 
The data were subjected to statistical verification using one-way ANOVA with an uncorrected Fisher’s 
LSD for follicular size. Values in graphs are means ± S.E.M., and differences were considered 
significant if *p<0.05. 
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In the 40+ y age group a significant increase in LHR was observed in the poor ovarian patient 
group, AFC group E compared to the B and D (p<0.005 and p<0.001, Figure 8.3.5). 
Furthermore, as the ovarian reserve was depleted (40+ y ovarian reserve E), the LHR protein 
level was initially reduced, but then increased with follicle size (Figure 8.3.5).  
 
Figure 8.3.5 Granulosal LHR density and ovarian reserve depletion in 40+ y. 
Ovarian reserve measured indirectly by the antral follicle count (AFC). AFC is the number of follicles 
between 2-10 mm on day 2-5 of a cycle. Mean fluorescent intensity (MFI) was obtained using an 
average of ~8000 granulosa cells per follicle for the direct measurement of receptor protein expression. 
The data were subjected to statistical verification using one-way ANOVA with an uncorrected Fisher’s 
LSD for follicular size. Values in graphs are means ± S.E.M., and differences were considered 
significant if *p<0.05, ***p<0.005, and ****p<0.001. The letter, such as ‘a’ signifies a statistical 
difference to the matching letter, and an attached asterisk (a*) which indicates the significance level 
for the size follicle. 
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A strong correlation was observed between the LHR density and the corresponding BMPR1B 
density with follicle size in the D & E 40+ y patients (R squared 0.872) but not observed in 
the 23-30 y patients (R squared 0.078, Figure 8.3.6). As the patient age increased, and the 
ovarian reserve declined, the correlation between BMPR1B and LHR density sequentially 
increased  
Figure 8.3.6 Correlation of LHR to BMPR1B with ageing and increasing follicular size. 
Sequential graphs show increasing age and declining ovarian reserve indicated by AFC. Linear 
regression analysis, R square indicated for each group. The data points were averages of the receptor 
expression for that follicle size group. Ovarian reserve measured indirectly by the AFC. AFC is the 
number of follicles between 2-10 mm on day 2-5 of a cycle.  
8.4 Discussion 
Ovarian ageing caused by the depletion of the ovarian reserve of primordial follicles results 
in the inevitable loss of fertility (Hansen, et al. 2011). Understanding the changes induced by 
the ageing process is of paramount importance to effective clinical treatment for infertility. In 
an alternative approach, the mature cell surface protein for LHR was measured by flow 
cytometric analysis. Immunolabelled granulosa cells were collected from individual antral 
follicles during the peri-ovulatory stage from patients receiving IVF treatment for infertility. 
The receptor density was quantified by the average fluorescent intensity of ~8000 isolated 
granulosa cells per follicle from a range of follicle sizes.  
8.4.1 Major findings 
In the present study, the LHR density was reduced significantly with the decline in ovarian 
reserve (Figure 8.3.2). The combination of a high level of BMPR1B (Chapter 6) and LHR 
density in the terminal-end follicles appear to give rise to the ovarian ageing effect; which 
may be associated with reduced fertility as we age. 
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8.4.2 LHR in early cyclic folliculogenesis  
 
The results of the current study show a constant level of LHR density in IVF treated patients, 
with a significant drop in granulosal LHR density in the largest follicles collected from the 
young patient group with a good ovarian reserve (Figure 8.3.2) The follicles from this group 
were collected from dominant follicle selection (8 mm) to pre-ovulatory terminal-end 
follicles (26 mm); having all been exposed to a hCG/LH trigger for 36 hours (Figure 8.3.2). 
 
The role of the LHR in folliculogenesis is predominantly involved in the morphological and 
stereological changes taking place in the follicle in preparation for ovulation and corpus 
luteum function to support pregnancy (Minegishi, et al. 1997). However, during dominant 
follicle selection, LHR expression on the granulosa cell influences the rate of growth and 
development of the follicle and the fertilisation potential of the oocyte (Maman, et al. 2012, 
Rice, et al. 2007).  
 
Previously published data describe the positive staining of the LHR protein in human 
granulosa cells from very small antral follicles (0.03 mm), with increasing density and 
follicular size, in unstimulated natural cycles; which supports an earlier role for LHR (Yung, 
et al. 2014). In addition, the same study reports that a 5 mm follicle contained granulosa cells 
with a greater density of LHR protein than the theca equivalent (Yung, et al. 2014). Thecal 
cell LHR expression appears to peak and then drop at the time of dominant follicle selection, 
whereas granulosal expression steadily increases. (Xu, et al. 1995). Maman et al. (2012), and 
Jeppesen et al. (2012) also demonstrated that the early acquisition of LHRs on granulosa 
cells, at the time of dominant follicle selection which supports a substantial role for LHRs in 
the selection of the dominant follicle cohort. In addition, during in vitro maturation (IVM), 
small antral follicles with insufficient LHR in the cumulus cells failed to respond to the 
hCG/LH trigger surge and remained immature (Yerushalmi, et al. 2014). 
8.4.3 Natural Healthy cycle and IVF infertility treatment 
In the current IVF study, the level of LHR density was sufficient to elicit the changes 
required prior to ovulation by the clinical confirmation of serum LH and progesterone levels 
surging, cumulus expansion, and expulsion of the polar body (Fan, et al. 2009, Shimada, et 
al. 2003). In the rodent in vivo studies, (Camp, et al. 1991, Nakamura, et al. 1991) and human 
in vitro culture (Maman, et al. 2012), PMSG and rFSH, respectively, increased the LHR 
expression on granulosa cells. Given the large dose of rFSH stimulation during IVF, the LHR 
density appears not to be increased in the pre-ovulatory follicles compared to the natural 
cycle 18.5 mm follicle, (Figure 8.3.1). 
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8.4.4 Ovarian ageing and pre-ovulatory maturation  
Older patients, typically, have increased circulating FSH and reduced inhibin B, which gives 
rise to an initial accelerated early follicle development, and results in a shorter cycle length 
(MacNaughton, et al. 1992, Robertson 2009, Santoro, et al. 2003, Seifer, et al. 1999). The 
granulosa cell proliferation was found to be reduced and the size of the follicle to be smaller 
in older patients (Bomsel Helmreich, et al. 1979, Robertson 2009, Seifer 1996 , Seifer, et al. 
1993). The reduced rate of follicular growth found in older patients may result in reduced 
quality of the follicle and oocyte (Santoro, et al. 2003). A shorter cycle and a reduction in the 
follicle size due to ovarian ageing would reduce the capacity of the follicle to produce 
sufficient oestrogen to down-regulate pituitary FSH during dominant follicle selection.  
 
In the Booroola sheep, affected by the BMPR1B mutation the follicle size and the amount of 
oestrogen per follicle is reduced, yet the overall oestrogen reaches the threshold because of 
the number of follicles developing simultaneously (Gonzalez Bulnes, et al. 2004, McNatty 
and Henderson 1987a). A reduced follicle size in older patients may cause over thickening of 
the granulosa layer which would reduce the diffusion concentration gradient of serum to 
follicular fluid, and lead to reduced follicle and oocyte quality (Bächler, et al. 2014).  
 
In several studies in humans, the magnitude of the LH surge has not been found to be 
significantly different in older patients. Several inconsistencies exist in those studies, which 
mainly centred on the classification of ‘old’ and ‘poor’ ovarian reserve, which was based on 
the day three FSH serum concentration (Klein N A, et al. 1996, Leach, et al. 1997, 
MacNaughton, et al. 1992, Pal, et al. 2010, Santoro, et al. 2003). However, in Ginther et al. 
(2008), the LH surge in the mare, is reported to be markedly reduced with declining ovarian 
reserve, based on chronological age (Ginther, et al. 2008). Regardless, a distinction needs to 
be made between patients with an uncompromised reproductive cycle, the transitional phase 
of peri-menopause and the anovulatory post-menopause cycle (Hale 2007).  
 
In this study we are comparing the difference between young and old with a range of ovarian 
reserves, some of whom would have entered the early peri-menopausal stage of life, 
equivalent to the patients with an ovarian reserve of E AFC. and/or an AMH of ~1 µg/L 
(Hale 2007). Depletion of the ovarian reserve is a slow, sequential process, and therefore, the 
changes to receptor density occur gradually (Hansen, et al. 2011). By comparing the patterns 
of expression with reducing AFC, the ageing effect can be observed. In the typical older 
patient with a poor ovarian reserve (40+ y D), compared to the younger patients, the LHR 
density is reduced (Figure 8.3.1).  
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The amplitude of the LH surge has been observed previously to reduce with a decline in the 
ovarian reserve (Anzalone, et al. 2001, LaPolt and Lu 2001).With a decline in the LH surge 
with ovarian ageing, the corresponding impact on the desensitisation by the degradation of 
the LHR mRNA would be consequently reduced (LaPolt and Lu 2001, Nair, et al. 2006). 
Therefore, it is probable that the ovarian ageing effect results in a lack of down-regulation of 
the LHR density in the older poor ovarian reserve patients compared to the younger patients.  
8.4.5 Down-regulation and the terminal-end of folliculogenesis 
In the present study, the LHR density reduced significantly in the pre-ovulatory follicle of the 
young, good ovarian reserve group (Figure 8.3.2). The down-regulation of the LHR is 
consistent with the results from the sheep study (Chapter 5), where the LHR peaked in the 
largest of the subordinate follicles; yet, the leading dominant follicle had reduced LHR 
density in both the wild type and mutation affected Booroola Merino sheep (Regan, et al. 
2015) . The drop in LHR expression in the WT sheep also indicated that the drop is short 
lived, as the granulosa cells differentiate into granulosa-lutea cells (Micevych, et al. 2003, 
Regan, et al. 2015). The down-regulation of the ovulating follicle has also been reported by 
others in the bovine and human (Jeppesen, et al. 2012, Ndiaye, et al. 2005, Ophir, et al. 2014, 
Xu, et al. 1995); however, conflicting reports exist (Irving-Rodgers, et al. 2009, Jakimiuk, et 
al. 2001, Maman, et al. 2012). When comparing reported levels of receptor density, it is 
important to consider whether or not exogenous IVF stimulation was administered, and if the 
follicles had been exposed to a hCG/LH surge.  
 
Clinical administration of hCG or the natural cycle LH surge induces cytoskeletal 
reorganisation of the granulosa cell, cessation of mitogenic proliferation, cumulus expansion, 
gap junction closure, resumption of meiosis, and maturation of the oocyte (Fan, et al. 2009, 
Izadyar, et al. 1998b). These changes would have an effect on the LHR mRNA and mature 
LHR protein density (LaPolt and Lu 2001, Lapolt, et al. 1990, Peng, et al. 1991b). Therefore, 
pooling of follicles would potentially mask the down-regulation by averaging-out the LHR 
density, and thereby may reduce the accuracy of the data. For example, Jakimiuk et al. 
(2001), grouped the follicles, and found that the 4.2 to 8.7 mm follicles expressed the same 
amount of LHR mRNA as follicles from 9.1 to 23.2 mm. In the Maman et al. (2012), study, 
no difference in the LHR mRNA expression was found in the small follicles of <10 mm 
compared to 10 to14 mm; however, it was reported that the pre-ovulatory 17+ mm follicles 
peaked with no reported down-regulation observed. The standard deviation was much higher 
in the 17+ mm group, which may be as a result of masking of the down-regulation in the 
largest follicles.  
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8.4.6 Correlation of BMP and LHR 
It has been reported that the hCG/LH induced surge effect occurs 12 hours later in the theca 
cells and 24 hours later in the granulosa cells (Chaffin and Stouffer 2000), which indicates 
that the follicles with sufficient LHR would undergo the pre-luteinisation changes described 
above. Disruption to this regulatory mechanism was evident with a decline in AFC related to 
age, and is mirrored in the changing correlation between BMPRIB and the LHR (Figure 
8.3.6). The relationship between the high levels of BMPR1B (Chapter 6) and the LHR in the 
terminal-end follicles appear to give rise to the ageing effect; which may be associated with 
reduced fertility as we age. 
8.4.7 Conclusion 
Taken together, the results demonstrate the disrupting effect of age-related depletion of the 
ovarian reserve has on granulosal LHR. The present study’s data extends previous research 
by the comprehensive nature of the range of follicle size and age groups examined, together 
with measurement of the translated mature LHR protein as opposed to measurement of 
receptor expression at the mRNA level (Ascoli, et al. 2002). Further work is needed to 
confirm the identity of the locally-produced TGFβ family ligand(s) whose signalling may be 
impacted by the change in LHR density on the granulosa cell surface, and also to explore the 
consequences of altered signalling. 
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CHAPTER 9 Ovarian Ageing and GHR 
9.1 Introduction  
It is apparent that GH treatment in vivo and in vitro in conjunction with recombinant rFSH 
increases the oocyte survival rate, and increases the pregnancy rate (Barreca, et al. 1993b, 
Folch, et al. 2001, Izadyar, et al. 1996, Izadyar, et al. 1998b). Tesarik et al. (2005), found 
convincingly, that the number of oocytes retrieved and conceptions were the same, whereas, 
the pregnancy rate was increased; which is in line with the previous findings of increased 
pregnancy rate, enhanced mitochondrial activity and up-regulation of the GHR on the oocyte 
(Weall, et al. 2014, Yovich and Stanger 2010).  
 
GHR have been reported to be continuously expressed and have a half-life of one hour 
(Brooks, et al. 2008). GH is activated by changing the conformation of the receptor to form a 
complex with janus kinase 2 (JAK2), (Lan, et al. 2014). In vitro culture with GH has 
demonstrated its stimulating effect on the synthesis of oestrogen, BMP2 and BMP4 mRNA 
(Karamouti 2008, Li, et al. 1998). 
 
The granulosa, cumulus, and the oocyte of antral follicles express GHR, and are therefore 
able to react to ovarian or pituitary derived sources of GH (Abir, et al. 2008b, Izadyar, et al. 
1999). In addition, granulosa cells and the oocyte have been shown to produce GH mRNA 
(Abir, et al. 2008b, Bevers and Izadyar 2002, Izadyar, et al. 1998a, Izadyar, et al. 1997b, 
Izadyar, et al. 1999). The GHR forms a complex with JAK2 and initiates phosphorylation of 
the signal transducer and activator of transcription (STAT1, 3, 5), which leads to other 
ERK1/2- MAPK pathways. GH activation of the GHR induced transcription activity in the 
nucleus that leads to an increase in mitogenesis, lipogenesis, and protein synthesis (Bevers 
and Izadyar 2002, Izadyar, et al. 1997a, Izadyar, et al. 1998b, Moore, et al. 2001a). In 
addition, GH has been shown to accelerate granulosal luteinisation and to promote cumulus 
expansion and resumption of meiosis in the oocyte (Hutchinson, et al. 1988, Izadyar, et al. 
1997a). 
 
This study reports on the changes to GHR density during the development of the follicle from 
dominant follicle selection, to the pre-ovulatory maturation before ovulation in IVF patients. 
Previously, we have presented comprehensive results on the density profiles of patient 
follicle receptors and ovarian ageing, in young patients through to the older poor response to 
rFSH stimulation patients (Chapter 6-8). It has been demonstrated that the BMPR1B profile 
was significantly altered with a decrease in AFC and an increase in age. The biphasic down-
regulation of BMPR1B density observed in wild type Merino sheep (Regan, et al. 2015) was 
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also present in young human patients and sequentially deteriorates with ovarian ageing, 
culminating in the loss of receptor density and a reversal of the biphasic down-regulation 
(Chapter 6). The changes to FSHR and LHR density have also demonstrated an ovarian 
ageing effect, with the lack of pre-ovulatory down-regulation in the largest follicles, 
previously presented (Chapter 7 and 8) and also present in the sheep model (Chapter 5) 
(Regan, et al. 2015). 
 
The current study aims, to further explore the changes that take place due to a decline in 
ovarian reserve, by measuring the granulosa cell surface-expressed mature receptor protein 
density for GHR by immunofluorescent labelling via flow cytometry. A comprehensive 
range of follicle sizes from 4 to 27 mm were collected from patients receiving IVF treatment, 
and an average of ~8000 granulosa cells from individual follicles were used to determine the 
density of the GHR. 
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9.2 Methods  
Methods are described in detail in the General Methods Chapter (page 38).  
Granulosa cells were collected from hCG/LH induced follicles from patients receiving IVF 
exogenous gonadotrophins to artificially stimulate multiple follicles (Table 9.2:1). The 
granulosa cells were isolated and incubated with antibodies to detect the level of BMPR1B, 
FSHR, LHR, and GHR mature protein. In addition, apoptosis and necrosis were also 
determined by immunolabelling via flow cytometric analyses (page 39).  
Table 9.2:1 Patient ovarian reserve, based on antral follicle count (AFC) and the number 
of follicles collected per group 
 
 
 
Patient ovarian reserve, based on antral follicle count (AFC) and the number of follicles collected per 
group. Total number of follicles from patients receiving IVF treatment or a natural unstimulated. 
Follicles are classified into subgroups based on the patients’ antral follicle count (AFC) on 
approximately day 5 of a cycle. Major groups based on AFC are the most common patient profile; and 
patient subgroup follicles are described. Ovarian reserve measured indirectly by the Antral Follicle 
Count (AFC). AFC is the number of follicles between 2-10 mm on day 2-5 of a cycle: A+ = 30-39 
follicles; A = 20-29; B = 13-19; C = 9-12, D = 5-8; E = ≤4. 
  
AGE 
Year 
IVF 
Patient 
Total   
Follicle AFC 
Major 
Group  Number of Follicles Collected Per Group 
      Sub 
Group # 
Sub 
Group # 
Sub 
Group # 
Sub 
Group # 
21-30 8 95 20-40 A+ &A  A+ 31 A 64 C 6   
31-34 11 86 13-29 A & B  A 60 B 26 C 17   
35-39 16 102 9-19 B & C  A+ 6 B 50 C 16 D 30 & E 6 
40-45 18 118 3-8 D & E  D 59 E 19 B 34   
              
40          1         Natural Cycle Healthy D 2       
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9.3 Results 
The patients groups were selected to represent the best prognosis patients, based on their ovarian 
reserves, measured by AFC for the age class (Figure 9.3.1A). GHR density increased, based on the 10 
mm follicle size with chronological age from 23-30 y patients to 40+ y, (indicated by ‘a’, 
p<0.05,Figure 9.3.2A). In the 31-34 y patients, there was a decline in the density towards the terminal-
end of folliculogenesis, (p<0.05, Figure 9.3.1A). In the 40+ y B & C AFC a sequential significant 
decline in density of GHR was shown as the follicles increased in size (p<0.005, Figure 9.3.3A), even 
though the gonadotrophin treatment dose was higher (Figure 9.3.3B). The increasing dose of rFSH 
appears to be ineffective in restoring the younger profile of recptor density of the largest follicles in 
the oldest patients. 
 
 
  
 
 
Figure 9.3.1 Granulosal GHR density and age of IVF patients with good ovarian reserve 
and rFSH dose. 
GHR expression density with increasing chronological age; from young 23-30 y patients to old 
patients of 40+ y , in the best ovarian response groups within each age class. Ovarian reserve measured 
indirectly by the antral follicle count (AFC). AFC is the number of follicles between 2-10 mm on day 
A 
B 
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2-5 of a cycle. Mean fluorescent intensity (MFI) was obtained using an average of ~8000 granulosa 
cells per follicle for the direct measurement of receptor protein expression. The data were subjected to 
statistical verification using one-way ANOVA with an uncorrected Fisher’s LSD for follicular size. 
Values in graphs are means ± S.E.M., and differences were considered significant if *p<0.05, 
**p<0.01, *** and p<0.005. The letter, such as ‘a’ signifies a statistical difference to the matching 
letter, and an attached asterisk (a*) which indicates the significance level for the size follicle. (B) IVF 
patient exogenous gonadotrophin treatment dose for rFSH based on a declining AFC and age group; 
based on data from (Yovich, et al. 2012). 
 
It was evident that the density of GHR in the 23-30y A+ patients, was significantly lower in 
the small 10 mm follicles compared to the young patients with an AFC of A, (p<0.05, Figure 
9.3.2). 
 
 
  
Figure 9.3.2 Granulosal GHR density and ovarian reserve depletion in 23-30 y. 
Ovarian reserve measured indirectly by the antral follicle count (AFC). AFC is the number of follicles 
between 2-10 mm on day 2-5 of a cycle. Mean fluorescent intensity (MFI) was obtained using an 
average of ~8000 granulosa cells per follicle for the direct measurement of receptor protein expression. 
The data were subjected to statistical verification using one-way ANOVA with an uncorrected Fisher’s 
LSD for follicular size. Values in graphs are means ± S.E.M., and differences were considered 
significant if *p<0.05. The letter, such as ‘a’ signifies a statistical difference to the matching letter, and 
an attached asterisk (a*) which indicates the significance level for the size follicle. 
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In the 31-34 y age class a significant drop in GHR density was evident in the pre-ovulatory 
follicles of 19 mm (p<0.005, Figure 9.3.3). As the ovarian reserve declined the GHR density 
was reduced significantly in AFC group B and C, p<0.05, Figure 9.3.3). 
 
  
Figure 9.3.3 Granulosal GHR density and ovarian reserve depletion in 31-34 y. 
Ovarian reserve measured indirectly by the antral follicle count (AFC). AFC is the number of follicles 
between 2-10 mm on day 2-5 of a cycle. Mean fluorescent intensity (MFI) was obtained using an 
average of ~8000 granulosa cells per follicle for the direct measurement of receptor protein expression. 
The data were subjected to statistical verification using one-way ANOVA with an uncorrected Fisher’s 
LSD for follicular size. Values in graphs are means ± S.E.M., and differences were considered 
significant if *p<0.05, **p<0.01 and ***p<0.005. The letter, such as ‘a’ signifies a statistical 
difference to the matching letter, and an attached asterisk (a*) which indicates the significance level 
for the size follicle. 
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The GHR density was significantly greater in the 35-39 y, with an AFC of B & C whereas, 
with a further decline in ovarian reserve the GHR density failed to response to the FSH 
treatment producing significantly less GHR particularly in the smaller antral follicles 
(p<0.05, Figure 9.3.4).  
 
 
Figure 9.3.4 Granulosal GHR density and ovarian reserve depletion in 35-39 y. 
Ovarian reserve measured indirectly by the antral follicle count (AFC). AFC is the number of follicles 
between 2-10 mm on day 2-5 of a cycle. Mean fluorescent intensity (MFI) was obtained using an 
average of ~8000 granulosa cells per follicle for the direct measurement of receptor protein expression. 
The data were subjected to statistical verification using one-way ANOVA with an uncorrected Fisher’s 
LSD for follicular size. Values in graphs are means ± S.E.M., and differences were considered 
significant if *p<0.05. The letter, such as ‘a’ signifies a statistical difference to the matching letter, and 
an attached asterisk (a*) which indicates the significance level for the size follicle. 
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In the 40+ y patients there was a dramatic loss of GHR density in the D & E AFC groups, 
particularly in the small antral follicles of 8 to14 mm when compared to the 40+ y B & C 
profile (p<0.01, Figure 9.3.5). In the 40+ y B & C group the density is reduced sequentially 
with increasing follicle size. (p<0.005, Figure 9.3.5). 
 
 
Figure 9.3.5 Granulosal GHR density and ovarian reserve depletion in 40+ y. 
Ovarian reserve measured indirectly by the antral follicle count (AFC). AFC is the number of follicles 
between 2-10 mm on day 2-5 of a cycle. Mean fluorescent intensity (MFI) was obtained using an 
average of ~8000 granulosa cells per follicle for the direct measurement of receptor protein expression. 
The data were subjected to statistical verification using one-way ANOVA with an uncorrected Fisher’s 
LSD for follicular size. Values in graphs are means ± S.E.M., and differences were considered 
significant if *p<0.05, **p<0.01 and ***p<0.005. The letter, such as ‘a’ signifies a statistical 
difference to the matching letter, and an attached asterisk (a*) which indicates the significance level 
for the size follicle. 
  
130 
 
9.4 Discussion 
The oocyte and the granulosa cells produce GH mRNA and GHR mRNA (Abir, et al. 2008b, 
Bevers and Izadyar 2002, Izadyar, et al. 1998a, Izadyar, et al. 1997b, Izadyar, et al. 1999) and 
express the GHR on the cell membrane surface, on the endoplasmic reticulum and on the 
nuclear membrane (Abir, et al. 2008b, Brooks, et al. 2008, Izadyar, et al. 1999, Weall, et al. 
2014, Zhu, et al. 2001). The GHR is regulated by the gonadotrophins and growth factors, 
such as GH binding proteins, BMPs and somatostatin (Le Roith, et al. 2001, Nakamura, et al. 
2012).The granulosal GHR mRNA expression during folliculogenesis or the impact of a 
declining ovarian reserve on the receptor density has not been previously documented.  
9.4.1 Major Finding 
Chronological ageing is associated with an initial increase in granulosal GHR particularly in 
the smaller antral follicles selected into the dominant follicle cohort at 10 mm. However, 
within the same age class, the density of the receptors reduces as the ovarian reserve declines 
(Figure 9.3.1). A correlation between the increasing level of rFSH treatment and the increase 
in GHR was evident; however the effect of exogenous rFSH to increase the GHR expression 
diminished in the older age groups with the poorest ovarian reserve (Figure 9.3.1 to Figure 
9.3.5). 
9.4.2 The effect of increasing rFSH and the level of GHR density 
As the ovarian reserve declines the ovarian response indicated by the number of growing 
small antral follicles diminishes. An increased dose of rFSH is given to patients to maximise 
the ovarian response to stimulation during an IVF treatment cycle (Yovich, et al. 2012). The 
increasing levels of GHR density may be in response to the increasing amounts of rFSH or a 
compensatory mechanism in response to a declining ovarian reserve (Figure 9.3.1).  
 
The youngest patients with an ovarian reserve of A+ receive the least amount of rFSH, 
whereas, the 31-34 y A patients receive two times more rFSH, and have an increased GHR 
density in the 10 to16 mm follicles with no effect on the GHR density of the pre-ovulatory 
follicle (Figure 9.3.1). Very high doses of rFSH appear to be ineffective in increasing GHR 
density in the later stages of follicular development compared to the earlier stage of follicular 
development (Figure 9.3.1). The lack of any effect on the pre-ovulatory follicles may be as a 
result of the naturally reducing granulosal FSHR during the maturation phase, previously 
reported in Chapter 7 and in sheep (Regan, et al. 2015). The lower density of FSHR and LHR 
in patients with a poor ovarian reserve would also reduce the sensitivity to exogenous rFSH 
stimulation previously described (Chapter 7 and 8) and previously reported in (Cai, et al. 
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2007). In addition, clinical experience correlates well with the lack of response to rFSH as 
the AFC diminishes with increasing age (Yovich, et al. 2012).  
9.4.3 Conclusion 
The reduced ability of the granulosa to express GHR as the ovarian follicle reserve depletes 
demonstrates a potential mechanism responsible for the reduction in oocyte quality. In 
addition, the saturation of the FSH-FSHR signalling pathway failed to change the GHR 
density in the poor ovarian reserve patients. The sensitivity of FSHR and LHR appear to be 
compromised in poor response patients as abundant levels of rFSH are available in increasing 
doses. It is therefore, probable that the rFSH treatment reaches an ineffective threshold, via 
the classic FSH-FSHR-cAMP-PKA signalling pathway as the ovarian reserve declines. 
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CHAPTER 10 Ovarian Ageing and GH Co-treatment  
10.1 Introduction  
 
Ovarian depletion of primordial follicles is a continual natural process from gestation to 
adulthood, which culminates in the loss of ovarian function that produces a state of 
menopause (Gougeon 1986, Richards 1994). The primordial follicles when activated grow 
and develop into small antral follicles, and then succumb to apoptosis (Ginther, et al. 2005, 
Hillier 2001). At puberty sufficient FSH recruits an initial cohort of small antral follicles to 
the menstrual cycle (Austin, et al. 2001, Ginther, et al. 2005). The follicles grow under the 
influence of FSH and express FSHR, and LHR. FSH activation of the FSHR stimulates 
oestrogen synthesis, which stimulates proliferation of the granulosa and thecal cells and 
development of the oocyte; all of which are contained within the follicle (Campbell, et al. 
1999, Ginther, et al. 2012, Luo, et al. 2011, Picton and McNeilly 1991). 
 
The ovulation rate is determined by the stage-specific decrease in pituitary secreted FSH, and 
results in follicles with insufficient LHRs succumbing to apoptosis (Mihm, et al. 2006, 
Minegishi, et al. 1997, Yung, et al. 2014).The follicle continues to grow until pre-ovulatory 
maturation when proliferation ceases and granulosa cell differentiation occurs in preparation 
for ovulation of the oocyte. 
 
As the ovarian reserve of primordial follicles is depleted, regulation of folliculogenesis is 
altered, which results in decreased fertility (Klein N A, et al. 1996). Ovarian depletion can be 
indirectly measured by the number of small antral follicles present at the beginning of a 
cycle, and is highly correlated to chronological age (Hansen, et al. 2011). During IVF 
treatment, high doses of rFSH are used to recruit more of the small antral follicles and to 
maintain the growth during pituitary FSH-down regulation (Yovich and Stanger 2010). 
Infertility patients with a poor ovarian reserve have fewer small antral follicles available for 
recruitment, and higher doses of rFSH become ineffective in recruiting more follicles during 
IVF cycles. In an attempt to improve the pregnancy rate patients have been routinely co-
treated with GH and other adjuvant treatments (Tesarik, et al. 2005, Yovich and Stanger 
2010). 
 
The patients with a poor response to rFSH treatment represent a large group of patients with 
critically diminishing ovarian reserve (de Ziegler, et al. 2011, Kyrou, et al. 2009). The 
challenge was to identify the changes taking place as the ovarian reserve declines and to find 
alternative stimulation to provide quality oocytes for fertilisation.  
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Previously, GH co-treatment in vivo and in vitro in conjunction with rFSH increased the 
oocyte survival rate, and increased the pregnancy rate (Barreca, et al. 1993b, Folch, et al. 
2001, Izadyar, et al. 1996, Izadyar, et al. 1998b). The granulosa, cumulus, and the oocyte of 
antral follicles express GHR and are therefore able to react to ovarian or pituitary derived 
sources of GH (Abir, et al. 2008b, Izadyar, et al. 1999). In addition, granulosa cells and the 
oocyte produce GH, whereas cumulus and theca cells have not been shown to produce GH 
mRNA (Abir, et al. 2008b, Bevers and Izadyar 2002, Izadyar, et al. 1998a, Izadyar, et al. 
1997b, Izadyar, et al. 1999). GHRs are activated by GH by changing the conformation of the 
receptor forming a complex with JAK2, (Lan, et al. 2014). GH induced steroidogenesis was 
found not to be mediated by the FSH-FSHR-cAMP-PKA signalling pathway (Nakamura, et 
al. 2012). Alternatively, the GHR-JAK2 complex initiates the subsequent phosphorylation of 
the signal transducer and activator of transcription STAT1, 3, 5, or a number of other 
pathways such as the ERK1/2 -MAPK pathway, which results in GH transcription activity in 
the nucleus leading to an increase in mitogenesis, lipogenesis, and protein synthesis (Bevers 
and Izadyar 2002, Izadyar, et al. 1997a, Izadyar, et al. 1998b, Moore, et al. 2001a). The 
GHR-JAK2 complex can stimulate over 400 different types of signals, such as cell 
differentiation and oocyte maturation (Waters, et al. 2006).  
 
The cellular mechanism underpinning the GH induced improvement has not been reported in 
human studies. However, many attempts have been made to delineate the indirect changes 
taking place to serum and follicular fluid hormone levels. Previously, we have presented 
comprehensive results on the receptor density profiles of patients during ovarian ageing 
(Chapter 5-9). A decline in granulosal BMPR1B and FSHR density occurred at the time of 
cyclic dominant follicle selection, and again during the terminal stage of folliculogenesis, in 
the good ovarian reserve IVF patients of 23-30 y. The older poor ovarian reserve patients of 
40+ y experienced a reversal of this pattern. In addition, the LHR density failed to be down-
regulated during pre-ovulatory maturation in the 40+ y group, and GHR density was reduced 
with ovarian reserve. 
 
The current study aims, to further explore the effect of GH co-treatment on the changes to the 
density of BMPR1B, FSHR, LHR and GHR induced by the depletion of the ovarian 
primordial follicle reserve. An average of ~8000 granulosa cells/follicle were analysed, and 
the ovarian follicles collected from IVF patients ranged in diameter from 4 to 27 mm. The 
granulosa cell, surface-expressed mature receptor protein density was measured by 
immunofluorescent labelling via flow cytometry.  
10.2 Methods  
135 
 
Methods are described in detail in the General Methods Chapter (page 38).  
Granulosa cells were collected from hCG/LH induced follicles from patients receiving IVF 
exogenous gonadotrophins to artificially stimulate multiple follicles (Table 10.2:1). The 
granulosa cells were isolated and incubated with antibodies to detect the level of BMPR1B, 
FSHR, LHR, and GHR mature protein. In addition, apoptosis and necrosis were also 
determined by immunolabelling via flow cytometric analyses (page 39).  
 
Table 10.2:1 Patient ovarian reserve, based on antral follicle count (AFC) and the number 
of follicles collected per group. 
 
Patient ovarian reserve, based on antral follicle count (AFC) and the number of follicles collected per 
group. Total number of follicles from patients receiving IVF treatment or a natural unstimulated. 
Follicles are classified into subgroups based on the patients’ antral follicle count (AFC) on 
approximately day 5 of a cycle. Major groups based on AFC are the most common patient profile; and 
patient subgroup follicles are described. Ovarian reserve measured indirectly by the Antral Follicle 
Count (AFC). AFC is the number of follicles between 2-10 mm on day 2-5 of a cycle: A+ = 30-39 
follicles; A = 20-29; B = 13-19; C = 9-12, D = 5-8; E = ≤4. 
  
AGE 
IVF 
patient 
Total  
follicle 
AFC 
Major 
Group 
Total  
Follicle 
Sub 
Group 
# 
Sub 
Group 
# 
Sub 
Group 
# 
Sub 
Group 
# 
21-30 11 101 20-40 A+ & A 96 A++ 14 A+ 31 A 64   
31-34 11 86 13-29 A & B 86 A 60 B 26 C 17   
35-39 16 102 9-19 B & C 66 A+ 6 B 50 C 16 D&E 30&6 
40-45 18 118 3-8 D & E 78 D 59 E 19 B 34 C 6 
40-45 GH 11 78 3-8 D & E 47 D 22 E 23 B 16 C 5 
40 Natural Cycle Healthy D 2       
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10.3 Results 
Growth hormone treatment increased the FSHR receptor density in the follicles from 40+ y D 
& E AFC group patients in the 16 mm follicles (p<0.005), with a significant down-regulation 
of FSHR in the terminal-end 19 mm pre-ovulatory GH co-treated follicles (p<0.01, Figure 
10.3.1). Granulosal FSHR density significantly increased from 7 to 10 mm, 14 mm, and 16 
mm follicles in the GH co-treated patient group (p<0.05 and p<0.005).  
 
 
Figure 10.3.1 Granulosa cell density of FSHR in poor response 40+ y patients co-treated 
with GH compared to untreated. 
Ovarian reserve measured indirectly by the antral follicle count (AFC). AFC is the number of follicles 
between 2-10 mm on day 2-5 of a cycle. Mean fluorescent intensity (MFI) was obtained using an 
average of ~8000 granulosa cells per follicle for the direct measurement of receptor protein expression. 
The data were subjected to statistical verification using one-way ANOVA with an uncorrected Fisher’s 
LSD for follicular size. Values in graphs are means ± S.E.M., and differences were considered 
significant if *p<0.05, **p<0.01, and ***p<0.005. The letter, such as ‘a’ signifies a statistical 
difference to the matching letter, and an attached asterisk (a*) which indicates the significance level 
for the size follicle. The two natural cycle follicles were combined for statistical comparison as the 
values were similar. 
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The BMPR1B density was significantly increased in the GH co-treated 10 mm to 16-18 mm 
follicles compared to the untreated with GH, and age matched, 40+ y D & E patient group 
(p<0.001 and p<0.01, respectively, Figure 10.3.2). A significant down-regulation of the 
BMPR1B density occurred from 10 mm to 19 mm (p<0.05, Figure 10.3.2). The receptor 
density of the natural cycle was significantly lower than the GH co-treated patients (p<0.01, 
Figure 10.3.2).
 
 
Figure 10.3.2 Granulosa cell density of BMPR1B in poor response 40+ y patients treated 
with GH compared to untreated. 
Ovarian reserve measured indirectly by the antral follicle count (AFC). AFC is the number of follicles 
between 2-10 mm on day 2-5 of a cycle. Mean fluorescent intensity (MFI) was obtained using an 
average of ~8000 granulosa cells per follicle for the direct measurement of receptor protein expression. 
The data were subjected to statistical verification using one-way ANOVA with an uncorrected Fisher’s 
LSD for follicular size. Values in graphs are means ± S.E.M., and differences were considered 
significant if *p<0.05, **p<0.01, ***p<0.005, and ****p<0.001. The letter, such as ‘a’ signifies a 
statistical difference to the matching letter, and an attached asterisk (a*) which indicates the 
significance level for the size follicle.The two natural cycle follicles were combined for statistical 
comparison as the values were similar. 
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The LHR density of the granulosa cells collected from patients who received GH co-
treatment during an IVF cycle was significantly elevated compared to untreated, age and 
ovarian reserve matched patient group (40+D and E); particularly in the 16 mm follicles 
(p<0.001, Figure 10.3.3). The GH co-treated terminal-end down-regulation of LHR was 
significant in the 19-23 mm follicles (p<0.005, Figure 10.3.3). The peak receptor density in 
the 16 mm follicles from patients treated with GH was greater than other younger patient 
groups (p<0.001, Figure 10.3.3 ). The receptor density of the natural cycle appeared lower in 
the 10 mm follicle compared to the 10 mm follicle of the age matched GH co-treated IVF 
patients; whereas the 18.5 mm terminal-end pre-ovulatory follicle appeared similar in density 
of LHR as significance was not reached due to the small number of follicles. 
  
 
Figure 10.3.3 Granulosa cell density of LHR in poor response 40+ y patients co- treated 
with GH compared to untreated. 
Ovarian reserve measured indirectly by the antral follicle count (AFC). AFC is the number of follicles 
between 2-10 mm on day 2-5 of a cycle. Mean fluorescent intensity (MFI) was obtained using an 
average of ~8000 granulosa cells per follicle for the direct measurement of receptor protein expression. 
The data were subjected to statistical verification using one-way ANOVA with an uncorrected Fisher’s 
LSD for follicular size. Values in graphs are means ± S.E.M., and differences were considered 
significant if *p<0.05, **p<0.01, ***p<0.005, and ****p<0.001. The letter, such as ‘a’ signifies a 
statistical difference to the matching letter, and an attached asterisk (a*) which indicates the 
significance level for the size follicle. 
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The level of GHR was significantly increased in IVF patients receiving GH co-treatment in 
follicles from 10 to 23 mm compared to the same age patients of 40+ y with an ovarian 
reserve of D & E (p<0.01 to p<0.001, Figure 10.3.4 ). The receptor density was also greater 
in the GH co-treated IVF patients compared to the younger patients from 10 mm to 23 mm. 
The receptor density of the natural cycle healthy patient of 40+ y was significantly lower than 
the GH co-treated patients (p<0.05 and p<0.01). 
 
 
Figure 10.3.4 Granulosa cell density of GHR in poor response 40+ y patients co- treated 
with GH compared to untreated. 
Ovarian reserve measured indirectly by the antral follicle count (AFC). AFC is the number of follicles 
between 2-10 mm on day 2-5 of a cycle. Mean fluorescent intensity (MFI) was obtained using an 
average of ~8000 granulosa cells per follicle for the direct measurement of receptor protein expression. 
The data were subjected to statistical verification using one-way ANOVA with an uncorrected Fisher’s 
LSD for follicular size. Values in graphs are means ± S.E.M., and differences were considered 
significant if *p<0.05, **p<0.01, ***p<0.005, and ****p<0.001. The letter, such as ‘a’ signifies a 
statistical difference to the matching letter, and an attached asterisk (a*) which indicates the 
significance level for the size follicle. The two natural cycle follicles were combined for statistical 
comparison as the values were similar. 
10.4 Discussion 
10.4.1 Overview 
In this study we report on the changes to granulosal receptor density for FSHR, LHR, GHR, 
and TGFβ type 1 receptor, BMPR1B in GH co-treated IVF patients. Reduced ovarian reserve 
patients have a poor response to IVF rFSH treatment, and produce oocytes of poor quality 
(Cai, et al. 2007). The poor response group of patients also have an associated high risk of 
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foetal aneuploidy that has been correlated to AFC (Grande, et al. 2014). Recently published 
data has shown that GH co-treatment increases the pregnancy rate by a suggested 
improvement in oocyte quality not quantity (Tesarik, et al. 2005, Yovich and Stanger 2010). 
Overshadowing the GH clinical debate, is the confounding clinical evidence that when 
young, good response patients and young or old poor response patients are combined, it 
results in a multivariate clinical patient group, which is difficult to treat uniformly. 
Furthermore, in the past, many cycles were cancelled that would otherwise still be continued 
in current times, which may impact the outcome. Several studies have been conducted on 
IVF patients, classified as having a ‘poor response’ to IVF stimulation, and were older than 
35 y (Kucuk, et al. 2008, Suikkari 1996, Tesarik, et al. 2005, Yovich and Stanger 2010). 
When these studies are combined, with the studies that report failed cycles or no pregnancies 
(Eftekhar, et al. 2013, Levy, et al. 1993, Volpe, et al. 1989), a pregnancy rate of 36% for GH 
co-treated patients and 12% for non-GH treatment can be conservatively calculated. It is, 
therefore, probable that a cellular regulatory mechanism is affected by GH to produce an 
increase in pregnancy rate. 
10.4.2 Major findings 
In an attempt to reverse the poor prognosis of older patients, rGH was provided as an adjunct 
to IVF rFSH stimulation. While previous research has focused predominantly on clinical and 
biochemical evidence and basic science studies, using rodents and other species, the current 
study demonstrates that GH co-treatment increased receptor density in humans. The 
dysregulation of the ovarian micro-environment caused by ovarian depletion was partially 
reversed, providing an explanation for the reduction in pregnancy loss, with GH co-
treatment. This study provides novel information on the effect exogenous GH has on the 
density of FSHR, BMPR1B, LHR, and GHR on granulosa cells from a wide range of follicle 
sizes. 
10.4.3 No change to small antral follicles 
In this study, GH co-treatment increased the receptor density for FSHR, BMPR1B, LHR and 
GHR compared to the non-GH treated patients of the same age and ovarian reserve (Figure 
10.3.1 to Figure 10.3.4). Given that the driving force of folliculogenesis is FSH, it is apparent 
that increasing rFSH dose is not effective past a point, in the poor ovarian reserve patients as 
the pool of small antral follicles available for recruitment is diminished. Previously, poor 
ovarian response to rFSH stimulation has been associated with reduced granulosal FSHR 
expression (Cai, et al. 2007). In the current study, the improvement to the FSHR, LHR, and 
BMPR1B density occurred after the pituitary FSH down-regulation and dominant follicle 
selection, as this takes place at ~7-10 mm. In addition, in a previous study, GH co-treatment 
was found not to alter the FSHR density in human small follicles, which is consistent with 
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the findings for small follicles (Garverick, et al. 2002). Conflicting reports however, show 
that granulosal FSHR and LHRs from pre-ovulatory follicles from young adult cows were 
not altered by rGH co-treatment (Gong, et al. 1991). GH co-treatment may not have resulted 
in any change to the receptor density because the cows were young, with an uncompromised 
ovarian reserve and sufficient receptor density.  
 
Further research is needed to ascertain the effect of GH co-treatment has on receptor density 
in good ovarian reserve patients  
10.4.4 Oocyte number and LHR 
In this study, GH co-treatment increased the level of FSHR in the larger pre-ovulatory 
follicles of 16-18 mm (Figure 10.3.1). Recruitment of the dominant follicle cohort is initially 
dependent on FSHR, followed by LHR sufficient to sustain the oestrogen requirements of the 
follicle as the pituitary FSH declines (Rice, et al. 2007). In the current study, FSHR was high 
in the 4 mm follicle of the older patients, which suggests that the level of FSHR was 
sufficient to enable initial growth of the small antral follicles before dominant follicle 
selection. However, the LHR level in the 4 mm follicle was significantly reduced compared 
to the level in the younger patients with good ovarian reserve (Figure 10.3.3). The lower 
density of LHR would reduce the oestrogen producing capacity of the follicle and limit the 
number of oocytes selected during dominant follicle selection (Yung, et al. 2014).  
 
GH co-treatment did not alter the LHR density of the small follicles, and would therefore not 
improve the number of follicles recruited during dominant follicle selection. This finding is 
consistent with the reported increase in the pregnancy rate without an increase in the number 
of oocytes in GH co-treatment during an IVF cycle (Tesarik, et al. 2005, Yovich and Stanger 
2010).  
10.4.5 Maturation 
The improvement in pregnancy rate could therefore, be attributed to an improvement in the 
follicle micro-environment, which produces a better quality oocyte. In this study, the GH co-
treatment increased the receptor density of BMPR1B, FSHR and LHR, and restored the pre-
requisite down-regulation during pre-ovulatory maturation, previously discussed in Chapter 
5-9 and reported (Jeppesen, et al. 2012, Ophir, et al. 2014, Regan, et al. 2015).  
 
Specifically, the biphasic down-regulation of the BMPR1B was observed in 4 year old sheep 
and again in the human 23-30 y AFC group A+ &A (Chapter 5 and 6) (Regan, et al. 2015). 
The current study provides evidence of a GH-induced increase in BMPR1B density in the 10 
mm onwards follicles; which reverses the increasing density pattern of BMPR1B observed in 
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the patients of 40+ y with an AFC of D & E (Figure 10.3.2). The return to the younger 
patient biphasic pattern of BMPR1B density may improve oocyte quality, and account for the 
improvement in pregnancy rates observed in GH co-treated patients with reduced ovarian 
reserve (Yovich and Stanger 2010).  
 
During the follicular phase, the BMPR1B activity has been shown to supress progesterone 
synthesis in favour of oestrogen production (Glister, et al. 2004a, Otsuka 2010). Importantly, 
it is the down-regulation of the BMPR1B density that is reversed in the 40+ y AFC D & E 
patients (Figure 10.3.2). The increase in LHR density (Chapter 5 and 8) inhibits the 
luteinisation required for pre-ovulatory maturation of the follicle and oocyte, and progression 
to the peri-luteal phase of differentiation. In addition, GH co-treatment also produced 
significantly higher LHR density in the 40+ D & E patients, when the follicle size was 14 to 
16 mm (Figure 10.3.3). The increased LHR density would provide an increase in sensitivity 
during the hCG/LH surge to trigger ovulation and maturation of the oocyte (Donadeu 2005, 
Greisen, et al. 2001). In agreement, a previous study’s examination by electron microscopy 
revealed that oocytes that did not fertilise had reduced levels of granulosal luteinisation and 
were less responsive to hCG (Rotmensch, et al. 1986).  
 
In conclusion, the increase in LHR sensitivity and the restored pre-ovulatory maturation 
provide a possible cellular mechanism responsible for the improved pregnancy rate reported. 
10.4.6 The GHR is regulated by the GH binding proteins 
The poor ovarian reserve older patients co-treated with GH had increased granulosal GHR 
density. GHRs are predominantly found on the granulosa cell membrane surface and in the 
endoplasmic reticulum, and to a lesser degree, but common, in the nuclear membrane of 
highly prolific cells such as the peri-implantation embryo and in tumours (Brooks, et al. 
2008, Zhu, et al. 2001). The GHR is regulated by the GH binding proteins, which are the 
soluble form of the GHR, and by other growth factors such as FSH, BMPs (Nakamura, et al. 
2012), and somatostatin (Le Roith, et al. 2001).  
 
Given that the granulosa cell and the oocyte produce their own GH mRNA, it is possible that 
the increase in FSHR, LHR, and BMPR1B density leads to an increase in intracellular GH 
production; which potentially improves oocyte quality, as reported and previously reviewed 
(de Ziegler, et al. 2011, Homburg, et al. 2012, Tesarik, et al. 2005, Yovich, et al. 2012, 
Zhuang, et al. 1994). Exogenous GH co-treatment via the granulosa GH mRNA may have an 
effect on the GH synthesis in the granulosa cell or oocyte, which may lead to an 
improvement in oocyte quality.  
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10.4.7 In vitro culture studies 
Several studies on the effect of GH on cultured granulosa cells have inadvertently induced 
spontaneous luteinisation (Karamouti 2008, Ovesen 1998, Tapanainen, et al. 1992 ), which 
has produced a result that reflects the effect of GH in the luteal phase, and not the follicular 
phase of follicle development (Erickson, et al. 1991, Gutierrez, et al. 1997). In natural cycle 
studies, employing serum-free culture, granulosa cells from the follicular phase in humans, 
increased oestrogen and decreased progesterone levels when treated with GH combined with 
rFSH (Carlsson, et al. 1992, Mason, et al. 1990).  
 
These findings support the hypothesis that GH co-treatment increased FSHR activity that 
increases oestrogen synthesis in the granulosa cell. 
10.4.8 GHR signalling and GH induced changes to receptor density 
The FSH-BMP activity during folliculogenesis predominantly activates the ERK1/2 pathway, 
and the BMP ligands 2, 4, 6, 7, and 15 appear to regulate GH by the suppression of StAR 
mRNA, HSD3B1, and CYP11A1 which is required for activation of the ERK1/2 pathway to 
produce progesterone (Pierre, et al. 2004). In vitro culture with GH, without FSH also 
increased STAT3 signalling, which can be regulated by BMP ligands, and have the effect of 
reducing STAT3 in rodents (Nakamura, et al. 2012). In the goat, BMP ligands in granulosa 
cell culture were shown to regulate FSHR and LHR receptor density (Zhu, et al. 2001); and 
in the human, BMP4, 6, 7, and 15 appeared to increase FSHR and LHR density, which 
demonstrates the interrelated in vivo balance present in the ovarian follicle (Shi, et al. 2012, 
Shi, et al. 2009b, Shi, et al. 2011, Shi, et al. 2010).  
 
An increase in the density of FSHR observed in the present study would increase the FSH 
induced AC-cAMP- PKA activity, leading to an increased transcription of intermediate 
components that would directly up-regulate the receptor density of FSHR itself (Fan 2010, 
Miyoshi, et al. 2006, Nakamura, et al. 2012), LHR (Jia, et al. 1986), BMPR1B (Shi, et al. 
2009b, Shi, et al. 2011) and GHR (Nakamura, et al. 2012).  
 
Given the above evidence, the sensitivity of the FSHR appears to be compromised in poor 
ovarian reserve patients because abundant levels of rFSH were available. It is, therefore, 
probable that the GH co-treatment increased the GHR-JAK-STAT activity, and hence 
increased the intermediate products of transcription, which has led to an overall increase in 
reproductive receptor density (Figure 10.4.1). 
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Figure 10.4.1 Diagram of cellular interactions of growth hormone and receptor expression 
in the granulosa cell. 
The GH co-treatment increased the GHR-JAK-STAT activity to increase intermediate products of 
transcription, which leadsto an overall increase in reproductive receptor density. 
10.4.9 Conclusion 
The complexity of the in vivo balance of gonadotrophins and growth factors regulating 
follicular growth and differentiation makes it difficult to define the cellular mechanism 
involved. However, the present study has revealed several cellular mechanisms that could 
contribute to an improved oocyte quality in GH co-treated IVF patients with a poor ovarian 
reserve. 
 
GH co-treatment would increase GHR-JAK-STAT activity, and result in an increase in the 
intermediate products of transcription, which explain the increase in reproductive receptor 
density. GH co-treatment did not alter the LHR density of the small follicles, and would 
therefore account for the lack of improvement in the number of follicles recruited during 
dominant follicle selection. However, the increase in LHR sensitivity of the larger follicles 
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would restore the pre-ovulatory maturation and provides another possible cellular mechanism 
responsible for the improved pregnancy rate. In addition, the return to the younger patient 
biphasic pattern of BMPR1B density may improve oocyte quality observed in GH co-treated 
patients with reduced ovarian reserve 
 
Further research is needed to ascertain the effect GH co-treatment has on receptor density in 
good ovarian reserve patients, and the direct effect on the synthesis of granulosa/oocyte GH 
synthesis.  
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Apoptosis and Necrosis and Ovarian Ageing 
 
 
 
 
Title: The decline in ovarian ageing and the effect on granulosa cell 
apoptosis or necrosis in humans 
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CHAPTER 11 Apoptosis and Necrosis and Ovarian Ageing 
11.1 Introduction 
In human subjects a decline in the ovarian reserve of follicles leads to a relative dysregulation 
of folliculogenesis and ovulation. The changes to the micro-environment and hormonal 
systemic levels is responsible for the reduced fertility and the reduction in quality of the 
oocyte (Klein N A, et al. 1996). Older patients typically have increased circulating FSH and 
reduced inhibin B, which gives rise to accelerated early follicle development, and results in a 
shorter cycle length; yet the growth rate is reduced and the follicles are smaller with fewer 
granulosa cells (MacNaughton, et al. 1992, Robertson 2009, Santoro, et al. 2003, Seifer, et al. 
1999) 
 
Previously, we have presented comprehensive results on the density profiles of patient 
follicle receptors, correlated with ovarian follicle depletion in young patients through to the 
older poor ovarian response patients (Chapter 6-9). Reproductive ageing is linked to the 
decline in capacity to express receptors that cause an irreversible change to ovarian cellular 
dynamics, and ultimately reduces the capacity to reproduce (Cai, et al. 2007, Nelson, et al. 
2013). As the ovarian reserve declines, the health of the follicles appears to decline which 
results in an increase in pregnancy loss (Hansen, et al. 2005, Lapolt, et al. 1986, Santoro, et 
al. 2003).  
 
The apoptotic granulosa cell continues to synthesise progesterone until the mitochondrial 
membrane is disrupted (Amsterdam, et al. 2003). The functioning apoptotic granulosa cell 
undergoes reorganisation of the cell, which creates blebs of cytoplasmic organelles (Guraya 
1971, Motta 1969). The cytoskeleton is reorganised and clusters of lipid droplets, 
mitochondria, endoplasmic reticulum, and lysosomes are assembled around the nucleus 
(Aharoni, et al. 1995, Amsterdam, et al. 1997). The condensed chromatin in the nucleus 
moves to the periphery of the nucleus, and the cell membranes disintegrate, which allow the 
nucleic contents to be stained (Demchenko 2013). 
 
The heterogeneous population of granulosa cells collected during the peri-luteal stage of 
folliculogenesis are at different stages of luteinisation and apoptosis (Centurione, et al. 2010, 
Nottola, et al. 2006). The oocyte potential can be compromised by an increase in the level of 
granulosa cell death caused by either apoptosis or necrosis, and may result in the demise of 
the follicle (Oosterhuis, et al. 1998b, Seifer 1996 ). 
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The granulosa cells closely regulate the health of the follicle, and ultimately the oocyte; and 
are susceptible to apoptosis and necrosis in the follicle. However, apoptosis is a normal 
regulatory process that occurs in the follicle, yet high levels of granulosa cell death could 
impact follicle development and suppress oocyte growth (Irving-Rodgers, et al. 2003, Sasson 
and Amsterdam 2002). The response of the ovaries to cyclic recruitment of primordial 
follicles forms the basis of the clinical measurement of the AFC (Almog, et al. 2011). The 
AFC and age are strongly correlated with histologically determined ovarian primordial 
reserve (Hansen, et al. 2011, van Rooij, et al. 2005).  
 
The BMPR1B expression profile is significantly altered with a decrease in AFC and age 
(Chapter 6). It has been previously reported that a similar biphasic down-regulation of 
BMPR1B density in wild type Merino sheep occurs, which was also present in young human 
patients (Chapter 5 and 6 ) (Regan, et al. 2015). The direct measurement by flow cytometry 
of the granulosal protein density of FSHR, LHR, and BMPR1B mature membrane-bound 
receptors was applied. The granulosal receptor expression deteriorates with ovarian ageing, 
which culminates in the loss of receptor density and the lack of down-regulation of the 
maturing pre-ovulatory follicle (Chapter 6-9).  
 
The current study aims to further explore the changes to granulosal apoptosis and necrosis 
that transpire as the ovarian reserve declines. The frequency of granulosa-luteal cell apoptosis 
or necrosis from individual follicles collected from patients who received treatment for 
infertility was examined. The change to the relationship between reproductive receptor 
density and the level of apoptosis or necrosis with ovarian follicle reserve depletion was also 
examined. 
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11.2 Methods  
Methods are described in detail in the General Methods Chapter (page 50). Granulosa cells 
were collected from hCG/LH induced follicles from patients receiving IVF exogenous 
gonadotrophins to artificially stimulate multiple follicles (Table 11.2:1). Flow cytometry 
provides a rapid and reliable method to quantify viable cells in a cell suspension. 7-AAD is a 
membrane impermeant dye that is generally excluded from cells with an intact cell 
membrane. It binds to double stranded DNA. 7-AAD can be excited at 488 nm, emitting at a 
maximum wavelength of 647 nm.  
 
Table 11.2:1Patient ovarian reserve, based on antral follicle count (AFC) and the number 
of follicles collected per group. 
 
 
Ovarian reserve measured indirectly by the Antral Follicle Count (AFC). AFC is the number of 
follicles between 2-10 mm on day 2-5 of a cycle: A+ = 30-39 follicles; A = 20-29; B = 13-19; C = 9-
12, D = 5-8; E = ≤4.  
 
 
 
 
  
AGE 
Year 
IVF 
Patient 
Total   
Follicle AFC 
Major 
Group  Number of Follicles Collected Per Group 
      Sub 
Group # 
Sub 
Group # 
Sub 
Group # 
Sub 
Group # 
21-30 8 95 20-40 A+ &A  A+ 31 A 64 C 6   
31-34 11 86 13-29 A & B  A 60 B 26 C 17   
35-39 16 102 9-19 B & C  A+ 6 B 50 C 16 D 30 & E 6 
40-45 18 118 3-8 D & E  D 59 E 19 B 34   
              
40          1         Natural Cycle Healthy D 2       
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11.3 Results 
In the youngest patient group, with an AFC of A+ & A, the level of apoptosis was increased 
during the dominant follicle selection and the maturation of the largest follicle (p<0.05 and 
p<0.01, Figure 11.3.1). In the patient group A+ & A, the level of apoptosis and necrosis was 
significantly greater compared to patients of the same age with ovarian reserve depletion in 
the 10 mm follicle (p<0.05, AFC: C).The size corresponds to the time of dominant follicle 
selection.  
Figure 11.3.1 Granulosal apoptosis and necrosis and ovarian reserve depletion in 23-30 y. 
 
Granulosa cells from individual follicles of different sizes collected from young IVF patients with a 
good ovarian reserve compared to young patients with a poor ovarian reserve. Ovarian reserve 
measured indirectly by the antral follicle count (AFC). AFC is the number of follicles between 2-10 
mm on day 2-5 of a cycle. Mean fluorescent intensity (MFI) was obtained using an average of ~8000 
granulosa cells per follicle for the direct measurement of receptor protein expression. The data were 
subjected to statistical verification using one-way ANOVA with an uncorrected Fisher’s LSD for 
follicular size. Values in graphs are means ± S.E.M., and differences were considered significant if 
*p<0.05, **p<0.01 and ***p<0.005. The letter, such as ‘a’ signifies a statistical difference to the 
matching letter, and an attached asterisk (a*) indicates the significance level for the size follicle. 
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The level of apoptosis was reduced in the 40+ y age group compared to the youngest patients 
receiving IVF stimulation at the time of dominant follicle selection (p<0.005) and at the 
maturation of the pre-ovulatory follicle, at 19 mm (p<0.01). The granulosa cells from the 
natural cycle follicle of 18.5 mm had an elevated level of apoptosis and necrosis (23%) 
similar to the mature pre-ovulatory follicles from the younger patients (18 ± 4%). In the 
natural cycle the smaller follicle of 10 mm had a low level of apoptosis and necrosis (2.5%). 
The size of the follicle corresponds to the time of dominant follicle selection, and is similar to 
the level reported for the 40+ y D & E patient (1.5 ± 0.5%). 
  
 
Figure 11.3.2 Granulosal apoptosis and necrosis and ovarian reserve depletion in young 
and older patients. 
Percentage of apoptotic or necrotic granulosa cells and follicle size collected during a natural healthy 
cycle from an unstimulated patient of 41 y, with an AFC of D, (blue). Patients, 23-30y stimulated, IVF 
cycle with an AFC of A+ & A, (olive green). Patients, 40+y stimulated IVF cycle with an AFC of D & 
E,(orange). Ovarian reserve measured indirectly by the antral follicle count (AFC). AFC is the number 
of follicles between 2-10 mm on day 2-5 of a cycle. Mean fluorescent intensity (MFI) was obtained 
using an average of ~8000 granulosa cells per follicle for the direct measurement of receptor protein 
expression. The data were subjected to statistical verification using one-way ANOVA with an 
uncorrected Fisher’s LSD for follicular size. Values in graphs are means ± S.E.M., and differences 
were considered significant if *p<0.05, **p<0.01 and ***p<0.005. 
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A strong correlation was observed between the granulosal FSHR and BMPR1B density and 
the corresponding level of apoptosis and necrosis based on follicle size. High levels of FSHR 
and BMPR1B density were associated with reduced apoptosis and necrosis levels in the 
youngest patients of 23-30 y with an AFC of A+ & A, R square 0.752 and 0.835, 
respectively. The correlation was reversed in the next age group of 31-34 y for both FSHR 
and BMPR1B, and sequentially reduced in association with increasing age and a reducing 
AFC. In the 40+ y patient the correlation for FSHR and BMPR1B was R square 0.137 and 
0.011, respectively. 
 
 
Figure 11.3.3 Correlation of granulosal FSHR and BMPR1B density and apoptosis and 
necrosis, and depletion of the ovarian reserve during folliculogenesis. 
Ovarian reserve measured indirectly by the antral follicle count (AFC). AFC is the number of follicles 
between 2-10 mm on day 2-5 of a cycle. Sequential graphs show increasing age and declining ovarian 
reserve indicated by AFC. Mean fluorescent intensity (MFI) was obtained using an average of ~8000 
granulosa cells per follicle for the direct measurement of receptor protein expression. The data were 
subjected to statistical verification using one-way ANOVA with an uncorrected Fisher’s LSD for 
follicular size. Linear regression analysis; R square is indicated for each group. The data points are the 
average of the receptor expression for that follicle size group.   
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The level of apoptosis and necrosis was strongly correlated to the dose of rFSH treatment 
received by IVF patients. (A). AFC declines with age with considerable overlap of the 
ovarian response to stimulation. Patients were grouped into age classes and follicles of 
different sizes were combined. (B). The clinical administration of exogenous FSH during 
treatment for infertility is dependent on the ovarian reserve (AFC) and age (Yovich, et al. 
2012). Dosage was averaged across the range of AFC for each age class. (C). A strong 
correlation exists between the level of apoptosis and necrosis and the dose of rFSH 
administered to patients receiving IVF treatment. 
 
 
 
Figure 11.3.4 Correlation between the dose of rFSH and the level of apoptosis and 
necrosis. 
(A) Age and the level of granulosal apoptosis and necrosis as the ovarian reserve declines; based on 
major AFC groups per age class. (B) Corresponding dose of exogenous recombinant FSH given to IVF 
patients to stimulated follicular growth based on antral follicle count and age group. (C) Correlation 
between the level of apoptosis and necrosis of granulosa cells and the dose of rFSH used during IVF 
treatment. Ovarian reserve measured indirectly by the antral follicle count (AFC). AFC is the number 
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of follicles between 2-10 mm on day 2-5 of a cycle. Mean fluorescent intensity (MFI) was obtained 
using an average of ~8000 granulosa cells per follicle for the direct measurement of receptor protein 
expression. The data were subjected to statistical verification using one-way ANOVA with an 
uncorrected Fisher’s LSD for follicular size. Values in graphs are means ± S.E.M., and differences 
were considered significant if **p<0.01 and ****p<0.001. Linear regression analysis, R square is 
indicated for each group. The data points are the average of the receptor expression for that follicle 
size group, R square 0.52. 
11.4 Discussion 
11.4.1 Overview of the study 
The ovulation rate is generally governed by the limitation of the number of follicles growing 
in a stage-specific manner, and follicle growth is limited by the stimulation to continue 
growth to ovulation. The gonadotrophins FSH and LH govern the growth rates of the follicles 
during cyclic folliculogenesis, and the level of receptor density controls the response of the 
follicles to the gonadotrophin stimulation. Intraovarian growth factors, such as the BMPs, 
impact the receptor expression that ultimately controls the growth rate of the follicle. 
Reduced growth leads to an accumulation of precursor molecules that can stimulate 
signalling pathways to induce programmed cell death or apoptosis. Apoptosis of 
unfavourable granulosa cells and follicles can lead to follicle collapse, and establishes the 
dominant follicle that continues to grow to ovulation (Yuan and Giudice 1997). 
11.4.2 Major Findings 
The major findings of this study are that the level of apoptosis increased during dominant 
follicle selection and during pre-ovulatory maturation in young IVF patients with an 
uncompromised ovarian reserve. Secondly, that the granulosal BMPR1B and FSHR density 
was strongly associated with a reduction in apoptosis; and thirdly, that the level of apoptosis 
was reduced as the ovarian reserve declined with age.  
11.4.3 Dominant follicle selection  
A significant increase in apoptosis and necrosis occurred at the time of dominant follicle 
selection (Figure 11.3.1). At the time of dominant follicle selection, the circulating FSH 
decreases, and the follicles with greater FSHR and LHR density are stimulated to produce 
oestrogen and proliferate. FSH has been reported to be anti-apoptotic. Therefore it may be 
expected that the drop in pituitary FSH (mid-follicular phase) may initiate an increase in 
apoptotic signalling in the granulosa cell. In humans, it has been reported that the majority of 
intense staining for P450 aromatase is located in the basal mural granulosa cells, and radiates 
towards the antral cavity of the follicle (Guigon 2003, Sakurada, et al. 2006, Turner, et al. 
2002). The link between high levels of aromatase activity and an anti-apoptotic effect 
appears to exist, as it has been previously reported that the majority of apoptosis occurs in the 
antral region of the follicle, which is consistent with the reduced aromatase activity 
155 
 
(Matsuda, et al. 2012). During the different stages of follicle development the level of 
apoptosis changes. Essentially, primordial, primary, secondary, and pre antral follicles <1 
mm in size were found to be free of DNA breakdown (Yuan and Giudice 1997). Small antral 
follicles (1 to 9.9 mm) from natural cycles that were androgen dominant (androgen > 
oestrogen) were found to have substantial levels of DNA fragmentation (DNA fragmentation, 
27% to50 %) whereas, follicles (>10 mm) that were oestrogen dominant (oestrogen > 
androgen), had a very low rate of cell death (0%) (Yuan and Giudice 1997).  
 
In the current study, the apoptosis peaked at the time of dominant follicle selection and then 
maintained a consistent level of apoptosis and necrosis in the follicles from 10 to 19 mm. The 
plateau could signify a base rate of the continuous removal of atretic granulosa cells via 
phagocytosis as part of the normal clean-up of the decaying debris (Figure 11.3.1, AFC A+ & 
A) (Amsterdam, et al. 2003, Giampietro, et al. 2006). 
11.4.4 Pre-ovulatory maturation 
Previous research has shown that when FSH levels decline, a reduction in BMP6 (Erickson 
and Shimasaki 2003), BMP15 (Feary, et al. 2007), AMH (Andersen, et al. 2010, Ogura Nose, 
et al. 2012, Weenen, et al. 2004), GnSAF (Martinez, et al. 2002) and BMPR1B (Feary, et al. 
2007, Regan, et al. 2015), occurs after dominant follicle selection to the termination of 
folliculogenesis. Once selected, the dominant follicles’ granulosa cells continue to 
proliferate, which leads to an increase in oestrogen and inhibin B production by the granulosa 
cells. Together, these hormones suppress pituitary FSH output further, ensuring the demise of 
subordinate follicles. When the threshold for oestrogen’s positive feedback action on the 
hypothalamus-pituitary axis is met, preparation for the ovulation phase begins with a 
cessation of cell proliferation and early luteinisation changes taking place.  
 
The decline in gonadotrophin and growth factors possibly induce apoptosis and necrosis in 
the largest follicle during the pre-ovulatory maturation phase, which culminates in the peri-
luteal LH surge. Considerable morphological changes take place to facilitate the rupture of 
the follicle and expulsion of the egg, which may also contribute to the increase in apoptosis 
or necrosis observed in the 23-30 y with a good ovarian reserve (Figure 11.3.2) (Fan, et al. 
2009).  
11.4.5 Ovarian Ageing 
The lack of peri-ovulary luteinisation has been previously shown to be associated with 
reduced fertility as the ovarian reserve diminishes (Seifer 1996 ). In the present study, the 
level of apoptosis was reduced as the ovarian reserve declined with age (Figure 11.3.2). A 
disruption to the density of receptor expression during antral follicular growth was previously 
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shown to contribute to the reduced fertility experienced as the ovarian reserve became 
depleted (Chapter 6-9). 
 
The greater level of apoptosis and necrosis of the young uncompromised ovarian reserve 
patients, compared to the older poor ovarian reserve may reflect the overall greater mitogenic 
proliferation in the younger patient cohort (Figure 11.3.2) (Seifer 1996 , Seifer, et al. 1993). 
The base line level of apoptosis and necrosis in the 23-30 y patient group was approximately 
two fold greater compared to that of the 40+ y patient group (Figure 11.3.2). The oldest 
patients did not have elevated levels of apoptosis at the time of dominant follicle selection or 
during the maturation of the largest follicle size (Figure 11.3.2). Previously, in reduced 
ovarian reserve patients, the antral stages of follicular growth have a reduced rate of growth 
(Santoro, et al. 2003); that possibly results in reduced maturation of the follicle and oocyte 
(Seifer 1996 ). A reduced growth rate and number of growing follicles in the current study 
limited the size of the largest follicles collected from the older patients to 19-22 mm 
compared to the younger patients’ largest follicles of 23-26 mm (Figure 11.3.2). 
 
In older patients, the granulosa cell proliferation was found to be reduced and the size of the 
follicle to be smaller (Bomsel Helmreich, et al. 1979, Robertson 2009, Seifer 1996 , Seifer, et 
al. 1993). Furthermore, a previous study reported that the level of apoptosis was decreased 
(7%) in patients who fell pregnant compared to those that did not (20%) (Oosterhuis, et al. 
1998a). In addition, the study reported that age, rFSH, and the number of oocytes produced 
and fertilised were similar, yet the lower apoptosis group fell pregnant. The granulosa cells 
were pooled from each patient and the patient numbers were low, which may have had an 
impact on the study or the findings were associated with other fertility issues. 
 
In a previous study, the women with a poor ovarian reserve who had greater levels of 
apoptosis, had fewer granulosa cells undergoing luteinisation (Seifer 1996 ), yet were of the 
same age (36 y), received a similar rFSH dose, and produced a corresponding different 
number of oocytes (Seifer 1996 ). The level of apoptosis measured via flow cytometry was 
reported to be, 0.5% from a good ovarian reserve patient and 2% from a poor ovarian reserve. 
However, it is difficult to compare results between studies, because of the differences in 
methodology. The current study’s findings are novel, because of the range of patient ages and 
ovarian reserves, and different follicle size analysed on an individual basis within the one 
study  
 
Previously, the density of FSHR and LHR receptors have been associated with reduced 
fertility as the ovarian reserve declines (Chapter 7-8) (Cai, et al. 2007, Maman, et al. 2012). 
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A combination of high BMPR1B and LHR levels in the terminal-end follicles from poor 
ovarian reserve older patients (Chapter 6 and 8) may explain the low levels of luteinisation of 
granulosa cells reported (Seifer 1996 ). Maturation of the pre-ovulatory follicle requires 
down-regulation of the BMPR1B, FSHR and LHR (Regan, et al. 2015). Furthermore, the 
lack of maturation of the pre-ovulatory cells observed in (Chapter 6 and 8), would potentially 
reduce the level of apoptosis in the current study, as demonstrated in the younger patients 
with a poor ovarian reserve (AFC C, Figure 11.3.1), and with an increase in age and decline 
in AFC (Figure 11.3.2). 
11.4.6 rFSH 
Austin et al. (2001), described the reduction in apoptosis in granulosa cells treated with FSH 
in heifers (young cow) (Austin, et al. 2001). In the current study, the reduced level of 
apoptosis in the poor ovarian reserve patients was strongly correlated to the level of rFSH 
drugs administered (Figure 11.3.4). It was also observed that the natural cycle patients’ pre-
ovulatory follicle had a high level of apoptosis (24%) compared to the same age patient 
receiving IVF rFSH treatment (Figure 11.3.4). In the present study, the follicles > 10 mm had 
a greater level of apoptosis than the previously reported 0% in a natural cycle (Yuan and 
Giudice 1997). However, the sensitivity of the method of analysis may be different. In 
another study of IVF patients, a similar method of annexin V staining and flow cytometry 
was applied, and the level of apoptosis of 33 y olds was 7.8-9.8% (Giampietro, et al. 2006). 
The follicles were pooled, whereas in the current study the follicles were individually 
analysed and ranged in size from 4 -26 mm. The previous study applied a second method on 
the same patient group, and the level was found to be much higher (20%). The difference 
highlights the inaccuracy that may occur when comparing results using different 
methodologies (Giampietro, et al. 2006).  
11.4.7 Granulosal BMPR1B and FSHR density correlation 
Previously we presented data which showed that ovarian ageing generates dysregulation of 
the stage-specific receptor expression of BMPR1B, FSHR, LHR and GHR (Chapter 6-9) 
(Regan, et al. 2015). The reduced levels of receptor density and lack of pre-requisite down- 
regulation in older poor ovarian reserve patients results in a lack of correlation with the level 
of apoptosis and necrosis observed in the current study (Figure 11.3.4) In the young patients 
with an AFC of A+ & A, the granulosal BMPR1B and FSHR density was strongly correlated 
with a reduction in apoptosis (Figure 11.3.4). Under normal ovarian conditions (young 
patients with an AFC of A+ & A) the level of apoptosis and necrosis was lower when 
BMPR1B and FSHR were up-regulated. The biphasic down-regulation of BMPR1B and 
FSHR may give rise to the strong anti-apoptotic qualities associated with receptor-induced 
gene transcription. A reduction in BMP activity reduces the suppression of progesterone 
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synthesis and facilitates luteinisation of the granulosa cells (Kayamori, et al. 2009). The 
follicular-luteal phase differentiation causes a shift to progesterone as the anti-apoptotic 
protector in the luteal phase (Kayamori, et al. 2009). Meanwhile, in vitro studies have shown 
that the BMP ligands 2, 4, 6, and 7 inhibit apoptosis in goat granulosa cells (Zhu, et al. 2013). 
11.4.8 Conclusion 
In conclusion, apoptosis was reduced with the depletion of the ovarian reserve and may 
reflect the overall greater mitogenic proliferation in the younger patient cohort.  
 
The ovarian reserve is rapidly depleted with chronological age and was associated with the 
disruption to the receptor density of FSHR, BMPR, and LHR at the time of dominant follicle 
selection and during pre-ovulatory maturation. Furthermore, the dysregulation of receptor 
expression (Chapter 6 and 8) would potentially reduce the level of apoptosis by the 
suppression of maturation of the pre-ovulatory cells. 
 
Further work is required to distinguish between the associated anti-apoptotic effect that rFSH 
has on the level of apoptosis and the influence that ovarian ageing has on specific BMP 
ligand activity in relation to apoptosis.  
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CHAPTER 12 Apoptosis and Necrosis and GH Treatment 
12.1 Introduction  
Artificially increasing the level and the duration of circulating FSH extends the window of 
growth, which produces multiple ovulatory follicles. As the ovarian primordial follicle 
reserve declines, the rate of recruitment to primary follicles is reduced, which leads to a 
diminished recruitment of follicles into the cycle. The number of small antral follicles at the 
beginning of each cycle is representative of the ovarian reserve of primordial follicles 
remaining in the ovary (Almog, et al. 2011, Baerwald, et al. 2012b, Hadlow, et al. 2013, 
Hansen, et al. 2011, van Rooij, et al. 2005). AMH and chronological age also have a strong 
correlation to ovarian reserve; however, AFC demonstrates a more sensitive test over time 
(van Rooij, et al. 2005); and in the older patients, AMH is less accurate at low levels (i.e. the 
lower range of 0-1 ng/ml) (Hansen, et al. 2011).  
 
During an IVF cycle, the concentration of exogenous FSH required to recruit a cohort of 
dominant follicles increases as the ovarian reserve is depleted, indirectly indicated by a lower 
AFC. As the ovarian reserve depletes, the available number of antral follicles available for 
recruitment is reduced. Clinicians have developed protocols based on ovarian response to 
rFSH stimulation to maximise the number of antral follicles recruited; however, the 
effectiveness is reduced as the potential cohort is diminished because fewer primordial 
follicles are activated to grow.  
 
The average age of patients seeking pregnancy assistance in Australia is approaching 40 y, 
increasing the number of patients who respond poorly to gonadotrophin stimulation. Reduced 
sensitivity to rFSH stimulation has resulted in the development of adjunctive treatments such 
as GH. In the 1980s, clinical evidence alluded to an increase in birth rate (Homburg, et al. 
1988), followed by a more accurate confirmed increase in serum oestrogen and reduced 
progesterone (Karamouti 2008). Recently, the GHR has been localised on the surface of 
follicular cells and found bound to the endoplasmic reticulum, golgi apparatus and the 
nuclear membrane (Brooks, et al. 2008). Moreover, GHRs are predominantly found on the 
surface of highly prolific cells such as the peri-implantation embryo and in tumours (Brooks, 
et al. 2008, Zhu, et al. 2001). Other studies have employed large sample groups and have 
demonstrated an increase in the pregnancy rate after stimulation with GH during IVF 
treatment (Tesarik, et al. 2005, Yovich and Stanger 2010). 
 
The capacity of the ovarian follicle to generate steroids is governed by FSH and LH 
stimulation and the density of FSHRs and LHRs on the surface of the follicle cells. 
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Programmed granulosa cell death can reduce the steroid function of the follicle, and high 
levels of apoptosis can result in the complete breakdown of the follicle and oocyte. Granulosa 
cell apoptosis is a normal regulatory process during folliculogenesis. In the Booroola Merino 
sheep, the attenuation of the BMPR1B has been previously shown to increase the ovulation 
rate by reducing the level of granulosal apoptosis or necrosis (Regan, et al. 2015). In Chapter 
11 it was reported that the level of apoptosis increased during dominant follicle selection and 
during pre-ovulatory maturation in young IVF patients with an uncompromised ovarian 
reserve. However, as the ovarian reserve declined with age, the level of apoptosis was 
reduced (Chapter 11). In the current study, we explore the effect of GH co-treatment with 
rFSH on the level of apoptosis or necrosis of granulosa cells from IVF patients.  
12.2 Methods  
Methods are described in detail in the General Methods Chapter (page 38). Granulosa cells 
were collected from hCG/LH induced follicles from patients receiving IVF exogenous 
gonadotrophins to artificially stimulate multiple follicles (Table 12.2:1). 
For the detection of early DNA fragmentation, the assessment was applied on the same 
aliquots used for the immunolabelling of FSHR since antibody CD45 was not required 
because of the uniqueness of FSHR to granulosa cells, hence there would be no spectral 
overlap. 7-AAD is a nucleic acid dye used in place of propidium iodide to reduce spectral 
overlap, and is excluded from cells with an intact cell membrane. The 7-AAD positive 
granulosa cells did not distinguish between necrotic cell death and apoptotic cell death; 
however, trypan blue exclusion revealed a consistent low level of cell death.  
Table 12.2:1 Patient ovarian reserve, based on antral follicle count (AFC) and the number 
of follicles collected per group. 
 
 
Ovarian reserve measured indirectly by the Antral Follicle Count (AFC). AFC is the number of 
follicles between 2-10 mm on day 2-5 of a cycle: A+ = 30-39 follicles; A = 20-29; B = 13-19; C = 9-
12, D = 5-8; E = ≤4.  
 
 
 
 
 
AGE 
Year 
IVF 
Patient 
Total   
Follicle AFC 
Major 
Group  Number of Follicles Collected Per Group 
      Sub 
Group # 
Sub 
Group # 
Sub 
Group # 
Sub 
Group # 
21-30 8 95 20-40 A+ &A  A+ 31 A 64 C 6   
31-34 11 86 13-29 A & B  A 60 B 26 C 17   
35-39 16 102 9-19 B & C  A+ 6 B 50 C 16 D 30 & E 6 
40-45 18 118 3-8 D & E  D 59 E 19 B 34   
              
40          1         Natural Cycle Healthy D 2       
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12.3 Results  
The level of apoptosis was not significantly altered by the addition of GH co-treatment to the 
40+ y IVF patients with an AFC of D or E. The younger 23-30 y group demonstrated greater 
levels of apoptosis and necrosis combined compared to the GH co-treated group, in the 10 
mm, and 16 mm to 19 mm follicle sizes (p<0.05, Figure 12.3.1). The level of apoptosis was 
less in the GH treated patient follicles of 16 mm when compared to the 31-34 y patients 
(p<0.05), and 19 mm compared to the same size follicle in the 35-39 y B & C group (p<0.05, 
Figure 12.3.1).  
 
Figure 12.3.1 Granulosa cell apoptosis and necrosis combined in poor response 40+y 
patients treated with GH compared to untreated. 
Ovarian reserve measured indirectly by the Antral Follicle Count (AFC). AFC is the number of 
follicles between 2-10 mm on day 2-5 of a cycle Mean fluorescent intensity (MFI) was obtained using 
an average of ~8000 granulosa cells per follicle for the direct measurement of receptor protein 
expression. The data were subjected to statistical verification using one-way ANOVA with an 
uncorrected Fisher’s LSD for follicular size. Values in graphs are means ± S.E.M., and differences 
were considered significant if *p<0.05, **p<0.01 and ***p<0.005. The letter, such as ‘a’ signifies a 
statistical difference to the matching letter, and an attached asterisk (a*) indicates the significance 
level for the size follicle.The characters Ф, ω, and b were used in a similar manner to denote a 
significant difference between the symbol and the same symbol with an asterisk *. The number of 
follicles analysed are indicated. 
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Patients with a poor ovarian reserve and 40+ y treated with GH did not have any significant 
change to apoptosis and necrosis levels of granulosa cells. However, GH co-treatment 
increased the level of apoptosis and necrosis AFC of B compared to patients without GH 
treatment of the same age and AFC of B. These results are considered preliminary because 
the follicles were from a single patient with an AFC of B.  
Figure 12.3.2 Granulosa cell apoptosis and necrosis was correlated to the dose of 
exogenous rFSH treatment. 
Apoptosis and necrosis percentage level found in granulosa cells removed from patients with declining 
ovarian reserve with increasing age. The numbers of follicles are indicated in (A), and the 
corresponding dose of rFSH administered to IVF patients (B). Ovarian reserve measured indirectly by 
the antral follicle count (AFC). AFC is the number of follicles between 2-10 mm on day 2-5 of a cycle. 
Mean fluorescent intensity (MFI) was obtained using an average of ~8000 granulosa cells per follicle 
for the direct measurement of receptor protein expression. The data were subjected to statistical 
verification using one-way ANOVA with an uncorrected Fisher’s LSD for follicular size. Values in 
graphs are means ± S.E.M., and differences were considered significant if *p<0.05 and**p<0.01. The 
letter, such as ‘a’ signifies a statistical difference to the matching letter, and an attached asterisk (a*) 
indicates the significance level for the size follicle. 
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The level of apoptosis and necrosis was strongly correlated to the dose of rFSH treatment 
received by IVF patients (Chapter 11). AFC declines with age with considerable overlap of 
the ovarian response to stimulation (Yovich, et al. 2012). In the GH treated 40+ y patients 
with an AFC of B, a significant difference was observed in the level of apoptosis and 
necrosis compared to the 40+ y IVF patients without GH with an AFC of B (p<0.05, Figure 
12.3.3). The increase in the 40+ y patients with an AFC of B was similar from 15 mm to 19 
mm, and was very low in the one 24 mm follicle.  
 
Figure 12.3.3 Growth hormone treatment in 40+ y IVF patients and the level of apoptosis 
and necrosis in granulosa cells of different size follicles 
Ovarian reserve measured indirectly by the AFC. AFC is the number of follicles between 2-10 mm on 
day 2-5 of a cycle. Percentage of apoptotic or necrotic granulosa cells and follicle size collected from 
patients, 40+y in a stimulated IVF cycle with an AFC of either B (pink) or D & E, (orange) compared 
to 40+y in a stimulated IVF cycle co-treated with GH; with an AFC of either B (blue check) or D & E, 
(blue). Mean fluorescent intensity (MFI) was obtained using an average of ~8000 granulosa cells per 
follicle for the direct measurement of receptor protein expression. The data were subjected to 
statistical verification using one-way ANOVA with an uncorrected Fisher’s LSD for follicular size. 
Values in graphs are means ± S.E.M., and differences were considered significant if *p<0.05, ** and 
p<0.01.  
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FSHR and BMPR1B density reduced apoptosis levels in the youngest patients of 23-30 y 
with an AFC of A+ & A (R square 0.752 and 0.835, respectively). The level of apoptosis and 
necrosis declined with ovarian ageing, reversing the relationship between BMPR1B and 
FSHR, and the level of apoptosis or necrosis. As the ovarian reserve of primordial follicles 
decreased, no correlation was observed between the receptors and the apoptosis and necrosis. 
Growth hormone treatment in the poor ovarian reserve patients of 40+ y had a strong effect 
on the positive relationship with BMPR1B (R square 0.65), but not with FSHR (R square 
0.0). 
 
Figure 12.3.4 The relationship between the density of the receptor for FSH and BMPR1B 
and the level of granulosa cell DNA Fragmentation. 
Sequential graphs show increasing age and declining ovarian reserve indicated by AFC. Linear 
regression analysis, R square is indicated for each group. The data points are the average of the 
receptor expression for that follicle size group. Ovarian reserve measured indirectly by the antral 
follicle count (AFC). AFC is the number of follicles between 2-10 mm on day 2-5 of a cycle. 
12.4 Discussion 
12.4.1 Overview 
During the preparation for ovulation, the level of apoptosis and necrosis combined was 
amplified in the largest follicles of the young age groups, whereas in the older 40+ y patient 
the apoptosis and necrosis was significantly reduced compared to the youngest patient group 
(Chapter 11). Furthermore, the elevated granulosal BMPR1B and LHR density previously 
reported in the older, poor ovarian reserve patient group appears to prevent peri-luteal 
granulosa cell maturation (Chapter 6 & 8). 
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12.4.2 Major findings 
In the current study, GH co-treatment of the 40+ y poor ovarian reserve (D & E) patient 
group did not significantly change the level of apoptosis or necrosis in the same age group 
and AFC, compared to without GH co-treatment (Figure 12.3.1). Whereas GH co-treatment 
increased the level of apoptosis in the 40+ y group with a good ovarian reserve of B; however 
although there were 16 follicles in total, from the B group, they were from a single patient, 
and are therefore preliminary results.  
 
Previously, the correlation of the dose of rFSH to the level of apoptosis indicated that the 
high levels of rFSH may reduce the apoptotic pathways (Chapter 11). Alternatively, the 
reduction in apoptosis may be associated with the reduced growth of the follicle and 
proliferation of the granulosa cells as the ovarian reserve was depleted (Chapter 11).  
 
The 40+ y B patient without GH had the same level of apoptosis and necrosis as the D & E 
patients who received more rFSH, which indicates that rFSH may not affect apoptosis as the 
ovarian reserve declines. GH treatment did increase the level of apoptosis in the 40+ y B 
patients, which suggests an improvement in the growth and development of the follicle as the 
level of apoptosis is similar to the younger patient levels (Figure 12.3.2). The level of 
apoptosis in the youngest patient’s follicles after dominant follicle selection and before 
terminal-end maturation of the pre-ovulatory follicle is approx. 10% (14-19 mm ,Figure 
12.3.1), which is similar to the level of apoptosis in the GH treated AFC B patients (Figure 
12.3.3). Ovarian ageing has been previously shown to reduce the rate of follicle growth, 
reduce the number of granulosa cells, and reduce the length of the cycle (Seifer 1996 ). In the 
oldest patients, very few follicles were greater than 19-22 mm, yet one follicle was collected 
in the GH treated B patient of 24 mm. The follicle was healthy and the oocyte fertilised 
which indicates that the level of apoptosis was low in the largest follicle of a GH treated 
patient. A previous study showed that the pregnancy rate was greater in IVF patients with a 
lower level of apoptosis from pooled follicles of different sizes (Oosterhuis, et al. 1998b).  
 
The two methods used to determine apoptosis and necrosis were very early apoptotic markers 
of phospholipid externalisation of the cell membrane, and the 7-AAD marker detects cell 
membrane disruption in cells undergoing apoptosis and necrosis; however, it is limited to not 
differentiating between functionally intact mitochondria with apoptosis, and both 
mitochondrial and DNA total breakdown (Amsterdam, et al. 1997, Amsterdam, et al. 2003). 
In hindsight, a more appropriate detection of steroid capacity of a granulosa cell would be 
CYP19A1. The results however, are still valid because the level of DNA breakdown is a 
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measure of cellular health, and further research is yet to determine how long the apoptotic 
luteal cells continue to contribute to steroidogenic activity in the corpus luteum.  
 
The stage-specific sequential decline in receptor density observed previously in the different 
age classes, provides evidence of the loss of function with age and declining ovarian reserve 
(Chapter 6-9). Apoptosis and necrosis declined with ovarian reserve depletion, therefore it is 
more likely to be associated with reduced proliferation and not the level of rFSH 
administered as previously proposed in Chapter 11. 
12.4.3 Conclusion 
The addition of GH combined with rFSH provides an alternative cellular mechanism to 
increase the level of receptor density however it did not affect the level of apoptosis and 
necrosis in the older poor ovarian patient group. Apoptosis and necrosis was more likely to 
be associated with reduced proliferation and not the level of rFSH administered.  
 
Preliminary work on older patients with good ovarian reserve showed that GH co-treatment 
increased the level of apoptosis or necrosis. Further work is required to determine if GH co-
treatment increases apoptosis in, good ovarian reserve patients, and if the increase is 
associated with an increase in proliferation and the impact on the oocyte.  
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CHAPTER 13 Serum and Follicular Fluid and Ovarian Ageing 
13.1 Introduction 
In human subjects a decline in the ovarian reserve of primordial follicles leads to a relative 
dysregulation of folliculogenesis and ovulation. The change to the micro-environment of the 
ovary and circulating hormone levels are responsible for the reduced fertility and a reduction 
in the quality of the ovulating oocyte (Klein N A, et al. 1996). Older patients typically have 
increased circulating FSH and reduced inhibin B, that give rise to accelerated early follicle 
development and results in a shorter cycle length (MacNaughton, et al. 1992, Robertson 
2009, Santoro, et al. 2003, Seifer, et al. 1999). In poor ovarian reserve patients, the later 
stages of follicular growth have a reduced rate of growth which reduces maturation of the 
follicle and oocyte (Santoro, et al. 2003). The granulosa cell proliferation was found to be 
reduced and the size of the follicle to be smaller in older patients (Bomsel Helmreich, et al. 
1979, Robertson 2009, Seifer 1996 , Seifer, et al. 1993). The follicle increases its capacity to 
produce oestrogen by increasing the number of granulosa cells by increasing the size of the 
follicle and not the thickness of the granulosa layer (Bächler, et al. 2014). A shorter cycle and 
a reduction in the follicle size due to ovarian ageing would reduce the capacity of the follicle 
to produce sufficient oestrogen to down-regulate pituitary FSH during dominant follicle 
selection. Potentially, reduced oestradiol output could also disrupt the positive feedback 
mechanism responsible for generating the pre-ovulatory LH surge. The present study aims to 
profile the changing levels of oestrogen, progesterone, FSH, LH, and testosterone in IVF 
patients, and observe the impact ovarian reserve has on the levels of serum and follicular 
fluid.  
13.2 Methods 
Methods are described in detail in the General Methods Chapter (page 38). The peak 
oestrogen concentration in serum was used to predict the follicular health of the follicle as 
opposed to the serum levels collected at the time of follicle aspiration. When the largest 
follicles reached 18 mm, a LH surge trigger injection of 10 000 IU hCG/LH was 
administered. Then 36 hours later, the follicles were punctured and aspirated by guided 
ultrasound to collect the fluid, granulosa cells, and oocyte via transvaginal oocyte aspiration 
(TVOA). Serum was analysed using biochemical analysis on the days leading up to 
collection and on the day of collection. IVF patients undergoing treatment were examined in 
a natural cycle and during exogenous rFSH stimulated cycles. In addition, a patient with 
normal fertility (naturally conceived births) provided a control sample during a natural cycle.  
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13.3 Results and Discussion 
13.4 Follicular Fluid 
13.4.1 Results 
Pure follicular fluid was collected from IVF patients with a range of ovarian depletion, and 
analysed for hormone content (Figure 13.4.1). The majority of the follicles were 20 mm and 
ranged from 16 mm to 25 mm. Oestrogen, progesterone, and testosterone were not 
significantly different as the ovarian reserve declined (Figure 13.4.1). FSH was significantly 
increased commensurate with an increase in IVF rFSH treatment (p<0.05, Figure 13.4.1 and 
Figure 13.4.2). FSH increased as the ovarian reserve increased, and was correlated to the 
dose of rFSH administered. Follicular fluid LH data were not shown, as the level was low 
(less than 0.7 IU/L) for all patients due to GnRH suppression of LH release from the anterior 
pituitary. LH in the serum was much higher, ranging from 1.7-5.2 IU/L (Figure 13.4.2). 
13.4.2 Discussion  
Serum and follicular fluid are an indirect reflection of the growth and maturation of the 
follicle and the oocyte. The hormone profile reaches a peak just before TVOA collection. 
The administration of the LH trigger changes the hormone profile from the follicular phase to 
the luteal phase of development. The follicular fluid hormone concentration is therefore, not 
a reflection of the follicular phase but rather the peri-luteal phase (Rotmensch, et al. 1986, 
Westergaard, et al. 1986). In the current study, the concentration of follicular fluid, 
oestrogen, LH, progesterone, and testosterone were constant with age and ovarian reserve 
(Figure 13.4.1). This is not surprising as the majority of the follicles were at the pre-
ovulatory stage (20 mm) producing maximum amounts of oestrogen and progesterone. 
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Figure 13.4.1 Follicular fluid levels of IVF patients during stimulated cycles. 
Pure follicular fluid was collected 36 hours after the hCG/LH surge trigger by TVOA. The follicles 
ranged in size from 16-25 mm, with a mean of 20 mm. The number of samples is indicated by the 
numbers in the bars. Ovarian reserve measured indirectly by the antral follicle count (AFC). AFC is 
the number of follicles between 2-10 mm on day 2-5 of a cycle. Mean fluorescent intensity (MFI) was 
obtained using an average of ~8000 granulosa cells per follicle for the direct measurement of receptor 
protein expression. The data were subjected to statistical verification using one-way ANOVA with an 
uncorrected Fisher’s LSD for follicular size. Values in graphs are means ± S.E.M., and differences 
were considered significant if *p<0.05, **p<0.01, ***p<0.005, and ****p<0.001. The letter, such as 
‘a’ signifies a statistical difference to the matching letter, and an attached asterisk (a*) which indicates 
the significance level for the size follicle. 
 
FSH increased significantly with age, which reflected the increase in rFSH dose administered 
as part of the fertility treatment provided (Figure 13.4.1 and Figure 13.4.2) (Yovich, et al. 
2012). The follicle size ranged from 16 to 25 mm, with the majority being ~20 mm; hence, 
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the high progesterone level compared to the oestrogen level, which indicates luteinisation 
(Figure 13.4.3) (Westergaard, et al. 1986). 
Figure 13.4.2 Exogenous recombinant FSH (rFSH) treatment dose, dependent on age and 
antral follicle count (AFC). 
Based on data from Yovich et al. (2012). 
 
Figure 13.4.3 Changes in follicular fluid concentration of oestrogen and progesterone 
with follicle sized during dominant follicle selection and maturation. 
The acquisition of FSHR (pink arrow) and LHR (green arrow) during the process of dominant follicle 
selection in a natural cycle. Follicle differentiation and maturation of the granulosa cells increase the 
progesterone concentration (blue arrows). Modified from previously published data (Westergaard, et 
al. 1986). 
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13.5 Oestrogen 
During the follicular phase, the oestrogen peaks followed by the hCG/LH surge, and the 
oestrogen drops at the time of oocyte collection 36 hours post hCG/LH trigger. 
Therefore, the earlier peak-oestrogen serum analysis time point reveals distinct information 
on the follicular development rather than the start of the peri-luteal phase at the time of 
oocyte collection (Andersen, et al. 1993). 
13.5.1 Result: Oestrogen natural cycle compared to IVF young patients 
The serum from 23-30 y, natural, unstimulated IVF patients was collected during an 
assessment cycle and compared to the same age patients during an IVF cycle (Figure 13.5.1). 
The oestrogen levels were significantly higher in the IVF cycle, except for the D & E patients 
who had reduced oestrogen production (p<0.001, Figure 13.5.1). The level of oestrogen 
corresponded to the number of large antral follicles, and the ‘per follicle rate’ was not 
significantly different during an IVF cycle(Figure 13.5.3).The young patient oestrogen levels 
decreased significantly as the ovarian reserve declined from an AFC of C to D & E combined 
(p<0.05, Figure 13.5.2). 
 
Figure 13.5.1 Serum oestrogen level during a natural cycle compared to a stimulated IVF 
cycle from young patients. 
Peak serum oestrogen measured during a natural cycle, and a stimulated IVF cycle from patients 23-30 
y with a range of ovarian depletion. Ovarian reserve measured indirectly by the antral follicle count 
(AFC). AFC is the number of follicles between 2-10 mm on day 2-5 of a cycle. Mean fluorescent 
intensity (MFI) was obtained using an average of ~~8000 granulosa cells per follicle for the direct 
measurement of receptor protein expression. The data were subjected to statistical verification using 
one-way ANOVA with an uncorrected Fisher’s LSD for follicular size. Values in graphs are means ± 
S.E.M., and differences were considered significant if *p<0.05, **p<0.01, ***p<0.005, and 
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****p<0.001. The letter, such as ‘a’ signifies a statistical difference to the matching letter, and an 
attached asterisk (a*) which indicates the significance level for the size follicle. 
 
In the 31-34 y age group, the oestrogen level was also constant, followed by a significant 
drop from D to the E patient group (p<0.01, Figure 13.5.2). The 35-39 y age group showed 
an earlier sequential decline in the oestrogen level from the B level of ovarian reserve to the 
D & E level (p<0.001, Figure 13.5.2). The change in the 40+ y age group produced a 
dramatic reduction in oestrogen production by the granulosa cells from the AFC A to the E 
patient group as the ovarian reserve declined (p<0.001, Figure 13.5.2).  
13.5.2 Discussion: Oestrogen and ovarian depletion 
The total oestrogen peak was similar between the age groups; however, it is not until the 
antral follicle count is applied to distinguish the ageing process, that the differences are 
revealed. Peak oestrogen is consistently produced at approximately 6000 pmol/L for all age 
groups, but falls away progressively in the C, D, and E AFC groups with increasing 
chronological age (Figure 13.5.1). Age alone was not predictive of oestrogen levels, 
demonstrating no difference between age groups (see appendix). The reduction in oestrogen 
output per follicle as the ovarian reserve is depleted is a reflection of diminished number of 
follicles and the oestrogen output capacity. In the older 40+ y group, the per number of 
follicles rate of oestrogen synthesis was reduced as the ovarian reserve depleted (Figure 
13.5.3). The reduced follicular capacity to produce oestrogen would compromise oocyte 
survival. In Chapter 7 the level of FSHR density was similar in the older patients with 
reduced AFC. This indicates that the decrease in oestrogen synthesis capability is not solely 
associated with the FSHR density.  
 
Figure 13.5.2 Peak serum oestrogen levels from IVF patients during stimulated cycles. 
Serum oestrogen levels were taken at the time of peak oestrogen during a stimulated IVF cycle. 
Ovarian reserve measured indirectly by the antral follicle count (AFC). AFC is the number of follicles 
between 2-10 mm on day 2-5 of a cycle. Mean fluorescent intensity (MFI) was obtained using an 
average of ~8000 granulosa cells per follicle for the direct measurement of receptor protein expression. 
The data were subjected to statistical verification using one-way ANOVA with an uncorrected Fisher’s 
LSD for follicular size. Values in graphs are means ± S.E.M., and differences were considered 
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significant if *p<0.05, **p<0.01, ***p<0.005, and ****p<0.001. The letter, such as ‘a’ signifies a 
statistical difference to the matching letter, and an attached asterisk (a*) which indicates the 
 significance level for the size follicle. 
 
 
 
 
 
Figure 13.5.3 Peak serum oestrogen levels from IVF patients during stimulated cycles. 
Serum oestrogen levels were taken at the time of peak oestrogen during a stimulated IVF cycle. 
Ovarian reserve measured indirectly by the antral follicle count (AFC). AFC is the number of follicles 
between 2-10 mm on day 2-5 of a cycle. Mean fluorescent intensity (MFI) was obtained using an 
average of ~8000 granulosa cells per follicle for the direct measurement of receptor protein expression. 
The data were subjected to statistical verification using one-way ANOVA with an uncorrected Fisher’s 
LSD for follicular size. Values in graphs are means ± S.E.M., and differences were considered 
significant if *p<0.05, **p<0.01, ***p<0.005, and ****p<0.001. The letter, such as ‘a’ signifies a 
statistical difference to the matching letter, and an attached asterisk (a*) which indicates the 
significance level for the size follicle. 
 
13.6 FSH 
13.6.1 Result: FSH natural cycle compared to IVF young patients 
The serum from 23-30 y, natural, unstimulated IVF patients was collected during an 
assessment cycle, and compared to the same age patients during an IVF cycle (Figure 
13.6.1). There was no significant difference in the FSH surge levels at the time of peak 
oestrogen, except for the B group of young IVF cycle patients who had significantly more 
FSH in serum (p<0.001).  
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Figure 13.6.1 Serum FSH level during a natural cycle compared to a stimulated IVF cycle 
from young patients. 
Serum FSH levels were taken at the time of peak oestrogen during a natural cycle, and a stimulated 
IVF cycle from patients 23-30 y with a range of ovarian depletion. Ovarian reserve measured 
indirectly by the antral follicle count (AFC). AFC is the number of follicles between 2-10 mm on day 
2-5 of a cycle. Mean fluorescent intensity (MFI) was obtained using an average of ~8000 granulosa 
cells per follicle for the direct measurement of receptor protein expression. The data were subjected to 
statistical verification using one-way ANOVA with an uncorrected Fisher’s LSD for follicular size. 
Values in graphs are means ± S.E.M., and differences were considered significant if *p<0.05, 
**p<0.01, ***p<0.005, and ****p<0.001. The letter, such as ‘a’ signifies a statistical difference to the 
matching letter, and an attached asterisk (a*) which indicates the significance level for the size follicle 
 
 
. 
At the time of the peak oestrogen, FSH serum levels were reflective of the dose of rFSH 
administered to the patient groups. In the 40+ y age group a low serum level was found in the 
AFC group A, followed by a commensurate rise in serum FSH in the B to E patient groups 
(p<0.005, Figure 13.6.2). rFSH administered to patients was based on AFC, BMI, AMH, and 
age (Yovich, et al. 2012). The FSH serum levels were strongly correlated to the exogenous 
dose of rFSH administered. Age was also significantly correlated to the increasing FSH in 
serum levels (see appendix). 
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Figure 13.6.2 FSH serum levels at the peak of the follicular phase from IVF patients 
during stimulated cycles. 
Serum FSH levels were taken at the time of peak oestrogen during a stimulated IVF cycle. Ovarian 
reserve measured indirectly by the antral follicle count (AFC). AFC is the number of follicles between 
2-10 mm on day 2-5 of a cycle. Mean fluorescent intensity (MFI) was obtained using an average of 
~8000 granulosa cells per follicle for the direct measurement of receptor protein expression. The data 
were subjected to statistical verification using one-way ANOVA with an uncorrected Fisher’s LSD for 
follicular size. Values in graphs are means ± S.E.M., and differences were considered significant if 
*p<0.05, **p<0.01, ***p<0.005, and ****p<0.001. The letter, such as ‘a’ signifies a statistical 
difference to the matching letter, and an attached asterisk (a*) which indicates the significance level 
for the size follicle. 
 
In the current study, the level of FSH at the start of the cycle was significantly greater in the 
older patients with a poor ovarian reserve compared to the younger patients during a natural 
cycle or during an IVF cycle (Figure 13.6.3A). The FSH level at the time of peak oestrogen 
(FSH surge) was not significantly different between the old and young patients during a 
natural cycle (Figure 13.6.3B). However, during an IVF cycle, the FSH surge was 
substantially greater in the older patients with a dose dependent increase as the ovarian 
reserve declined (p<0.001, Figure 13.6.3D).  
13.6.2 Discussion   
In a natural cycle, depletion of the ovarian reserve has been associated with an increased FSH 
serum level at the start of the cycle (Figure 13.6.3A and C) (Seifer, et al. 1999). The elevated 
FSH at the start of the cycle accelerates growth of the small antral follicles; however, the 
follicles grow slowly and the length of the cycle is reduced due to early luteinisation with a 
weaker LH surge (Baerwald, et al. 2009, Klein N A, et al. 1996) The follicles have a reduced 
number of granulosa cells with a lower percentage of luteinised granulosa cells present at 
TVOA (Baerwald, et al. 2009, Santoro, et al. 2003, Seifer, et al. 1993).  
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Figure 13.6.3 FSH at the start and during the peak oestrogen phase of a cycle. 
Serum FSH level at the start of the cycle and the FSH surge level at the time of peak oestrogen, was 
collected during a natural cycle and an IVF cycle, from patients of 23-30 y and 40+ y, with a range of 
ovarian depletion. Ovarian reserve measured indirectly by the antral follicle count (AFC). AFC is the 
number of follicles between 2-10 mm on day 2-5 of a cycle. Mean fluorescent intensity (MFI) was 
obtained using an average of ~8000 granulosa cells per follicle for the direct measurement of receptor 
protein expression. The data were subjected to statistical verification using one-way ANOVA with an 
uncorrected Fisher’s LSD for follicular size. Values in graphs are means ± S.E.M., and differences 
were considered significant if *p<0.05, **p<0.01, ***p<0.005, and ****p<0.001. The letter, such as 
‘a’ signifies a statistical difference to the matching letter, and an attached asterisk (a*) which indicates 
the significance level for the size follicle. 
 
 
 
 
 
 
 
 
A B
C D 
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13.7 LH 
The level of serum LH in a natural cycle surges, followed soon after by the progesterone and 
the FSH surge. In an IVF stimulated cycle, the LH is supressed and remains very low 
throughout the cycle to inhibit spontaneous ovulation in order to allow multiple follicles to 
mature (p<0.001, Figure 13.7.1).  
 
Figure 13.7.1 Serum LH level during a natural cycle compared to a stimulated IVF cycle 
from young patients. 
Serum LH levels were taken at the time of peak oestrogen, during a natural cycle and a stimulated IVF 
cycle from patients 23-30 years old with a range of ovarian depletion. Ovarian reserve measured 
indirectly by the antral follicle count (AFC). AFC is the number of follicles between 2-10 mm on day 
2-5 of a cycle. Mean fluorescent intensity (MFI) was obtained using an average of ~8000 granulosa 
cells per follicle for the direct measurement of receptor protein expression. The data were subjected to 
statistical verification using one-way ANOVA with an uncorrected Fisher’s LSD for follicular size. 
Values in graphs are means ± S.E.M., and differences were considered significant if *p<0.05, 
**p<0.01, ***p<0.005, and ****p<0.001. The letter, such as ‘a’ signifies a statistical difference to the 
matching letter, and an attached asterisk (a*) which indicates the significance level for the size follicle. 
 
Serum LH was consistent across the AFC of the 23-30 y patients (Figure 13.7.2). The 31-34 
y and 35-39 y age groups with ‘good ovarian’ reserve had lower levels of LH in serum 
compared to the poorer E AFC groups (p<0.05, Figure 13.7.2). The 40+ y patients had 
constant LH serum levels, which were ~two times the level of the youngest patients with a 
good ovarian reserve. LH serum levels were supressed by the IVF treatment (Figure 13.7.2). 
The GnRH agonist or antagonist IVF treatment induced LH suppression, and produced 
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consistently low LH serum levels (1.7-5.2 IU/L) across all ages and AFC, yet there was a 
significant increase in LH in the patients from the middle age groups (31-34y AFC: D-E & 
35-39 y AFC: C-E); however, this was not outside the range required in the IVF treatment 
protocol (follicular phase, natural cycle; 1.9-12 IU/L and IVF cycle; <6 UI/L) (Figure 13.7.2) 
(Stanger and Yovich 1985)  
Figure 13.7.2 LH serum levels at the peak of the follicular phase from IVF patients during 
stimulated cycles. 
Serum LH levels were taken at the time of peak oestrogen during a stimulated IVF cycle. Ovarian 
reserve measured indirectly by the antral follicle count (AFC). AFC is the number of follicles between 
2-10 mm on day 2-5 of a cycle. Mean fluorescent intensity (MFI) was obtained using an average of 
~8000 granulosa cells per follicle for the direct measurement of receptor protein expression. The data 
were subjected to statistical verification using one-way ANOVA with an uncorrected Fisher’s LSD for 
follicular size. Values in graphs are means ± S.E.M., and differences were considered significant if 
*p<0.05, **p<0.01, ***p<0.005, and ****p<0.001. The letter, such as ‘a’ signifies a statistical 
difference to the matching letter, and an attached asterisk (a*) which indicates the significance level 
for the size follicle. 
 
The LH concentration at the peak of the follicular phase was significantly lower in the natural 
cycle of the older, 40+ y D patient group compared to the younger, natural cycle patient 
group of 23-30 y A (Figure 13.7.3A). The measurement was taken at the time of peak 
oestrogen concentration, before the onset of the progesterone surge, and ranged between 20 
to 40 IU/L. The LH concentration during an IVF cycle was low and ranged between 1.7 to 
5.2 IU/L (Figure 13.7.3B). The LH concentration was significantly greater in the older IVF 
patients with a poor ovarian reserve of E compared to the younger patient group of A 
(p<0.01, Figure 13.7.3B). The level of LH increased sequentially from A+ to E in the 40+ y 
IVF patients (Figure 13.7.3B). 
13.7.1 Discussion  
The data from the current study suggest that the LH serum level, corresponding to the peak 
oestrogen level of the follicular phase, in an IVF cycle increased as the ovarian reserve 
depleted, and ranged between ~1.7 and 5.2 IU/L (Figure 13.7.3); whereas, in the young 
patients during a natural cycle, it ranged from 12 IU/L (AFC: A++) decreasing to 8 IU/L in 
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the AFC: A & B, which was greater than that seen with the IVF cycles. The elevated LH 
levels in the natural cycles may be a result of the unexplained infertility previously 
demonstrated by a similar increase in LH and FSH compared to healthy controls of the same 
age group (33 y) (Leach, et al. 1997).  
Figure 13.7.3 LH surge in a natural cycle compared to an IVF treatment cycle in old and 
young patients. 
Serum LH levels were taken at the time of peak oestrogen during a natural cycle and a stimulated IVF 
cycle from patients of 23-30 y and 40+ y with a range of ovarian depletion. Ovarian reserve measured 
indirectly by the antral follicle count (AFC). AFC is the number of follicles between 2-10 mm on day 
2-5 of a cycle. Mean fluorescent intensity (MFI) was obtained using an average of ~8000 granulosa 
cells per follicle for the direct measurement of receptor protein expression. The data were subjected to 
statistical verification using one-way ANOVA with an uncorrected Fisher’s LSD for follicular size. 
Values in graphs are means ± S.E.M., and differences were considered significant if *p<0.05, 
**p<0.01, ***p<0.005, and ****p<0.001. The letter, such as ‘a’ signifies a statistical difference to the 
matching letter, and an attached asterisk (a*) which indicates the significance level for the size follicle. 
 
One explanation for the incomplete suppression of GnRH with ovarian ageing is the high 
levels of BMP activity at the terminal-end of folliculogenesis (Chapter 5), Diminished 
ovarian response due to an early loss of ovarian reserve amongst young patients (IVF cycle < 
3 follicles, 21-35 y) has been previously shown to have significantly extended LH surges 
with reduced luteal progesterone (Pal, et al. 2010); whereas, in natural cycles, the effect of 
age reduced the amplitude of the LH surge and reduced oestrogen levels in mares (Ginther, et 
B 
A 
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al. 2008). The consistent elevated serum LH (4 IU/L) levels recorded in the poor response 
patient group of 40+ y AFC: A-E, may be a reflection of the lack of effectiveness of the 
GnRH suppression caused by the lack of BMPR1B down-regulation in ovarian ageing 
(Chapter 6), or alternatively, may be symptomatic of the increased exogenous rFSH 
treatment. 
13.8 Progesterone 
13.8.1 Result   
The progesterone level of the young 23-30 y group was similar in a natural cycle compared 
to an IVF cycle (Figure 13.8.1).  
Figure 13.8.1 Serum progesterone level during a natural cycle compared to a stimulated 
IVF cycle from young patients. 
Serum progesterone levels were taken at the time of peak oestrogen during a natural cycle and a 
stimulated IVF cycle from patients 23-30 years old with a range of ovarian depletion. Ovarian reserve 
measured indirectly by the antral follicle count (AFC). AFC is the number of follicles between 2-10 
mm on day 2-5 of a cycle. Mean fluorescent intensity (MFI) was obtained using an average of ~8000 
granulosa cells per follicle for the direct measurement of receptor protein expression. The data were 
subjected to statistical verification using one-way ANOVA with an uncorrected Fisher’s LSD for 
follicular size. Values in graphs are means ± S.E.M., and differences were considered significant if 
*p<0.05, **p<0.01, ***p<0.005, and ****p<0.001. The letter, such as ‘a’ signifies a statistical 
difference to the matching letter, and an attached asterisk (a*) which indicates the significance level 
for the size follicle. 
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Progesterone concentration was constant (1-6 nmol/L) followed by a decrease in the severely 
depleted patient groups of D and/or E, as the ovarian reserve depleted (p<0.05, Figure 
13.8.2). In the 40+ y A group, the level of progesterone was high, followed by a constant 
lower level (p<0.005) similar to the younger patients. Progesterone concentration was 
significantly greater during an IVF cycle compared to a natural cycle of 40+ y patients with 
the same ovarian reserve of B or D (p<0.05, Figure 13.8.3). Progesterone concentration 
ranged from 1.7 to 5.5 IU/L. The level of progesterone in the natural cycle of a healthy 
patient, with an ovarian reserve of D, was similar to the IVF cycle patient group with a 
matching AFC of D.  
 
 
Figure 13.8.2 Progesterone serum levels at the peak of the follicular phase from IVF 
patients during stimulated cycles. 
Serum progesterone levels were taken at the time of peak oestrogen during a stimulated IVF cycle. 
Ovarian reserve measured indirectly by the antral follicle count (AFC). AFC is the number of follicles 
between 2-10 mm on day 2-5 of a cycle. Mean fluorescent intensity (MFI) was obtained using an 
average of ~8000 granulosa cells per follicle for the direct measurement of receptor protein expression. 
The data were subjected to statistical verification using one-way ANOVA with an uncorrected Fisher’s 
LSD for follicular size. Values in graphs are means ± S.E.M., and differences were considered 
significant if *p<0.05, **p<0.01, ***p<0.005, and ****p<0.001. The letter, such as ‘a’ signifies a 
statistical difference to the matching letter, and an attached asterisk (a*) which indicates the 
significance level for the size follicle. 
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Figure 13.8.3 Progesterone serum levels at the time of peak serum oestrogen during a 
natural cycle compared to an IVF cycle. 
Serum progesterone levels were taken at the time of peak oestrogen during a natural cycle and a 
stimulated IVF cycle from patients 40+ y with a range of ovarian depletion. Ovarian reserve measured 
indirectly by the antral follicle count (AFC). AFC is the number of follicles between 2-10 mm on day 
2-5 of a cycle. Mean fluorescent intensity (MFI) was obtained using an average of ~8000 granulosa 
cells per follicle for the direct measurement of receptor protein expression. The data were subjected to 
statistical verification using one-way ANOVA with an uncorrected Fisher’s LSD for follicular size. 
Values in graphs are means ± S.E.M., and differences were considered significant if *p<0.05, 
**p<0.01, ***p<0.005, and ****p<0.001. The letter, such as ‘a’ signifies a statistical difference to the 
matching letter, and an attached asterisk (a*) which indicates the significance level for the size follicle. 
 
13.8.2 Discussion  
In an IVF cycle, the hCG/LH trigger initiates cessation of proliferation and a change in 
steroidogenic capacity from oestrogen to progesterone production in the granulosa cells. 
Progesterone synthesis during the follicular phase is inhibited, which promotes oestrogen 
synthesis and follicular growth. The LH surge reduces the inhibition and promotes 
progesterone production in the granulosa cells. The progesterone initially increases slowly in 
the first few hours, post LH trigger, followed by a progesterone surge, in preparation for 
luteinisation of the follicle to form the corpus luteum. Serum progesterone levels in older 
patients were higher compared to younger patients with an uncompromised ovarian reserve 
or good ovarian reserve (Figure 13.8.2). 
 
Ovarian ageing was evident in the poor ovarian reserve patient groups for each age class 
(Figure 13.8.2). Increased progesterone is an indicator of premature luteinisation, which can 
produce a decreased pregnancy rate (Legro, et al. 1993). The reduced oestrogen synthesis 
would also be associated with a reduced progesterone serum level, and may be related to 
granulosal receptor density. The higher progesterone levels in the poor ovarian reserve 
patient groups were below the concentration that other researchers have deemed to be of 
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detrimental significance (Legro, et al. 1993). Legro et al. (1993), found that elevated 
progesterone serum levels that were greater than 3.8 nmol/L (1.2 ng/ml)), were associated 
with an improved oocyte quality. The higher progesterone levels in the donor patients were, 
therefore, more likely to be related to endometrial receptivity, and not follicular progesterone 
concentration and oocyte quality (Legro, et al. 1993).  
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Serum and Follicular Fluid, GH co-treatment, and Ovarian Ageing 
 
 
 
 
Title: The decline in ovarian ageing and the effect on ovarian 
hormone regulation in IVF patients co-treated with GH 
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CHAPTER 14 Serum & Follicular Fluid & GH co-treatment 
14.1 Introduction  
Ovarian ageing has been associated with an increase in aneuploidy and a diminished 
recruitment or response to exogenous gonadotrophin stimulation (Hale 2007, Seifer, et al. 
2007, Seifer, et al. 1993, Seifer, et al. 2002). GH co-treatment of IVF patients with a poor 
response to ovarian stimulation with rFSH has been shown to improve the pregnancy and 
birth rate in an ageing population (Tesarik, et al. 2005, Yovich and Stanger 2010). 
 
Previously, it has been shown that GH co-treatment increased the density of receptors in the 
40+ y poor ovarian response group with an AFC of D or E (Chapter 10). In addition, it has 
been established that the type 1 TGFβ receptor, BMPR1B was reduced in a biphasic pattern 
during cyclic folliculogenesis in humans (Chapter 6), and in Merino sheep with an 
uncompromised ovarian reserve (Regan, et al. 2015). The spatiotemporal regulation occurred 
at the time of dominant follicle selection and during pre-ovulatory maturation. The results 
also showed that, as the ovarian reserve declined, the biphasic down-regulation of BMPR1B 
was disrupted (Chapter 6). In the poor response oldest patients, the BMPR1B failed to be 
down-regulated towards the end of folliculogenesis. The granulosal receptor density from 
older poor ovarian reserve patients, co-treated with growth hormone, was reversed. The 
younger higher receptor level and the pre-ovulatory down-regulation of the BMPR1B, FSHR 
and LHR were re-established. The aim of this investigation was to determine if GH co-
treatment of IVF patients influences the steroidogenic capacity of the follicle. 
14.2 Methods  
Methods are described in detail in the General Methods Chapter (page 38). The peak 
oestrogen concentration in serum was used to predict the follicular health of the follicle as 
opposed to the serum levels collected at the time of follicle aspiration. When the largest 
follicles reached 18 mm, a LH surge trigger injection of 10 000 IU hCG/LH was 
administered. Then 36 hours later, the follicles were punctured and aspirated by guided 
ultrasound to collect the fluid, granulosa cells, and oocyte via transvaginal oocyte aspiration. 
Serum was analysed using biochemical analysis on the days leading up to collection and on 
the day of collection. IVF patients undergoing treatment were examined in a natural cycle 
and during exogenous rFSH stimulated cycles. In addition, a patient with normal fertility 
(prior naturally conceived births) provided a control sample during a natural cycle.  
 
  
188 
 
14.3 Results  
The steroidogenic activity of theca and granulosa cells contained within the follicle supports 
the oocyte during folliculogenesis and pre-ovulatory maturation, has been referred to as the 
‘two cell’ theory (Hillier, et al. 1994b). Androgen produced by the theca is converted to 
oestrogen in the granulosa cell, and is regulated by a complex mechanism of paracrine and 
autocrine growth factors driven by a combination of FSH and LH secreted from the anterior 
pituitary (Miller 2011). The results from the current study indicate that the GH co-treatment 
did not alter the oestrogen level of the 40+ y with an ovarian reserve of D or E during an IVF 
cycle (Figure 14.3.1). Furthermore, the ratio of oestrogen was not altered, nor the levels of 
oestrogen secreted, based on either the total number of follicles or the number of follicles 
greater than 14 mm present in the ovary at the time of collection which were not significantly 
different (Figure 14.3.2). In addition, the follicular fluid concentration of oestrogen, 
progesterone, FSH, or testosterone was not significantly different to the age matched patients 
with a similar ovarian reserve that were co-treated with GH (Figure 14.3.3).  
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Figure 14.3.1 Serum levels of IVF patients during stimulated cycles, ovarian ageing and 
the effect of GH co-treatment. 
Serum oestrogen, progesterone, FSH, and LH levels were taken at the time of peak oestrogen during a 
stimulated IVF cycle. Ovarian reserve measured indirectly by the antral follicle count (AFC). AFC is 
the number of follicles between 2-10 mm on day 2-5 of a cycle. Mean fluorescent intensity (MFI) was 
obtained using an average of ~8000 granulosa cells per follicle for the direct measurement of receptor 
protein expression. The data were subjected to statistical verification using one-way ANOVA with an 
uncorrected Fisher’s LSD for follicular size. Values in graphs are means ± S.E.M., and differences 
were considered significant if *p<0.05, **p<0.01, ***p<0.005, and ****p<0.001. The letter, such as 
‘a’ signifies a statistical difference to the matching letter, and an attached asterisk (a*) which indicates 
the significance level for the size follicle. 
Figure 14.3.2 Serum peak oestrogen level from IVF patients with and without GH co-
treatment. 
(A) The peak oestrogen level was determined from blood samples from IVF patients during the 
follicular phase. The blood sample was taken before the hCG /LH trigger injection (B) The peak 
oestrogen was divided by the number of follicles greater than 14 mm. (C) The peak oestrogen was 
divided by the total number of follicles present at oocyte collection. Ovarian reserve measured 
indirectly by the antral follicle count (AFC). AFC is the number of follicles between 2-10 mm on day 
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2-5 of a cycle. Mean fluorescent intensity (MFI) was obtained using an average of ~8000 granulosa 
cells per follicle for the direct measurement of receptor protein expression. The data were subjected to 
statistical verification using one-way ANOVA with an uncorrected Fisher’s LSD for follicular size. 
Values in graphs are means ± S.E.M., and differences were considered significant if *p<0.05, and 
**p<0.01. The letter, such as ‘a’ signifies a statistical difference to the matching letter, and an attached 
asterisk (a*) which indicates the significance level for the size follicle.  
 
Figure 14.3.3 Follicular fluid levels of hormones from IVF patients during stimulated 
cycles and co-treatment with GH. 
Pure follicular fluid was collected from follicles at the time of oocyte collection for IVF treatment. 
Follicle size was between 16-23 mm, with an average of 20 mm. Ovarian reserve was measured 
indirectly by the antral follicle count (AFC). AFC is the number of follicles between 2-10 mm on day 
2-5 of a cycle. Mean fluorescent intensity (MFI) was obtained using an average of ~8000 granulosa 
cells per follicle for the direct measurement of receptor protein expression. The data were subjected to 
statistical verification using one-way ANOVA with an uncorrected Fisher’s LSD for follicular size. 
Values in graphs are means ± S.E.M., and differences were considered significant if *p<0.05, 
**p<0.01, ***p<0.005, and ****p<0.001. The letter, such as ‘a’ signifies a statistical difference to the 
matching letter, and an attached asterisk (a*) which indicates the significance level for the size follicle. 
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14.4 Discussion 
In a natural cycle, the selection of the dominant follicle is based on the follicle that is first to 
express the androgen-induced FSHR. The increased granulosal FSHR leads to the induction 
of LHR at the time of selection (Rice, et al. 2007). The diminishing ovarian reserve of 
primordial follicles limits the activation of primordial follicles in each cycle. Fewer growing 
primordial follicles reduce the pool of small antral follicles available for cyclic recruitment. 
Exogenous rFSH appears to reach a saturation point, beyond which more rFSH fails to alter 
the number of follicles recruited. Previously, it has been reported that GH increased the 
receptor density of BMPR1B, FSHR, LHR and GHR (Chapter 10); yet GH did not increase 
the number of recruited follicles (Yovich and Stanger 2010). The main effect of the GH co-
treatment was not during the dominant follicle selection stage of folliculogenesis, and 
therefore is supportive of an increase in quality, and not the quantity of oocytes. It is 
therefore probable that the improved pregnancy rate must involve other cellular mechanisms 
to improve the quality of oocytes. 
14.4.1 GH co-treatment and the FSH-FSHR activity 
In the present study the oestrogen output from GH co-treated IVF patients was consistent 
with other in vivo studies (Owen, et al. 1991, Tapanainen, et al. 1992 ). Oestrogen synthesis 
during an IVF cycle is driven by rFSH and the activation of the FSHR. Gonadotrophin 
receptor activation induces signalling via the AC-cAMP-PKA cascade, and regulates the 
ERK1/2 pathways (Tajima 2003). Regulation of folliculogenesis, apoptosis and 
steroidogenesis has been shown to be via the ERK1/2’s vast number of signalling routes, and 
GH has been shown to have a regulatory effect on ERK1/2 signalling (Caunt, et al. 2006, 
Nakamura, et al. 2012). 
 
The specificity of the signalling systems relies on compartmentalisation which involves a 
complex time and spatial gradient. Another possible regulating mechanism involved is the 
internalisation via arrestins and scaffolding proteins that influence intracellular 
concentrations, and importantly go on to modulate the intermediate messengers, that control 
protein synthesis (Caunt, et al. 2006, Tajima 2003).  
 
GH co-treatment increased the granulosal FSHR density, yet had no effect on the serum or 
follicular fluid oestrogen synthesis (Chapter 10).The level of FSHR expression was not 
significantly reduced in the poor ovarian reserve patients (Chapter 7), which indicates that 
the conversion of androstenedione to oestradiol in the granulosa cell is adversely impacted 
on, downstream of the hormone-receptor interphase in ovarian ageing.  
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14.4.2 Apoptosis and GH co-treatment 
In addition, it is possible that the total oestrogen level is not the cause of the reduced oocyte 
quality; rather, it is the lack of pre-ovulatory maturation brought about by the reduced density 
of receptors combined with the lack of down-regulation at the end of folliculogenesis. In 
particular the 40+ y B AFC patient group when treated with GH had an increase in the level 
of apoptosis possibly associated with an increase in proliferation commensurate with the 
increase in serum oestrogen (Chapter 11), whereas the apoptosis and oestrogen levels were 
not significantly altered in the D & E older patient group (Figure 11.3.2).  
 
14.4.3 BMPR1B and progesterone  
The level of progesterone, however, with GH co-treatment was significantly increased in the 
40+ y ovarian reserve E patient group (Figure 14.3.1). It has been previously shown that GH 
co-treatment induced mechanisms that caused an up-regulation and a pre-requisite down-
regulation maturation of the mature protein for the granulosal BMPR1B and LHR (Chapter 6 
and 8). The levels of BMPR1B were low in the D group compared to the younger patient 
groups, whereas in the E group the receptor density was initially low, yet increase and this 
was accentuated in the larger follicles (Figure 14.3.1). The GH induced change to 
progesterone level is therefore likely to reflect the greater difference in change of the receptor 
density in this sub-group. In particular, the effect on the GH co-treated E group was to 
dramatically reduce the BMPR1B density of the largest follicles compared to the effect in the 
ovarian reserve D patients (Figure 14.4.2). The greater suppression of the BMPR1B at this 
time would reduce the BMP suppression of progesterone synthesis and significantly increase 
the progesterone synthesis in the granulosa cell (Figure 14.4.1)  
The JAK2-MAPK signalling pathway can activate the ERK1/2 axis, and it is known that the 
BMPR1B activity involves the suppression of ERK1/2 to inhibit cytoskeletal changes and 
nuclear translocation activity during folliculogenesis to prevent luteinisation (Harris, et al. 
2002, Inagaki, et al. 2009, Le Roith, et al. 2001, Liang 2007, Moore, et al. 2001b, Nakamura, 
et al. 2012, Seger, et al. 2001, Su 2002). At the time of differentiation during the LH surge, 
the BMPs are down-regulated and the inhibition of the ERK 1/2 progesterone synthesis 
pathway is removed, which promotes progesterone synthesis by the granulosa cells (Moore, 
et al. 2001b). It has been reported that the levels of granulosal luteinisation in follicles from 
older patients was reduced in line with the lack of maturation down-regulation described in 
Chapter 6-8, and the reduced pregnancy rate influenced by the lack of luteinisation of 
granulosa cells (Seifer 1996 ). The current study provides evidence of an improvement in 
pre-requisite down-regulation and the corresponding significant increase in progesterone 
synthesis indicative of greater maturation of the granulosa-luteal cells.  
193 
 
Figure 14.4.1 GH co-treatment and the effect serum progesterone and the granulosal 
BMPR1B density as the ovarian reserve diminished.  
Estracted from Chapter 6.   
 
However, it is noted that IGF and GH signalling mechanisms have also been shown to have 
common pathways in poly-ovulatory animals (Nakamura, et al. 2012); whereas in the human 
ovary, GH and IGF pathways have been reported to be independent and therefore are 
unlikely to influence the current study (Mason, et al. 1990, Peñarrubia, et al. 2000).  
Figure 14.4.2 GH co-treatment on the granulosal BMPR1B density in 40+ y patients.  
Extracted from Chapter 10. 
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14.4.4 IVF patients in vitro cell culture 
Past research has provided many examples of in vitro cultured granulosa cells treated with 
GH; however, invariably the cells spontaneously luteinise in serum fortified medium or are 
collected from patients previously exposed to a LH surge (Ahumada-Solórzano, et al. 2012, 
Barreca, et al. 1993a, Bergh 1996 , Carlsson, et al. 1992, Karamouti 2008, Ovesen 1998). In 
addition, previously presented results have shown that the granulosa-luteal cells collected 
after the hCG/LH trigger, from small, medium, and large antral follicles (5-23 mm), when 
cultured in serum-free media produced a greater concentration of progesterone than 
oestrogen (Chapter 4). The ratio in favour of progesterone confirms that LH-induced 
steroidogenic differentiation had taken place after exposure to a LH surge (Baird, et al. 1975, 
McNatty, et al. 1975, Westergaard, et al. 1986). Notwithstanding, research conducted using 
granulosa cells collected from the follicular phase and cultured in a serum free environment 
demonstrated that GH treatment in culture, increased the oestrogen production (Carlsson, et 
al. 1992, Mason, et al. 1990).  
 
In conclusion, oestrogen and progesterone synthesis was reduced during ovarian reserve 
depletion, however, the effect of GH co-treatment on the oestrogen synthesis was not 
evident. The progesterone level, however, was significantly increased in the 40+ y E patients 
and was consistent with an improvement in the maturation process via the increase in 
BMPR1B density, and more importantly by promoting down-regulation of receptors during 
the maturation phase.  
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CONCLUSION 
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Conclusion 
In the young female adult, several regulatory mechanisms are in place to facilitate 
folliculogenesis and the maturation of the oocyte for ovulation. As the ovarian pool of 
primordial follicles diminishes over time in adulthood, the regulatory process is disrupted, 
which results in reduced fertility.  
 
At the time of cyclic dominant follicle selection, and again during the maturation stage of 
folliculogenesis, changes to receptor density and increased apoptosis were evident. The 
change in receptor density seen with declining ovarian reserve provides compelling evidence 
of a fundamental shift in granulosal receptor density with ovarian ageing. Ovarian ageing 
resulted in a reversal of this biphasic pattern of receptor expression, disrupting the 
luteinisation process. The dysregulation also resulted in a reduced level of apoptosis and 
necrosis, and the declining level of serum oestrogen and progesterone, and the higher LH 
level.  
 
The BB mutation-induced attenuation of BMPR1B signalling, led to an increased density of 
the FSHR and LHR, with a concurrent reduction in apoptosis or necrosis, which increased 
the ovulation rate. When the BMP signalling was attenuated in the BB mutation, the increase 
in reproductive receptors, together with a reduction in apoptosis, increased the ovulation rate. 
BMPR1B attenuation reduced apoptosis, which indicates an indirect role for BMPs in 
apoptosis activity.  
 
The attenuation of BMPR1B activity in sheep increased the receptor expression of BMPR1B, 
FSHR and LHR, while GH co-treatment in humans, increased these receptors in parallel. 
Therefore, the GH mode of action may attenuate BMPR1B activity in the human model to 
cause a similar outcome to that of the BB sheep. 
 
In contrast, in the human model, apoptosis was reduced with ovarian ageing and was not 
significantly altered by the GH co-treatment in the poor ovarian reserve patients. IVF 
treatment with rFSH reduced apoptosis, therefore any potential BMP effect on apoptosis was 
probably masked by the high dose of rFSH.  
 
The potential positive effect on apoptosis may have a greater impact if rGH was used in a 
stand-alone regime, or on patients with an uncompromised ovarian reserve, as was the case 
for the young adult sheep, and as was exemplified in preliminary results from good ovarian 
reserve patients in this thesis. 
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It is therefore, more probable, that the reduction in apoptosis is associated with the reduced 
growth of the follicle and proliferation of the granulosa cells, as the ovarian reserve becomes 
severely depleted. Preliminary data from rGH co-treated older patients, with good ovarian 
reserve, demonstrated an increased level of apoptosis or necrosis in the stage-specific 
dominant follicle selection and maturation phase, which was in line with the results from an 
uncompromised young ovarian reserve. Further work is required to determine if the increase 
is associated with an increase in proliferation, and the impact this may have on the oocyte.  
 
The corner stone of this thesis was the increase in ovulation rate caused by a naturally 
occurring point mutation to the BMPR1B. It is possible that, in sheep, proliferation of the 
granulosa cells is more strongly associated with the BMPR1B ligands; whereas, in humans, 
the affinity and precocious binding of the ligands may be different. Alternatively, the 
difference may be explained by the fact that the sheep were young and were not receiving 
high doses of rFSH. 
 
Further investigation is warranted to determine if a species difference exists in the affinity or 
precocious signalling of the BMP ligands, and the potential for GH to influence the ovulation 
rate in humans. The GH treated follicles in humans, were not significantly different in size 
and produced similar oestrogen serum levels, which leads to the question of an alternative 
mode of action to increase oocyte quality. 
 
This thesis has revealed several alternative cellular mechanisms that could contribute to an 
improved oocyte quality in GH co-treated IVF patients with a poor ovarian reserve. An 
increase in the density of FSHR would increase the FSH-induced AC-cAMP- PKA activity, 
leading to an increase in transcription of intermediate components that would directly up-
regulate the receptor density of FSHR itself, LHR, BMPR1B and GHR. GH co-treatment 
increased GHR-JAK-STAT activity, and would result in an increase in the intermediate 
products of transcription, which may explain the increase in reproductive receptor density 
observed.  
 
GH co-treatment did not alter the LHR or FSHR density of small follicles, and this would 
therefore account for the lack of improvement in the number of follicles recruited during 
dominant follicle selection. However, the increase in LHR sensitivity of the larger follicles 
would restore the pre-ovulatory maturation and provides another possible cellular mechanism 
responsible for the improved pregnancy rate. 
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In addition, rGH may attenuate all BMP activity; therefore, the proposed generalised partial 
attenuation of BMPR1B would most likely also affect BMPR1A receptor activity. The role 
of BMPR1A was beyond the scope of this thesis; however, it is duly noted that it contributes 
to ovarian regulation. The realisation that the systemic effect of rGH on the ovary is not 
isolated to the BMPR1B (activin receptor-like kinase (ALK6)) or even the BMPs alone, leads 
us to question the effect GH has on other TGFβ type 1 receptors, such as ALK2, 3, 4, and 5. 
Essentially, the phosphorylation of these pathways results in activation of either the 
SMAD2/3 pathway or the BMPR1B-induced SMAD1, 5, 8 pathway.  
 
Further research is also needed to delineate the effect of rGH co-treatment on the oocyte that 
would directly influence its quality, taking into consideration that the oocyte produces GH 
and expresses the BMPR1B and GHR. 
Significance 
The clinical significance of these findings is centred on the massive change to the profile of 
patients requesting assistance with fertility in recent years. The social fabric of our 
community has changed substantially since the inception of IVF in the 1970s, which was 
based on much lower doses of gonadotrophins. Since its inception, IVF treatment has been 
continuously refined to reduce overstimulation, and increase pregnancy rates. The pregnancy 
rate for frozen embryo transfer is ~50% in Australia, and the birth of children from IVF-
conceived parents is only now occurring. It will take another 30 years before the true impact 
of high rFSH treated patients is realised.  
 
With greater knowledge on the ovarian ageing process delivered in this thesis, and 
comprehensive quantitative data on the changes of receptor density and hormonal control 
during folliculogenesis, current practice should be reconsidered. Ovarian reserve challenged 
patients would benefit from a reduction in the supraphysiological doses of rFSH stimulation 
during the stage-specific maturation phase of folliculogenesis. A reduction in rFSH would 
reduce the cost of ART and importantly, reduce the mental and physical stress associated 
with sustained high doses of rFSH. 
  
The data presented in this thesis have revealed, several mechanisms that are involved in the 
improved quality of the follicle and the oocyte which has led to an improvement in 
pregnancy rate, reported in GH co-treated patients. rGH co-treatment increased the receptor 
expression in a similar way to the BMP attenuation in the BB mutation. The increased 
density of FSHR and LHR, induced by rGH, may provide a new minimal stimulation 
treatment which would reduce the reliance on high doses of rFSH in young and older 
patients. 
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APPENDIX 
Additional supporting evidence 
Figure 1 Relationship between AFC and chronological age. 
Figure 2 Relationship between AFC and chronological AMH. 
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Figure 3 Relationship between follicle size and chronological age. 
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Figure 4 Relationship between the number of follicles AFC and the receptor density for 
FSHR, BMPR1, LHR and GHR on the surface of human peri-luteal granulosa- cells. 
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Figure 5 Serum levels of steroid hormones from patients receiving infertility treatment in a 
stimulated cycle with rFSH; and age compared to patients treated with GH co-treatment.  
Note : The significance is brought about because the AFC in the 40+y group is mixed therefore the 
average is higher compared to the 40+ GH treated which is only AFC D&E. 
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Figure 6 Serum levels of steroid hormones from patients receiving infertility treatment in a 
stimulated cycle with rFSH; and age. 
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Figure 7 Follicular levels of steroid hormones from patients receiving infertility treatment 
in a stimulated cycle with rFSH and age. 
LH 
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Figure 8 Follicular levels of steroid hormones from patients receiving infertility treatment 
in a stimulated cycle with rFSH; and AFC, adjusted for the number of follicles between 
16-23mm. 
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Figure 9 Correlation between the concentration of follicular fluid (FF) steroid hormones 
and receptor density for LHR, GHR & level (%) of Apoptosis or necrosis of granulosa 
cells. 
Receptor density is a measure of mean fluorescent intensity in arbitrary units. Each point represents 
the average for that size follicle. 
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Figure 10 Correlation between the concentration of follicular fluid (FF) steroid hormones 
and receptor density for FSHR and BMPR1B on granulosa cells. 
Receptor density is a measure of mean fluorescent intensity in arbitrary units. Each point represents 
the average for that size follicle. 
 
